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Mammalian responses to stressors that alter homeostasis are mediated by the 
hypothalamic-pituitary-adrenal (HPA) and sympathetic-adrenal-medullary (SAM) axes. The 
SAM axis releases catecholamines, which include the neurotransmitters epinephrine (E) and 
norepinephrine (NE). The α- and β-adrenergic receptors (ARs) are encoded by 6 α- and 3 β-AR 
genes and these ARs mediate interactions between the stress hormones E and NE and immune 
cells. However, AR gene expression and function have been studied to a limited extent in bovine 
immune cells. Furthermore, a thorough survey has never been published in any species to 
determine which of the 9 AR genes are expressed in blood leukocytes and if there are significant 
differences in AR gene expression when comparing among leukocyte lineages.   
In this study, AR gene expression was quantified in bovine leukocytes isolated from 
whole blood, peripheral blood mononuclear cells (PBMCs), polymorphonuclear cells (PMNs), 
and purified T cells, B cells, monocytes, innate lymphoid cells, neutrophils and eosinophils. 
While transcript abundance for the β2-, α2A-, and α1A-AR genes tended to be greatest in 
leukocytes isolated from bovine whole blood, marked differences in AR gene expression were 
observed when leukocytes were separated into individual lineages. Variation in AR gene 
expression among leukocyte lineages provided the first evidence that individual bovine 
leukocyte lineages may also differ in their responses to E and NE. Adrenergic receptor gene 
expression was also quantified in whole blood leukocytes following maternal separation 
(weaning) and transportation of suckling beef calves. These stressors were associated with 
significant increases in transcript abundance for the β1-, β2, β3-, and α2A-AR genes in blood 
leukocytes at different time points throughout the 28-day post-weaning and transportation period. 
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Thus, the capacity of the immune system to respond to E and NE may increase significantly 
when animals respond to stressful changes in their environment.  
Following confirmation that AR genes were expressed in bovine leukocytes, PMNs were 
chosen for further analysis of AR gene expression and function. I developed and validated an 
appropriate flow cytometric method to specifically identify neutrophils and eosinophils and then 
flow cytometry was used to analyze the response of resting and activated PMN to adrenergic 
agonists. Eosinophils were identified as autofluorescence high and CD44 high cells, while 
neutrophils were characterized as autofluorescence low and CD44 low. PMNs are frequently 
assumed to be primarily neutrophils with a small proportion of eosinophils. However, I observed, 
depending on the individual animal and time of year, eosinophils comprised 1.8 - 29.4% of 
isolated PMN populations. Subsequent analysis of neutrophils and eosinophils confirmed each 
population responded differently to co-stimulation with opsonized zymosan and IFN and 
displayed significantly different responses to adrenergic agonists.   
Short-term treatment with E, NE, phenylephrine (an α1-AR agonist), dexmedetomidine (an α2-
AR agonist), and isoproterenol (a β-AR agonist) modified neutrophil and eosinophil expression 
of intracellular reactive oxygen species, CD11b, L-selectin, CD16 and CD44. Analysis of these 
markers revealed significant differences in the response of these two PMN subpopulations to 
these adrenergic agonists. Resting neutrophils demonstrated an L-selectin “shedding” response to 
E and NE, consistent with a phenotype which may lead to decreased neutrophil exit from, and 
increased marginated neutrophil entry, into circulation. At the same time, resting neutrophils 
treated with E and NE increased CD11b and intracellular reactive oxygen species (iROS), 
consistent with cell activation. This short-term state could be representative of increased 
neutrophil surveillance in response to stress, leading to an increased inflammatory response to 
iv 
 
tissue pathogens, as in the case of bovine respiratory disease. This response is consistent with the 
short-term neutrophilia and leukocyte activation that has been observed in response to multiple 
stressors such as weaning and transportation in cattle. Similar responses were observed in 
activated neutrophils in response to NE.  
My research also demonstrated a potential role for eosinophils during a stress response, as 
eosinophils responded to NE with an activation phenotype (L-selectin high, CD11b high, CD44 
high, CD16 high). This eosinophil activation may augment short-term tissue invasion by 
eosinophils following stimulation with agonists such as NE. Interestingly, synthetic agonists 
targeting individual AR families (phenylephrine, dexmedetomidine, and isoproterenol) induced 
some responses that were similar to those observed with E and NE. However, these agonists 
consistently decreased iROS in both neutrophils and eosinophils. Further research is required to 
determine why physiological and synthetic AR agonists had different effects on iROS. 
Collectively, my analyses of AR gene expression provided evidence that the sympathetic-
adrenal-medullary (SAM) axis may interact with all the leukocyte subpopulations examined. 
Further work is required to determine how this interaction may alter the function of individual 
leukocyte lineages or subpopulations. My analysis of AR function in PMNs provided evidence 
both neutrophils and eosinophils express functional 1-, 2- and -AR, but these two PMN 
subpopulations differ significantly in their response to adrenergic agonists. However, adrenergic 
agonists consistently increased iROS and altered expression of surface adhesion molecules by 
resting neutrophils and eosinophils. Therefore, an acute stress response with increased release of 
catecholamines could rapidly increase the capacity of neutrophils and eosinophils to respond to 
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Bovine Respiratory Disease (BRD) remains a major animal health problem despite 
decades of vaccination and aggressive use of antimicrobials (Miles, 2009). The persistence of 
BRD as a clinical problem may be the result of several factors, including new emerging viral and 
bacterial pathogens (Taylor et al., 2010). Antibiotics  provide a helpful therapeutic approach for 
the control of the bacterial component of BRD, both as metaphylactic and therapeutic treatments 
(Ball et al., 2019). However, societal pressure is increasing to reduce antibiotic usage due to 
increasing antibiotic resistance detected in bovine respiratory pathogens (Stanford et al., 2020). 
The suggestion has been made that a more effective strategy to control BRD may be to develop 
therapies which better control host responses to BRD pathogens (Miles, 2009), especially since 
many of the respiratory bacterial pathogens are part of the normal upper respiratory tract 
microbiota of cattle (Lima et al., 2016; Klima et al., 2019). 
The association between BRD and stressful events such as transportation and weaning 
has been well defined, hence the moniker “shipping fever” (Taylor et al., 2010; Hodgson et al., 
2012). However, how stress increases vulnerability to infection and death from BRD is less well 
defined. Some of the adverse effects of cortisol, of the hypothalamic-pituitary-adrenal (HPA) 
axis, on host immune responses have been explored (Kadmiel and Cidlowski, 2013; Earley, 
Buckham, Sporer and Gupta, 2017). However, there has been- less exploration of the impact of 
the sympathetic-adrenal-medullary (SAM) axis, which produces epinephrine (E) and 
norepinephrine (NE). Both E and NE may bind to 9 different adrenergic receptors (ARs), which 
in turn stimulate individual but overlapping biochemical pathways (Elenkov et al., 2000; Lorton 
and Bellinger, 2015; Schena and Caplan, 2019; BioRad.com, 2020a, 2020c, 2020b) (Table 3.1, 
Table 3.2, Table 3.3).  
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The 9 ARs are important drug targets in humans and animals. Targeting individual 
subtypes of these receptors has led to therapeutics for a great number of conditions including 
asthma, anaphylaxis, ADHD, heart conditions, and glaucoma (Barnes, 1993; Kemp et al., 2008; 
Giovannitti, Thoms and Crawford, 2015; Noguchi et al., 2015; Farzam and Lakhkar, 2019a; 
Ueda et al., 2020). Targeting the β2-AR subtype is also routinely used to increase lean muscle 
mass in cattle (Lean, Thompson and Dunshea, 2014; Loneragan, Thomson and Scott, 2014; 
Thomson et al., 2015; Buntyn et al., 2016; Frese et al., 2016). 
The ARs on bovine immune cells have received minimal attention. Exploration of the 
impact of these receptors on immune function during BRD also remains poorly defined but could 
yield important biological insights. These insights may reveal mechanisms by which stress 
increases vulnerability to respiratory disease and guide the discovery of effective 
immunotherapeutics to prevent BRD. Furthermore, exploration of the interactions between 
stress, ARs, and BRD may provide an important model for human medicine. There is already 
evidence that immunotherapy in the form of adrenergic drugs can reduce BRD morbidity when 
used as a prophylactic. A study in the 1980s in Czechoslovakia indicated that pre-treatment of 
calves with a drug that blocks β-adrenergic receptors reduced -BRD illness by approximately 
half (Rašková et al., 1987). Minimal follow-up on this study has been completed, and further 
research on the impact of adrenergic receptors on the bovine immune system holds promise for 






2.0  RESEARCH HYPOTHESES AND OBJECTIVES  
For the purpose of my research project, I addressed the following hypotheses by asking 
specific questions and used several methods to validate my results: 
1. Hypothesis: Differences in adrenergic receptor subtype expression occur among 
bovine blood leukocyte subpopulations with dominant expression of the β2-AR gene. 
o Determine which ARs are expressed on individual high-speed cell sorted bovine 
blood leukocytes lineages using Real-time RT-qPCR 
2. Hypothesis: Adrenergic receptor gene expression in blood leukocytes will be altered 
following the stress of maternal separation and transportation.  
o Quantify AR gene expression in blood leukocytes using real-time RT-qPCR 
analysis and compare AR gene expression in suckling calves versus calves 
subjected to maternal separation, with or without transportation 
3. Hypothesis: Adrenergic receptor agonists will suppress activation of stimulated 
neutrophils and eosinophils but have no effect on resting neutrophils and eosinophils. 
Furthermore, these two PMN subpopulations will differ in their responses to 
adrenergic agonists.   
o Use endogenous and synthetic AR agonists and flow cytometry to quantitatively 
analyze a variety of ex vivo cellular responses by both resting and activated 







3.0  LITERATURE REVIEW 
3.1 Stress: HPA vs. SAM axis 
Psychological stress in the body works through two axes: the hypothalamic-pituitary-
adrenal (HPA) axis and the sympathetic-adrenal-medullary (SAM) axis (Thornton and Andersen, 
2006). Stimulation of the HPA axis leads to the release of cortisol from the adrenal cortex. 
Stimulation of the SAM axis leads to the release of catecholamines from the adrenal medulla. 
These catecholamines include the neurotransmitters epinephrine (E), norepinephrine (NE), and 
dopamine (Thornton and Andersen, 2006; William Tank and Lee Wong, 2014). For the purposes 
of my project, I will be focusing on E and NE and their effects on bovine immune cells. 
Epinephrine is synthesized from NE by the enzyme phenylethanolamine n-methyltransferase, 
and NE is synthesized from dopamine by the enzyme dopamine β-hydroxylase (Végh et al., 
2016). Both these enzymes are abundant in the adrenal medulla (Rush and Geffen, 1980; Ziegler 
et al., 2002) but minimal evidence exists for significant expression of these enzymes in immune 
cells (Levite, 2012). 
3.2 Bovine Respiratory Disease, Neutrophils, and Stress 
Bovine Respiratory Disease (BRD) is a major health problem in the beef industry, 
compromising 40-50% of the industry’s infectious disease mortality (Edwards, 2010). This 
results in significant economic losses. BRD is associated with several primary viral infections, 
such as Bovine-Herpesvirus 1 (BHV-1), and several different secondary bacterial infections, 
such as Mannheimia haemolytica (M. haemolytica). Secondary bacterial infections frequently 
cause a necrotizing pro-inflammatory response in the lung that is dependent upon neutrophil 
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recruitment to the lung (McGuire and Babiuk, 1984; Slocombe et al., 1985; Breider et al., 1988; 
Caswell et al., 1998; Li et al., 2002). 
The greatest BRD morbidity and mortality commonly occurs following maternal 
separation (weaning) and transportation of 5-6 month old beef calves (Mormede et al., 1982; 
Chirase et al., 2004; Aich, Potter and Griebel, 2009; Edwards, 2010; Taylor et al., 2010). This 
increased BRD incidence has been associated with stress-induced changes in immune function 
which increases mortality following a combined viral and bacterial respiratory infection 
(Hodgson et al., 2012). Since BRD represents a disease complex involving multiple viruses and 
bacteria, stress-induced changes in immune function may represent an important therapeutic 
target for reducing BRD morbidity and mortality. 
3.3 Eosinophils in Respiratory Diseases of Cattle  
Atypical interstitial pneumonia (AIP) occasionally occurs in cattle. This condition is 
characterized by emphysema and diffuse edema in the lung (Doster, 2010). Eosinophilia in the 
lung is occasionally but unreliably associated with AIP. Some potential causes include exposure 
to L-tryptophan, 4-ipomeanol, perilla ketone (from purple mint), turnip, rape, or kale tops, or 
sweet potatoes that have gone moldy. In some cases, bacterial or viral infections may also 
contribute to AIP. However, AIP has not been associated with an allergic reaction (Doster, 
2010). In Europe, this condition is also called “fog fever”, and is often observed after cattle begin 
grazing pastures with lush regrowth of grass following hay cutting in moist “fog lands” (Doster, 
2010). AIP is a condition still being researched and investigated to better define etiology. 
Certain parasites have also been shown to elicit respiratory distress in cattle, provoking 
an eosinophil response in the lung. Infection with the bovine lungworm, Dictyocaulus 
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viviparous, often creates severe respiratory illness and interstitial pneumonia in cattle, raising 
both lung and blood eosinophil counts. Eosinophil activity in the lung has also been found to 
contribute to the pathogenesis of the disease (Gånheim, Höglund and Waller, 2004; Glasgow, 
2019). Migrating larvae of both Ascaris suum and Ascaris lumbricoides, which also commonly 
infect pigs and humans, have also been found to cause interstitial pneumonia in cattle. 
Eosinophils may also contribute to the pathogenesis of the lung reaction to these parasites as 
well. (Doster, 2010; Shapiro, Peregrine and Caswell, 2017). Thus, eosinophils can also be 
involved in bovine respiratory diseases. 
3.4 Adrenergic Receptors and Stress 
Numerous studies have shown that cortisol, of the HPA axis, has a range of 
immunosuppressive effects on immune cells (Kadmiel and Cidlowski, 2013). However, research 
on E and NE, of the sympathetic nervous system (SNS), has produced conflicting results, with 
either inhibition (Elenkov et al., 2000; Trabold, Gruber and Fröhlich, 2007; Gosain, Gamelli and 
DiPietro, 2009a; Scanzano et al., 2015; Margaryan et al., 2017) or enhancement of immune 
responses (Elenkov et al., 1995; Kim et al., 2014; Margaryan et al., 2017). I hypothesized that 
the stress hormones E and NE may alter the function of bovine immune cells in ways that may 
contribute to the increased susceptibility to fatal respiratory disease observed following maternal 
separation and transportation of suckling beef calves. However, there is very little information 
regarding the expression of ARs on bovine immune cells and this lack of knowledge makes it 
difficult to postulate how stress may alter bovine immune function. 
 Adrenergic receptors bind E and NE, and each receptor can mediate unique cellular 
responses. For example, ARs are expressed by myocardial cells in the heart and binding of 
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circulating E and NE facilitates increased contractility in response to stress. ARs are also 
expressed in adipose tissue to promote lipolysis and release of sugar into the bloodstream upon 
binding of catecholamines (Taylor, 2007; Alhayek and Preuss, 2018). ARs are also expressed on 
immune cells but their function may vary depending on the specific type of immune cell and the 
AR subtype expressed by the cell. There has been limited characterization of AR expression by 
bovine immune cells (LaBranche, Ehrich and Eyre, 2010). Furthermore, gaps remain as well in 
our understanding of AR expression and function in human immune cells. For example, α-AR 
expression has not been determined for human eosinophils. Thus, further research is required to 
determine the role ARs play in regulating immune cell function in many different species. 
In cattle, a drug known to block β-AR signaling, metipranolol, was shown to reduce BRD 
by ~50% in 1-2 week old weaned and transported calves (Raškova et al., 1987). Thus, insight 
into the effects of ARs on bovine immune cell function may provide important insights into new 
strategies for BRD prevention. Furthermore, drugs which influence AR signaling may provide an 
effective intervention that reduces industry reliance on antimicrobials.  
3.5 Adrenergic Receptor Expression and Function 
The ARs serve important functions in facilitating cellular responses to stress in many 
different organs (Table 3.1, Table 3.2, Table 3.3). Interestingly, these receptors are also 
expressed on immune cells. Here, their function is complex, and varies depending on the type of 
immune cell and the type of AR expressed (Table 3.4, Table 3.5, Table 3.6). Differential 
expression of ARs on different cell types may provide clues as to a cell’s response to stress 
(Lorton and Bellinger, 2015). Thus, the study of ARs on bovine immune cells may provide 




3.5.1 α1-Adrenergic Receptors: Expression and Function in Non-Lymphoid Tissues 
The three α1-ARs are encoded by the ADRA1A, ADRA1B, and ADRA1D genes. α1-ARs 
are coupled to the Gq or G11 proteins which stimulate Phospholipase C, occasionally 
Phospholipase A2 (Piascik and Perez, 2001; Chew and Ong, 2016), the L-type calcium channel, 
and protein kinase C (Barnes, 1993; Lorton and Bellinger, 2015; BioRad.com, 2020a, 2020c) 
(Table 3.1). Ultimately, this signaling leads to stimulation of the extracellular signal-regulated 
protein kinases 1 and 2 (ERK1/2) (BioRad.com, 2020a, 2020c). Human α1-ARs are expressed at 
high levels in the heart, brain, and smooth muscle such as that found in the urinary tract 
(Kavelaars, 2002; Uberti, Hall and Minneman, 2003; Karabacak et al., 2013). The α1A- and 
α1D-ARs are highly expressed in the human brain, urinary tract, and blood vessels (Karabacak et 
al., 2013; Scanzano and Cosentino, 2015).  The α1A-ARs tend to localize to renal and caudal 
arterial smooth muscle, and are involved in regulating blood pressure (Piascik and Perez, 2001). 
The α1B-AR has a particularly high expression in the human spleen and is also highly expressed 
in the human kidney (Perez, 2006). These receptors do not regulate blood pressure (Piascik and 
Perez, 2001). Similar to α1A-ARs, α1D-ARs are also highly expressed in the human brain, 
urinary tract, and blood vessels (Karabacak et al., 2013; Scanzano and Cosentino, 2015). 
However, the α1D-ARs tend to localize to the aorta and iliac, femoral and superior mesenteric 
arteries, also regulating blood pressure (Piascik and Perez, 2001). Thus, despite similarities 
among the α1-AR subtypes, they are differentially expressed and play distinct roles in different 
tissues. 
3.5.2 α1-Adrenergic Receptors: Expression and Function on Immune Cells 
The α1-ARs, when stimulated, have primarily a pro-inflammatory effect within the 
immune system (Grisanti et al., 2011) (Table 3.4). For example, pre-treatment of mice with 
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prazosin, an α1-AR antagonist, was associated with reduced TNFα production following LPS 
injection (Sugino et al., 2009). It has also been observed that an LPS treated human monocyte 
cell line increased IL-1β secretion when exposed to phenylephrine, an α1-AR agonist (Grisanti, 
Perez and Porter, 2011). Increased complement component C2 synthesis in human monocytes 
was also observed following phenylephrine stimulation. This effect was reversed by the α1-AR 
antagonist prazosin (Grisanti, Perez and Porter, 2011). Expression of α1-ARs has been detected 
during early human leukocyte development in the bone marrow and thymus. Following 
maturation and leukocyte entry into blood, α1B-AR expression tends to disappear from human 
leukocytes. For instance, dendritic cells (DCs) down-regulate α1B-AR expression as they mature 
(Kavelaars, 2002). Functional α1-ARs have, however, been identified on lymphocytes and most 
innate immune cells (Barnes, Carson and Nair, 2015; Scanzano and Cosentino, 2015). The α1-
ARs primarily bind NE (Barnes, Carson and Nair, 2015) and the effects of α1-ARs on immune 
cell function warrants further investigation. 
3.5.3 α2-Adrenergic Receptors: Expression and Function in Non-Lymphoid Tissues 
The three α2-ARs are encoded by the ADRA2A, ADRA2B, and ADRA2C genes. The α2-
ARs are coupled to the Gi or Go proteins, which inhibit adenylyl cyclase and consequently inhibit 
Protein Kinase A but stimulate Phospholipase C, activating intracellular calcium release 
(Scanzano and Cosentino, 2015; BioRad.com, 2020b) (Table 3.2). Ultimately, α2-AR signaling 
leads to stimulation of the ERK1/2 pathway (BioRad.com, 2020b). The α2-ARs primarily bind 
E, but can also bind NE (Barnes, Carson and Nair, 2015; Lorton and Bellinger, 2015). The α2-
ARs are highly expressed in brain, renal epithelial cells, and skin arteriole or vein smooth muscle 
cells (Saunders and Limbird, 1999). The α2A-ARs are also highly expressed in the rat brain 
stem, human spleen, and human kidney (Saunders and Limbird, 1999; Scanzano and Cosentino, 
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2015). Expression of the α2A-AR has also been reported for the bovine retina and brain 
(Venkataraman, Duda and Sharma, 1997; Inderwies et al., 2003). In humans, α2B-AR transcript 
has been studied, and demonstrated to have high expression in the kidney and liver (Perez, 
2006). Transcript for the α2C-AR is also highly expressed in the human brain and kidney 
(American Society of Anesthesiologists. et al., 1994; Scanzano and Cosentino, 2015) and in the 
brain is localized to the midbrain and thalamus (Saunders and Limbird, 1999). The α2-ARs play 
important roles in neuron differentiation and function. The α2B-ARs induce a short term, salt-
induced, vasoconstrictive hypertensive response, and α2A- and α2C-ARs can induce longer term 
systemic hypotension through an inhibition of sympathetic outflow and NE release (Philipp, 
Brede and Hein, 2002). Consequently, drugs which stimulate α2-ARs are commonly used as 
sedatives in humans (ex: dexmedetomidine) and animals (ex: xylazine) (Amouzadeh, 1991; 
Giovannitti, Thoms and Crawford, 2015; Wang et al., 2019a). Further study of α2-ARs in other 
cell types may reveal additional biological effects. 
3.5.4 α2-Adrenergic Receptors: Expression and Function on Immune Cells 
Stimulation of α2A-ARs has a variety of effects on immune cells (Table 3.5). The α2A-
ARs primarily bind E but can also bind NE (Barnes, Carson and Nair, 2015; Lorton and 
Bellinger, 2015). Human PMNs exposed to Escherichia coli. ex vivo decrease nitric oxide and 
nitric oxide synthase production when treated with dexmedetomidine (α2-AR agonist) (Chen et 
al., 2016). Clonidine, another α2-AR agonist, inhibited influenza virus replication both in vitro 
and in mice (Matsui et al., 2018). Given that drugs which stimulate α2A-ARs are commonly 
used as sedatives in humans, exploration of their impacts on the immune system is now being 
further explored. For instance, a systematic literature review and meta-analysis of stress and 
immune effects of dexmedetomidine on humans was recently completed. Correlations between 
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administration of dexmedetomidine as an anaesthetic and an inhibition of E, NE, cortisol, and 
blood glucose were observed. These physiological changes may contribute to the sedative effect. 
Dexmedetomidine was also associated with an anti-inflammatory state. This state included 
decreased release of TNFα, IL-6, C-reactive protein, and increased IL-10 production. Changes in 
blood leukocyte populations were also noted. These changes included increased numbers of B 
cells, NK cells and CD4 T cells but decreased numbers of CD8 T cells circulating in blood 
(Wang et al., 2019a). It is important to note that the effects associated with dexmedetomidine 
may reflect a direct interaction with immune cells or an indirect effect, possibly through an 
inhibition of stress hormones such as NE (Philipp, Brede and Hein, 2002). Human PMNs have 
been observed to express mRNA for the α2A and α2C-AR but not for the α2B-AR (Scanzano et 
al., 2015). It is clear from these studies that α2-ARs impacts on the immune system, either direct 
or indirect, warrant further exploration.  
3.5.5 β-Adrenergic Receptors: Expression and Function in Non-Lymphoid Tissues 
The three β-ARs are encoded by the ADRB1, ADRB2, and ADRB3 genes. These receptors 
are usually coupled to the Gs proteins, stimulating adenylate cyclase, producing cyclic AMP 
(cAMP) and stimulating protein kinase A (PKA) (Elenkov et al., 2000; Lorton and Bellinger, 
2015; Scanzano and Cosentino, 2015) (Table 3.3). Occasionally, β-ARs can couple with the Gi 
protein, consequently inhibiting this same signaling pathway. β2-ARs primarily bind E but β1-
ARs and β3-ARs can bind both E and NE with a greater affinity for E (Barnes, Carson and Nair, 
2015; Scanzano and Cosentino, 2015). A high level of β1-AR expression is routinely observed in 
human heart while high levels of β2-AR expression are observed on the smooth muscle of 
bronchioles (Taylor and Bristow, 2004; Cazzola, Calzetta and Matera, 2011). The β3-AR is 
abundant in human adipose tissue (Larsen et al., 2002; Scanzano and Cosentino, 2015). Bovine 
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β-AR transcript has been observed in 12 tissues, including muscle, subcutaneous fat, heart, liver, 
lung, kidney, large and small intestine, omasum, reticulum, and rumen, and spleen (Mei et al., 
2018). Transcript has also been detected in the bovine mammary gland (Inderwies et al., 2003). 
Although β- and α-ARs are relatively well-conserved among vertebrate species, their 
distribution and primary function can vary (Zavala et al. 2017; Mei et al. 2018; Taylor and 
Bristow 2004; LaBranche, Ehrich and Eyre 2010). For instance, β3-AR predominates in human 
adipose tissue and is associated with lipolysis (Taylor and Bristow, 2004) but primarily β2-AR is 
observed in bovine adipose tissue (Mei et al., 2018). Thus, species-specific neuromodulation of 
immune cell function may become apparent when investigating the distribution and modulation 
of ARs within bovine immune cells. Overall, there has been limited study of AR expression and 
function in cattle, particularly on immune cells (Labranche, 2005; Mei et al., 2018). 
3.5.6 β-Adrenergic Receptors: Expression and Function on Immune Cells 
The β-ARs are expressed on a wide range of human immune cells. Maisel et al. (1990) 
reported β-AR abundance with a decreasing order of NK cells > CD14 monocytes > CD8 T cells 
> B cells > CD4 T cells. Among the β-ARs, β2-AR is often expressed at the highest level on 
human immune cells, particularly ILCs and lymphocytes (Maisel et al., 1990; Lorton and 
Bellinger, 2015). Expression of β1- and β2-ARs, was detected with the radiolabeled antagonist 
CGP-12177 and was similar on leukocytes from male and female cattle. Bovine PBMCs also 
expressed a higher level of these receptors relative to bovine PMNs (Labranche, Ehrich and 
Eyre, 2010). 
Ligand binding by β-ARs, such as the β2-AR expressed on immune cells, appears to 
primarily suppress cell responses (Gu and Seidel, 1996; Lamas, Martínez and Marti, 2003; 
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Emeny, Gao and Lawrence, 2007; Grisanti et al., 2010; LaBranche, Ehrich and Eyre, 2010; 
Lorton and Bellinger, 2015) (Table 3.6). For example, Gu and Seidel (1996) observed decreased 
production of TNFα and reactive oxygen species (ROS) following treatment of bovine alveolar 
macrophages and differentiated human macrophages with salbutamol (β2-AR agonist) and 
isoproterenol (non-selective β-AR agonist) prior to stimulation with lipopolysaccharide (LPS) 
and zymosan, respectively. This is consistent with studies using human and murine monocytes 
and macrophages, which reported decreased release of the pro-inflammatory mediators TNFα, 
IL-12, and nitric oxide (NO), following isoproterenol (β-AR agonist) stimulation (Szelenyi et al., 
2006a). Of interest, Verhoeckx et al. (2005) demonstrated that following LPS injection into rats, 
zilpaterol, a β2-AR agonist commonly used to increase muscle mass in steers and heifers 
(Buntyn et al., 2016), reduced TNFα production. This was validated both in vivo and in vitro 
(Verhoeckx et al., 2006). Labranche et al. (2010) demonstrated induction of cAMP and 
decreased ROS production following stimulation of β-ARs on bovine PMNs (LaBranche, Ehrich 
and Eyre, 2010). The β-ARs remain the best studied group of ARs in immune cells, including 










Table 3.1: Signaling pathways used by individual α1-ARs. 
*associated with transglutaminase 2  (BioRad.com, 2020a)     
1. PLC = Phospholipase C    
2. PLA2 = Phospholipase A2 
3. IP3 = Inositol 1,4,5 triphosphate (product of processing of phosphatidylinositol-4,5-
biphosphate) 
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Table 3.2: Signaling pathways used by individual α2-ARs. 
1. PLC = Phospholipase C    
2. IP3 = Inositol 1,4,5 triphosphate (product of processing of phosphatidylinositol-4,5-
biphosphate) 
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Renal and caudal arterial 
smooth muscle contraction 
(Piascik and Perez, 2001), 
hypertrophic growth of 
neonatal cardiomyocytes 
(Piascik and Perez, 2001), 
smooth muscle 





synthesis on monocytes 
(Grisanti, Perez and Porter, 
2011), 
 
Increase in IL-1β secretion 
from LPS treated monocytes 
(Grisanti, Perez and Porter, 
2011), 
 
Increase of histamine release 
in murine mast cells (Moroni 
et al., 1977),  
 
Increased systemic levels of 
IL-10 in LPS treated animals 
(Dong et al., 2002; Sugino et 
al., 2009) 
 
Increases in dendritic cell 
differentiation and migration 
(Maestroni, 2000) 
Murine Arterial smooth 
muscle 
Human and other 
species’ cardiomyocytes 
Human Monocytes 
Murine Dendritic cells 
Murine Mast cells 
Human PBMCs 
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Hypertrophic growth of 
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in rats, 
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of aorta and femoral, iliac, 
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Brede and Hein, 2002) 
 
Inhibits murine langerhan cell 
migration (Maestroni, 2000), 
 
Induces resistance to 
Mycobacterium avium in 
mouse macrophages by 
increasing peroxynitrite 
production (Weatherby, 
Zwilling and Lafuse, 2003), 
 
Inhibits influenza virus 
replication in mice (Matsui et 
al., 2018) ,  
 
Inhibits blood levels of 
inflammatory cytokines such 
TNFα, IL-6. Increases 
numbers of cell groups such 
as NK cells, B cells, CD8 T 
cells (Wang et al., 2019b), 
 
Inhibits systemic levels of 
cytokines in humans such as 
eotaxin, interleukin-18, 
interleukin-2Rα, stem cell 
factor, stem cell growth factor 
and vascular endothelial 
growth factor (Kallioinen et 
al., 2019), 
 
Decreased nitric oxide and 
nitric oxide synthase release 
in E. coli treated human 
PMNs (Chen et al., 2016) 
 
Murine Neurons 
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Increases heart rate (Taylor, 
2007), (Alhayek and Preuss, 
2018), decreases plasma renin 
and increases renal vascular 
resistance (Bakris, Hart and Ritz, 
2006), thermogenesis and 
lipolysis in adipocytes (Soloveva 
et al., 1997) (Casteilla et al., 
1994) 
Increased IL-1β production in 
LPS-stimulated human monocytes 
(Grisanti et al., 2010), 
Increases TNFα in LPS treated 
mice (Elenkov et al., 1995),  
impairs cell mediated response to 
Listeria in mice (Emeny, Gao and 
Lawrence, 2007) 










Relaxes bronchial smooth muscle 
(Barnes, 1993; Grove, McFarlane 
and Lipworth, 1995; Cazzola, 
Calzetta and Matera, 2011), 
Increases glycogenolysis and 
gluconeogenesis (Erraji-
Benchekroun et al., 2005), 
Increases lean muscle mass in 
cattle and humans, particularly 
fast twitch muscles. Non-steroidal 
anabolic drugs  (Sato et al., 
2011), Increases systolic arterial 
blood pressure (Du et al., 2000) 
 
Gs coupled transduction generally 
immunosuppressive, inhibits NF-
κB signalling. β2-AR can 
desensitize with chronic 
stimulation leading to systemic 
inflammation (Elenkov et al., 
2000; Lorton and Bellinger, 2015) 
decreases TNFα, ROS release 
from bovine macrophages (Gu and 
Seidel, 1996), 
inhibits NETosis in human 
neutrophils (Marino et al., 2018),  
inhibits ROS production in bovine 





Mouse Heart cells 










Lipolysis, thermogenesis (Lowell 
and Flier, 1997; Moreno-Aliaga 
et al., 2002; Schena and Caplan, 
2019), increased bladder capacity 
(relaxes detrusor smooth muscle). 
Minimal cardiovascular effects 
(Sacco and Bientinesi, 2012; Di 
Salvo et al., 2017), retinal cell 
growth and migration (Schena 
and Caplan, 2019), Increased (Gs) 
or decreased (Gi) heart 
contractility (Schena and Caplan, 
2019) 
Increases CD4+ lymphocytes in 
mouse spleen (Lamas, Martínez 
and Marti, 2003) 
 
Inhibit ROS production in human 







Rat Bladder  




1A lack of drugs and antibodies with α1-AR subtype and α2-AR subtype selectivity has limited 
research in this area. However, a number of drugs target either α1-AR or α2-ARs. 




3.6 Adrenergic Receptor Gene Organization, Regulation, and Cross-Regulation 
 Genes for the nine bovine ARs are distributed across many different chromosomes and do 
not share a common promoter (National Center for Biotechnology Information, 2021). However, 
stress hormones can regulate AR gene expression. Hadcock, Wang and Malbon (1989) observed 
dexamethasone, a synthetic glucocorticoid receptor agonist, upregulated ADRB2 transcription. 
Furthermore, they observed β-AR agonists could destabilize β-AR mRNA. In combination, 
glucocorticoids and β-AR agonists were shown to counteract each other’s effects on ADRB2 
transcription. In 1993, Hadcock and Malbon, in a literature review, noted AR cross-regulation 
could occur. For example, increases in cellular cAMP stimulated by β-AR activity could increase 
the expression of α2A- and α1-AR mRNA. It was observed by Sakaue and Hoffman (1991) that 
an element promoting responsiveness to cAMP was located in the ADRA2A gene’s promoter 
region. This was later identified as the cAMP response element or CRE, and is also present in the 
ADRB2 gene (Hadcock and Malbon, 1993). More research has identified a glucocorticoid 
response element, or GRE, in the noncoding 5’ region of the ADRB2 gene (Hadcock and 
Malbon, 1993). In 1994, Kiely et al. observed that dexamethasone downregulated ADRB1 
mRNA and upregulated ADRB2 mRNA. They observed that both genes have a GRE. In 
monocytes, it has been observed that both glucocorticoids and β2-agonists up-regulate ADRA1B 
and ADRA1D mRNA but not ADRA1A mRNA (Kavelaars, 2002). Thus, both glucocorticoids 






3.7 Adrenergic Receptor Modulation of Granulocyte Responses  
3.7.1 Human and Murine Neutrophils  
Several studies have analyzed the in vitro and in vivo effects of adrenergic drugs on 
human and murine neutrophils. Trabold, Gruber and Fröhlich (2007) examined neutrophil 
responses to E and NE using fMLP stimulated whole blood cultures. Neutrophils were identified 
through flow cytometric gating on cell size and esterase activity. They observed that E and NE 
prevented fMLP-induced increases in CD11b expression and decreases in cell surface L-selectin. 
In 2009, Gosain, Gamelli and DiPietro examined the effect of NE on neutrophil recruitment to 
wounds created in mice. They collected leukocytes retained by sponges placed in the wound and 
used flow cytometric gating to identify neutrophils. They observed that pharmacological doses of 
NE reduced phagocytosis of fluorescent E. coli by neutrophils isolated from wounds 5 days after 
treatment. Both α- and β-ARs were observed to contribute to this effect. Thus, there is evidence 
that E and NE can modulate both adhesion molecule expression and phagocytosis by neutrophils. 
Further studies demonstrated that E can influence PMN trafficking to wounds and that 
adrenergic drugs can influence multiple aspects of PMN function. In 2014, Kim et al. examined 
the effect of E on immune cell involvement in wound healing in transgenic eGFP-lys mice. In 
eGFP-lys mice, greater than 95% of eGFP High cells are PMNs. Treatment with E doubled the 
number of Ly6C+/CD11b+ PMNs in mouse wounds, slowing wound repair. PMN trafficking 
was primarily mediated by the pro-inflammatory action of β2-ARs on macrophages and IL-6 was 
an important mediator of this effect. In 2015, Scanzano et al. tested the effects of E and NE on 
isolated human PMNs. They observed that E, NE, and the β2-AR agonist isoproterenol reduced 
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the fMLP stimulated ROS response, reduced cell migration, and decreased expression of 
CD11b/CD18. Resting PMNs did not respond to adrenergic drugs. The β-AR played an 
important role in mediating the changes in ROS production. However, transcripts for all ARs, 
except α2B, were detected in human PMNs. When PMNs were stimulated with fMLP, β-AR 
transcript expression was observed to increase. The β-ARs appeared to a play an important role 
in modulating PMN function in these studies. 
The role of adrenergic drugs in modulating different aspects of PMN function, including 
cytokine production and neutrophil NET formation, was also examined. Margaryan et al. in 2017 
used flow cytometry to specifically analyze human PMNs in whole blood cultures. 
Pharmacological concentrations of E had a slight pro-inflammatory effect (increased CD11b and 
IL-8) in resting PMNs. In contrast, E had an immunosuppressive effect (decreased CD11b and 
CD18, IL-8, IL-1β, and MCP-1) in LPS-stimulated PMNs. Marino et al. (2018) studied in greater 
detail the function of β-ARs in human PMNs. They observed that stimulation of β2-ARs 
inhibited neutrophil extracellular trap (NET) formation in human neutrophils. This response was 
measured by ROS and elastase production, and light and fluorescent microscopic evaluation. 
Activation of the β2-AR also inhibited PMN migration, as measured with a Boyden chamber 
assay. PMN inhibition by β2-AR agonists was most evident when cells were stimulated with 
LPS, fMLP, or IL-8. Taken together, there is increasing evidence that ARs, particularly β-ARs, 
play an important role in modulating PMN function. 
3.7.2 Human and Murine Eosinophils  
Several studies have examined the effect of adrenergic drugs on human and murine 
eosinophils as well. Humphreys and Raab (1950) demonstrated that epinephrine injection into 
humans caused a 61% decrease in blood eosinophils. Norepinephrine was also tested, but only 
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caused a 10% reduction in blood eosinophils. Collection of blood samples from medical students 
revealed a similar decrease (48%) in blood eosinophils prior to exams, suggesting this was part 
of a stress response. Koch Weser (1968) reported a similar 62% decrease in circulating blood 
eosinophils following epinephrine injection and this effect was blocked with propranolol, a β-AR 
antagonist. By itself, propranolol caused a 27.8% increase in blood eosinophils. Furthermore, α-
adrenergic blockers were unable to prevent the eosinopenia caused by epinephrine. Collectively, 
these results support the conclusion that the eosinopenia induced by epinephrine was mediated 
by β-ARs.  
Research on AR function in eosinophils has been limited primarily to their role in 
asthma. Treatment of asthma often includes the use of inhaled β2-agonists, and eosinophils are 
considered an important element of the asthmatic response (Noguchi et al., 2015). For example, 
in the interest of exploring a possible relationship between β2-ARs, eosinophils, and asthma, 
Yukawa et al. (1990) used radioligand binding to quantify β2-ARs on both human and guinea 
pig eosinophils. Eosinophils were isolated from patients with eosinophilia using Percoll 
gradients, achieving 80% or greater purity. Compared to neutrophils, the eosinophils appeared to 
have a higher density of β2 receptors (4300 receptors/eosinophil as compared to 900-
1800/neutrophil). Eosinophils also had higher affinity β2 receptors (as measured with 
salbutamol) than neutrophils (Kd ~28.7 pM for eosinophils compared to Kd ~1nM for 
neutrophils). Eosinophils were stimulated with opsonized zymosan or phorbol myristate acetate 
(PMA) and both stimuli elicited a superoxide anion and peroxidase response. However, exposure 
to salbutamol (albuterol), a β2 adrenergic agonist, failed to modify this reaction. A cAMP 
response was, however, elicited indicating β2-ARs were functional on human eosinophils 
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(Yukawa et al., 1990). Thus, the role of β2-ARs on eosinophils and their potential relationship to 
asthma is still being investigated. 
Bates et al. (1994) reported that blood epinephrine levels and eosinophil counts were 
significant predictors of nocturnal asthma. Normally, blood epinephrine levels begin decreasing 
in the late afternoon and are at their lowest concentration around 4 AM before increasing until 
wakefulness. It was observed that patients with lower than normal epinephrine levels around 4 
PM and 10 PM were at high risk of nocturnal asthma, and an episode often occurred around 4 
AM, when epinephrine was lowest. A higher blood eosinophil count over the course of 3 days 
was also predictive of nocturnal asthma in patients. However, the authors speculated eosinophilia 
may be representative of the overall level of inflammation in patients, rather than a mechanism 
mediating an episode of nocturnal asthma. An even more sensitive predictor of nocturnal asthma 
was the blood eosinophil to epinephrine ratio. Cortisol was measured, and also displayed 
standard rhythm. However, cortisol concentration did not correlate significantly with nocturnal 
asthma. Thus, the authors recommended that the eosinophil to epinephrine ratio be used as a 
sensitive predictor of nocturnal asthma episodes. 
Noguchi et al. (2015) also examined the function of β2-ARs on eosinophils enriched to 
98% purity with magnetic cell sorting. Purified eosinophils were stimulated with interleukin-5 
(IL-5), leukotriene D4 (LTD4) or IFNγ inducible protein of 10 kD (IP-10). Treatment with 
salbutamol, a standard β2-AR agonist, was found to not affect stimulated eosinophils. However, 
formoterol, a potent β2-AR agonist, altered multiple functions of activated eosinophils. This 
included suppression of eosinophil adhesion to ICAM-1 and suppression of both superoxide 
anion and eosinophil-derived neurotoxin production. Resting eosinophils demonstrated no 
detectable reaction to this agonist.  
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Kainuma et al. (2017) reported that when eosinophils and bronchial epithelial cells were 
co-cultured, bronchial epithelial cells transitioned to inflammatory mesenchymal cells, 
potentially contributing to fibrosis of the airway in asthma. These mesenchymal cells express a 
more pro-inflammatory phenotype. For example, they secrete greater levels of the Th17 cytokine 
transforming growth factor β1 (TGFβ1) and granulocyte-macrophage-colony stimulating factor 
(GM-CSF). Exposure of eosinophils to a β2-AR agonist (procaterol) prior to co-culture with 
bronchial epithelial cells prevented this epithelial cell transition effect. 
Few studies have analyzed -AR expression or function in eosinophils (Scanzano and 
Cosentino, 2015). Liu et al. (2020) analyzed eosinophils isolated from the conjunctiva of mice 
following exposure to the short ragweed allergen. Murine conjunctival eosinophils were 
confirmed to express transcript for the α1A-AR gene ADRA1A, but transcript for all other ARs 
was undetectable. Restraint stress significantly increased blood NE levels and eosinophil 
recruitment to the conjunctiva. The use of α1A-AR agonists A 61603 hydrobromide and 
tunsulosin hydrochloride helped confirm that the α1A-AR was responsible for increased 
eosinophil recruitment to the murine conjunctiva during restraint stress. 
3.7.4 Bovine PMNs 
There is also evidence that bovine PMNs express functional ARs. Labranche et al. (2005) 
used radioligand binding studies to confirm β1-AR and β2-AR expression on bovine PMNs and 
PBMCs. Functional β2-AR expression was confirmed using terbutaline, a β2-AR agonist, to 
inhibit ROS production by activated PMNs. There is evidence that adrenergic agonists modulate 
other aspects of bovine PMN function as well. Holroyde and Eyre (1976) demonstrated that the 
histamine response by allergen-sensitized bovine PMNs was increased with low concentrations 
(10-6 – 10-5 M) of β-AR agonist and decreased by a higher concentration (10-4-10-3 M) of an α1-
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AR agonist. To prepare sensitized bovine PMNs, 4–6-week-old calves were injected with horse 
plasma and PMNs were harvested from bovine blood and exposed to horse plasma antigen ex 
vivo to stimulate histamine release. The β-AR responsible for potentiating the histamine response 
at lower agonist concentrations was later demonstrated to be β1-AR (Perron and Eyre, 1982). 
They also reported a biphasic response to isoproterenol (β1- and β2-AR agonist) within a similar 
dose range. In other species, epinephrine and/or isoproterenol are known to have a suppressive 
effect on histamine release. New research is demonstrating that cell types such as neutrophils, 
not just basophils, can produce histamine (Xu et al., 2006; Smuda, Wechsler and Bryce, 2011). 
Thus, this research may confirm adrenergic modulation of several types of PMNs and bovine 
PMNs may be unique in their AR expression and function. 
A study by Raškova et al. (1987) indicated metipranolol, a β-AR antagonist, reduced 
BRD incidence by approximately 50%. This prompted a follow-up study to investigate possible 
mechanisms of action by β-AR antagonists. Given the important role of PMNs in BRD 
pathogenesis, Henricks et al. (1990) explored the effect of β-AR antagonists on bovine PMNs 
exposed to M. haemolytica, an important BRD pathogen. A key virulence factor for this 
bacterium is leukotoxin, a secreted protein which reduces the ROS response of bovine PMNs. 
The β-AR antagonists propranolol and alprenolol blocked inhibition of the ROS response 
induced by M. haemolytica leukotoxin. However, when β1- and β2-AR specific antagonists were 
evaluated neither reversed the decrease in ROS caused by leukotoxin. This may indicate that 
inhibition was mediated by the β3-AR. Thus, non-selective β-AR antagonists may block the 
suppressive immunomodulatory effects of ARs when bovine PMNs are exposed to M. 
haemolytica leukotoxin. These in vitro studies confirm that ARs may modulate the function of 
PMNs, which play an important role in BRD. Further, these data suggest one possible 
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mechanism by which an AR blocking agent may reduce the effect of stress on BRD (Raškova et 
al. 1987).  
Catecholamines have been shown to alter other aspects of bovine PMN function. Diez-
Fraile et al. (2000) examined the effect of several different adrenergic drugs on LPS induction of 
CD11b, a cell adhesion molecule, expression on bovine PMNs. L-Phenylephrine, an α1-AR 
agonist, had no effect on CD11b expression, while dexamethasone, a potent glucocorticoid 
receptor agonist, significantly decreased CD11b expression. Both isoproterenol, a β-AR agonist, 
and clenbuterol, a β2-AR agonist, decreased CD11b expression. A combination of 
dexamethasone and isoproterenol had a synergistic effect on decreasing CD11b expression. This 
study analyzed CD11b expression on bovine PMNs but whole blood was incubated with 
dexamethasone and AR agonists. Thus, the authors hypothesized that the LPS-induced increase 
in CD11b expression on PMNs may have been caused indirectly by TNFα released from LPS-
stimulated monocytes. This hypothesis was supported by the observation that adding TNFα by 
itself to blood samples increased CD11b expression on PMNs. Thus, the direct effect of 
adrenergic drugs on bovine neutrophils and eosinophils remains unknown. 
Collectively these studies provide evidence that bovine PMNs express functional ARs, 
including β1-AR, β2-AR, and possibly α1-ARs, and that individual ARs may mediate distinct 
PMN responses. However, there are several technical parameters that may impact the biological 
relevance of the reported observations. First, most analyses were performed using PMNs which 
consist of neutrophils, eosinophils and a minor population of basophils. It is not known if 
neutrophils and eosinophils, and basophils express the same ARs and if signaling by ARs is 
similar among these PMN subpopulations. Furthermore, all the cited studies, with the exception 
of LaBranche, Ehrich and Eyre (2005), conducted their experiments with cells incubated at 37°C. 
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LaBranche, Ehrich and Eyre (2005) were the only group to incubate PMNs at 39 °C, the normal 
body temperature of cattle. Many studies also used adrenergic agonists outside the normal 
physiological range for cattle (~15 to 150 nM; Buhler et al., 1978), as in the studies by 
LaBranche, Ehrich and Eyre (2005), Holroyde and Eyre (1976), and Diez-Fraile et al. (2000). 
Although these studies provide indications that bovine PMNs express functional ARs, there are 
limitations in the published data that leave substantial gaps in our knowledge regarding AR 
expression and function in bovine PMNs.   
3.7.5 Bovine Eosinophils  
 Few studies have addressed the effect of adrenergic drugs on bovine eosinophils. Based 
on the marked eosinopenia observed following E injection in humans, a similar study was 
performed with cattle (Alexander, 1958). However, no significant change in circulating 
eosinophils was observed following E injection in cattle. The injected E did have a biological 
effect, however, since there was a marked decrease in milk production. A similar failure to alter 
circulating eosinophils was also observed when E was injected into sheep (Zarrow et al., 1952) 
and horses (Alexander and Ash, 1955). However, injecting cattle with adrenocorticotropic 
hormone (ACTH), a potent inducer of cortisol release, reduced circulating eosinophils by more 
than 50%. A study analyzing the effects of transportation, also reported that transporting cattle 
over mountainous terrain reduced blood eosinophils. This effect may have been mediated by 
cortisol effect since a cortisolemia occurred  in the transported group (Ishizaki and Kariya, 
2010).  
3.8 Response of Bovine Neutrophils to Stress  
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Neutrophils can vary from 22 to 76% of the leukocytes present in normal bovine blood 
((George, Snipes and Lane, 2010) but their frequency can change rapidly during infection or 
stress. Short term increases in PMN number in blood are observed following abrupt weaning and 
transportation (Hickey, Drennan and Earley, 2003; Yagi et al., 2004; Ishizaki and Kariya, 2010; 
O’Loughlin et al., 2012). Ishizaki et al. (2010) observed a neutrophilia in cattle 4 hours after 
transportation over mountainous terrain, as well as an increase in the neutrophil to lymphocyte 
ratio. Yagi et al. (2004) observed neutrophilia at the end of a 4-hour transport that persisted 2 
hours later. They also noted a decrease in apoptotic PMNs, indicating an increase in immature 
PMNs from the marginated pool. O’Loughlin et al. (2012) recorded an increase in blood 
neutrophils one day after weaning suckling calves. Hickey et al. (2003) also noted a significant 
increase in blood neutrophils up to 3 days following weaning stress. Thus, both weaning and 
transport stress are known to alter neutrophil numbers in bovine blood. 
PMNs play an important role during BRD and previous literature implicates ARs as one 
mechanism that may influence the prevalence of respiratory disease (Raškova et al., 1987). 
However, modulation of bovine PMN function by adrenergic drugs remains an unexplored 
therapeutic approach to the control of infectious disease. PMNs play a key role in controlling 
bacterial and fungal infections (Roth and Kaeberle, 1981) but may also contribute to the immune 
pathology associated with respiratory infections in cattle (Slocombe et al., 1985; Li et al., 2002; 
Hodgson et al., 2012; Allen and Kurdowska, 2014). Given the important role of PMNs during 
BRD, and previous literature indicating that ARs play a role in BRD infection (Raškova et al., 
1987), modulation of bovine PMN function with adrenergic drugs appears worth further 
exploration.  
3.9 Measures of Neutrophil and Eosinophil Activation 
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There are numerous studies indicating adrenergic drugs modulate the responses of PMNs 
following activation with agents such LPS, fMLP, phorbol myristate acetate (PMA), or 
opsonized zymosan (Haskó et al., 1995a; Gu and Seidel, 1996; Szelenyi et al., 2006; Trabold, 
Gruber and Fröhlich, 2007; LaBranche, Ehrich and Eyre, 2010; Scanzano et al., 2015). There are 
fewer reports, however, indicating adrenergic drugs can alter the responses of resting PMNs 
(Margaryan et al., 2017). Thus, to analyze the effects of adrenergic drugs on bovine PMNs it is 
important to establish methods that consistently activate bovine PMNs and develop assays that 
quantitatively measure bovine neutrophil and eosinophil activation. The following sections 
review several methods used to measure activation in PMNs. 
3.9.1 Reactive Oxygen Species (ROS) 
The production of reactive oxygen species (ROS) is an important microbicidal response 
activated in neutrophils during inflammation. This begins with the intracellular generation of O2- 
superoxide anions by NADPH oxidase. These anions are converted by myeloperoxidase to 
hydrogen peroxide (H2O2) and H2O2 is further transformed by myeloperoxidase to a variety of 
secondary ROS. These include species such as hypochlorous acid, which is considered a 
particularly potent ROS. ROS are then directed towards microbes within PMN phagosomes. 
They can also be released extracellularly as part of DNA based Neutrophil Extracellular Traps 
(NETs) but excess production and release of ROS can cause tissue damage (Winterbourn, Kettle 
and Hampton, 2016; Villagra-Blanco et al., 2017). 
A comparison of human and bovine PMN responses to activation stimuli revealed bovine 
serum opsonized zymosan (BoZ) induced a broad range of activation responses in bovine PMNs, 
including a vigorous ROS response (Brown and Roth, 1991). For this reason, BoZ stimulation is 
frequently chosen as a strategy to “activate” bovine neutrophils. Un-opsonized zymosan 
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induction of ROS production in bovine PMNs is dependent on CD11b and Store Operated 
Calcium Entry (SOCE) (Conejeros et al., 2011). IgG2-Fc receptors have also been implicated in 
mediating the additional PMN activation caused by serum opsonization of zymosan (L. Leino 
and Paape, 1993).  
Combining recombinant bovine interferon gamma (rBoIFNγ) with BoZ was found to 
further increase the ROS response in bovine PMNs (Sample and Czuprynski, 1990). In my 
studies, it was observed a lower dose of BoZ can be combined with rBoIFNγ to amplify PMN 
responses to BoZ and reduce cell clumping. Stimulation with rBoIFNγ has been shown to reduce 
bovine PMN migration under agarose and increase bovine PMN cell-mediated toxicity against 
chicken erythrocytes. This has been shown to occur in both an antibody-dependent and antibody-
independent manner (Steinbeck, Roth and Kaeberle, 1986). By itself, however, rBoIFNγ did not 
alter ROS production (Steinbeck, Roth and Kaeberle, 1986; Sample and Czuprynski, 1990). 
Thus, rBoIFNγ is generally considered a potent bovine PMN activation factor (Steinbeck, Roth 
and Kaeberle, 1986). 
Human eosinophils, enriched to greater than 80% purity with Percoll gradients, 
responded to opsonized zymosan and phorbol myristate acetate (PMA) with increased levels of 
superoxide anion and eosinophil peroxidase (Yukawa et al. 1990). In asthma patients, eosinophil 
release of ROS has been found to be integral to the process of eosinophil extracellular trap (EET) 
formation and is an important contributor to the pathology of asthma in the lung and bronchioles 
(Silveira et al., 2019). There has been limited study of ROS in bovine eosinophils. However, in 
isolated bovine eosinophils and neutrophils, it was observed that PMA had a much stronger 
effect on the ROS response, as measured by chemiluminescence, in eosinophils versus 
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neutrophils (Freiburghaus, Jörg and Müller, 1991). Overall, ROS generation can be used as an 
important measure of neutrophil and eosinophil activation. 
3.9.2 CD11b 
CD11b, also known as alpha-M integrin, is part of the β2 integrin CD11b/CD18 complex 
and plays an important role in neutrophil adhesion to vasculature following stimulation by 
chemoattractants (Coxon et al., 1996; Ince, Weber and Scheiermann, 2019b). It is also involved 
in Fc receptor mediated PMN degranulation (Tang et al. 1997) and acts as complement receptor 
3 (CR3; Berends et al., 1993). Thus, CD11b plays an important role in PMN responses to and 
subsequent amplification of lung inflammatory responses. CD11b has also been shown to play an 
important role in apoptosis and turnover of extravasated neutrophils (Coxon et al., 1996). During 
systemic inflammatory conditions, such as those created by low endotoxin doses, a CD11b high 
neutrophil subpopulation emerges, characteristic of an “aged” neutrophil phenotype (Casanova-
Acebes et al., 2013). Increased CD11b expression is considered an indicator of an activated 
neutrophil with a pro-inflammatory phenotype (Cassetta et al., 2019). On eosinophils, CD11b 
has also been found to play an important role in recognition of fungi such as Alternaria 
alternata, an environmental fungus implicated in triggering asthma (Yoon et al., 2008). A strong 
correlation has also been found between high CD11b expression on blood eosinophils and 
histamine hyper-responsiveness (In’t Veen et al., 1998). Thus, increased expression of CD11b 
can be a marker of activation on both neutrophils and eosinophils. 
3.9.3 CD16 
CD16, also known as FcγRIII, is a low-affinity Fc receptor associated with PMN 
deployment of Ca2+, degranulation, oxidative burst, and phagocytosis (Huizinga et al., 1990; 
33 
 
Kimberly et al., 1990). High CD16 expression is associated with human neutrophil extracellular 
trap (NET) formation (Millrud et al., 2017) and is considered a marker of neutrophil maturation 
and activation (Brandau et al., 2011). Increased CD16 expression on PMNs is observed in 
patients with bacterial and viral respiratory infections and allergies, as well as patients given low 
doses of endotoxin (Pillay et al., 2012). Thus, CD16 may provide an important marker for 
adrenergic modulation of PMN function. A high level of CD16 expression on eosinophils has 
been characterized as an “allergic” phenotype. In healthy humans eosinophils have been shown 
to express low to no CD16. However, when patients with allergic asthma or allergic rhinitis were 
exposed to increasing doses of allergen, a CD16 high population of eosinophils emerged 
(Davoine et al., 2002). Thus, increased expression of this Fc receptor may be a marker of 
activation in both neutrophils and eosinophils. 
3.9.4 CD44 
CD44 is a surface receptor involved in adhesion to hyaluronan in the extracellular matrix. 
It was observed that CD44 deficient mice had 84% higher neutrophil recruitment to the lung 
during E. coli induced pneumonia. This increased recruitment was attributed to reduced CD44 
binding to hyaluronan of the extracellular matrix which normally restricts neutrophil motility 
(Wang et al., 2002). When an allergic response was induced in mice, administration of anti-
CD44 antibodies reduced eosinophil migration to the lung, allergen hyper-responsiveness, 
production of cytokines such as IL-4 and IL-5, and hyaluronan production in the lungs. Thus, 
there is evidence that CD44 plays an important role in regulating the eosinophil allergic airway 
response, as well as the allergic response in general (Katoh et al., 2003). On neutrophils, lower 
expression of CD44 may be a marker of activation, while a different CD44 response may be 




L-selectin, is an adhesion, homing, and signaling molecule present on most leukocytes. It 
is generally considered a “tethering/rolling” receptor. Upon cell activation, a process denoted as 
L-selectin “shedding” from cells occurs (Ivetic, Green and Hart, 2019) A process of 
“mechanical” L-selectin shedding while rolling on endothelium is also described in PMNs (Lee 
et al., 2007). A subset of activated, “mature” neutrophils with low L-selectin expression are 
observed at sites of inflammation (Casanova-Acebes et al., 2013; Tak et al., 2017). Trabold, 
Gruber and Fröhlich (2007) observed that E and NE prevented L-selectin shedding by fMLP 
stimulated human PMNs. In a study examining unchallenged moderate to severe atopic 
asthmatics, they found no difference in L-selectin expression on blood and sputum eosinophils 
relative to non-atopic controls (In’t Veen et al., 1998). However, in one study of allergic 
asthmatics, it was found that eosinophils in bronchoalveolar (BAL) fluid displayed an L-selectin 
low phenotype 4 hours after allergen challenge (Mengelers et al., 1993). Thus, changes in L-
selectin expression on eosinophils may be integral to the allergic asthmatic response. An L-
selectin “shedding” response would be expected on activated neutrophils, and possibly activated 
eosinophils as well. 
3.10 Adrenergic Receptors as Drug Targets  
3.10.1 Common Pharmacological Uses  
Adrenergic receptors are commonly used as drug targets; there are several important 
FDA approved uses of AR agonists and antagonists. These include Epipens, which contain 
epinephrine and consequently stimulate multiple ARs (Farzam and Lakhkar, 2019a). Epipens 
help reverse the large decrease in blood pressure that comes with anaphylactic shock, reduce 
airway constriction, and help reduce the release of inflammatory mediators (Kemp et al., 2008). 
35 
 
Agonists for the α2-AR such as clonidine and dexmedetomidine are regularly used as 
anaesthetics, for the treatment for attention deficit hyperactivity disorder, and as treatment for 
hypertension (Giovannitti, Thoms and Crawford, 2015). General β-AR antagonists such as 
propranolol are occasionally used as treatment for anxiety disorders and performance anxiety 
(Steenen et al., 2016). In asthma, β2-agonists such as salbutamol (albuterol) can be used in 
“puffers” to relax smooth muscle of the bronchioles and prevent the release of histamine from 
mast cells, improving breathing (Barnes, 1993; Noguchi et al., 2015; Ueda et al., 2020). 
In cattle and pigs, an important use of adrenergic drugs is the use of β2-agonists such as 
zilpaterol (trade name: Zilmax) and ractopamine to increase lean muscle mass (Lean, Thompson 
and Dunshea, 2014). Zilpaterol was temporarily removed from the market in the US and Canada 
by Merck Animal Health following anecdotal concerns of animals arriving at slaughterhouses 
with sloughed hooves. (Loneragan, Thomson and Scott, 2014; Thomson et al., 2015). Following 
further research, there was no clear evidence establishing a link between β2-agonists and this 
phenomenon and zilpaterol was reintroduced to the market (Buntyn et al., 2016; Frese et al., 
2016). However, its use is still banned in the EU, China, and Russia. Interestingly, β2-agonists 
are also used as performance-enhancing drugs in humans, and are thus considered a “doping” 
agent in professional sports (Bizec, 2017). Thus, controversy remains over the use of β2-agonists 
to increase lean muscle mass. 
3.10.2 Adrenergic Agonist and Antagonist Specificity 
Adrenergic drugs have varying degrees of specificity for adrenergic receptors. The β-
adrenergic receptors, which have received the most study, have the broadest array of available 
agonists and antagonists. Isoproterenol is commonly used as a non-selective β-AR agonist in 
experimental studies and therapeutically (Shimizu et al., 1996; Szymanski and Davinder, 
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2021). Several drugs are considered selective agonists for individual β-AR subtypes. For the 
study of β1-AR activity, for example, there is the agonist dobutamine. This drug is sometimes 
used for short-term support in heart failure. However, dobutamine can also bind to a lesser extent 
to both the β2- and α1-ARs, so is not completely selective (Mraz and Rorabaugh, 2007). Specific 
β2-AR agonists include albuterol (salbutamol) and formoterol. (Faulds, Hollingshead and Goa, 
1991). More recently, drugs that selectively target the β3-AR have been developed. This includes 
mirabegron, which is used therapeutically to treat overactive bladder. At higher than 
recommended doses (ex: 200 mg), some off-target effects on β1 and β2-ARs appear (Kashyap 
and Tyagi, 2013), but at therapeutic doses mirabegron is considered a selective β3-AR agonist. 
The availability of drugs that are agonists for β-ARs in general and for individual β-AR subtypes 
has facilitated a much better understanding of β-AR function. 
Although drugs are available that selectively target α1-ARs in general, there are few 
drugs which selectively target individual α1-AR subtypes (Chen and Minneman, 2005). 
Phenylephrine, for example, targets the entire α1-AR family (Richards, Lopez and Maani, 2019) 
and has become a standard reagent when studying the function of α1-ARs in general (Jensen, 
O’Connell and Simpson, 2011). A drug named A 61603 is a more selective agonist for just the 
α1A-AR (Knepper et al., 1995) and BMY 7378 is an antagonist that more selectively binds α1D-
AR  (Goetz et al., 1995) but also binds 5-HT1A receptors (Stubbs, Connor and Feniuk, 1991). 
Identifying drugs that specifically target the α1B-AR has proven more difficult (Chen and 
Minneman, 2005). Thus, research on the specific functions of individual α1-AR subtypes 
remains an emerging area.  
Drugs that target individual α2-AR subtypes have also not been identified, limiting the 
characterization of α2-AR subtype function. When targeting the family of α2-ARs, clonidine is a 
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commonly used agonist (Farzam and Lakhkar, 2019b). However, clonidine also binds with lower 
affinity to all α1-AR subtypes (a ratio of 220:1 for α2-ARs vs. α1-ARs) (Giovannitti, Thoms and 
Crawford, 2015). Furthermore, in competition binding experiments clonidine was found to have 
only a 22-fold binding preference for α2A-AR versus the 5-HT1A (serotonin) receptor 
(Newman-Tancredi et al., 1998). In contrast, dexmedetomidine exhibits a binding specificity of 
1620:1 for α2-ARs versus α1-ARs (Giovannitti, Thoms and Crawford, 2015) and 91-fold greater 
binding with α2A-AR versus 5-HT1A receptors. Dexmedetomidine is therefore considered a 
more selective α2-AR agonist than clonidine (Newman-Tancredi et al., 1997). More recently, a 
novel antagonist, AGN-209419, was identified that is specific for the α2B-AR. This drug has 
been used to characterize the expression and function of this AR in the brain (Luhrs et al., 2016), 
but has otherwise been used little to study α2B-AR function. Selective agonists or antagonists for 
α2-AR subtypes are still mostly unavailable, and most studies have used drugs that target the α2-
AR family. 
3.11 Knowledge Gaps and Potential Relevance 
To date, there has been limited study of ARs in bovine immune cells. Particularly, it 
remains largely unknown which bovine immune cells express individual ARs and what functions 
individual ARs may regulate within each immune cell type (LaBranche, Ehrich and Eyre, 2010). 
Gaps also remain in our understanding of the expression and function of ARs on human immune 
cells. Some potential benefits of studying ARs in cattle include a greater understanding of how 
stress modulates bovine immune function, a greater understanding of how β-agonist drugs such 
as zilpaterol may affect bovine health, and potential augmentation of human and bovine drug 




4.0  Methods and Materials 
4.1 Blood Collection  
The phlebotomy protocol (AUP #20170015) was reviewed and approved by the 
University of Saskatchewan University Animal Care Committee following Canadian Council on 
Animal Care gquidelines. Blood was collected from the jugular vein using 60 ml syringes 
(Becton Dickinson, Franklin Lakes, NJ) and an 18 g PrecisionGlide hypodermic needle (Becton 
Dickinson) with 0.3% EDTA (Sigma Aldrich, St. Louis, MO) used as an anticoagulant.  
3.2 Isolation of Blood Leukocytes 
Blood leukocytes were isolated by lysis of red blood cells (RBCs). Briefly, a 3 mL 
aliquot of bovine blood was diluted with 12 mL 1X RBC lysis buffer (0.17 M NH4Cl, 10 mM 
KHCO3, and 0.11 mM EDTA, pH 7.3). Cells were centrifuged for 8 minutes at 311X g to pellet 
leukocytes. Lysis buffer was discarded and the leukocyte pellet re-suspended in 1 mL 
Dulbecco’s Modified Eagle’s Medium (DMEM; Life Technologies Ltd., Paisley, UK) 
supplemented with 10% fetal bovine serum (FBS; SAFC Biosciences Inc., Lenexa, KS). 
Leukocyte concentration was determined with a Z2 Coulter Particle Count and Size Analyzer 
(Beckman Coulter, Indianapolis, IN). Leukocytes were diluted to a final concentration of 10 X 
106 cells/ml and aliquots of 10 X 106 cells transferred to 2 mL cryopreservation tubes (Corning, 
Inc. New York, NY). Cells were centrifuged at 350 X g for 5 minutes, supernatant was 
discarded, and cell pellets snap-frozen in liquid Nitrogen or re-suspended in TRIzol 
(ThermoFisher Scientific, Waltham, MA). Cell pellets were stored at -80 C prior to RNA 





4.3 Peripheral Blood Mononuclear Cell Isolation 
Peripheral Blood mononuclear cells (PBMCs) were isolated as follows. Briefly, blood 
was centrifuged at 1400g for 20 minutes without braking at room temperature. Following 
centrifugation, the buffy coat layer at the interface between plasma and the red blood cells was 
collected. The buffy coat was added to 20 mL calcium- and magnesium-free phosphate buffered 
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4; pH 7.3) 
containing 0.1% EDTA and layered over a 15 mL column of 60% Percoll (density = 1.13 g/mL; 
GE Healthcare BioSciences, Uppsala, Sweden). Samples were centrifuged at 2000X g for 20 
minutes without braking. The buffy coat was once again collected and re-suspended in PBS 
containing 0.1% EDTA before centrifuging at 311X g for 8 minutes. The pelleted PBMCs were 
re-suspended in PBS and centrifuged at 150X g for 8 minutes before being suspending cells at an 
appropriate concentration in PBS for staining with monoclonal antibodies (mAbs) in preparation 
for flow cytometry or high-speed cell sorting. 
4.4 PMN Isolation 
Briefly, 50 ml of blood was centrifuged at 1400 X g for 20 minutes without braking at 
4°C. Following centrifugation, plasma and the buffy coat layer with ~15% of the underlying red 
blood cells were removed. The remaining red blood cells and PMNs were re-suspended with 
PBS containing 0.1% EDTA and centrifuged again at 1400 X g for 20 minutes without braking. 
The PBS and red blood cells exceeding the 16 mL mark in a 50 mL tube were removed. The 
remaining blood was gently pipetted to re-suspend PMNs and 4 ml aliquots were distributed 
among four 50 mL tubes before adding 46 mL 1X RBC Lysis Buffer (0.17 M NH4Cl, 10 mM 
KHCO3, and 0.11 mM EDTA, pH 7.3) to each tube. Cells were centrifuged at 325 X g for 6 
minutes, and the lysis buffer was decanted. The PMN cell pellet was re-suspended in PBS 
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containing 0.1% EDTA before centrifuging at 325 X g for 5 minutes. PMNs were then washed 
twice with PBS.  
4.5 RNA Extraction 
RNA was extracted from blood leukocytes using a combined TRIzol/RNEasy Mini Kit 
extraction method. Frozen cell pellets were lysed with 1 mL TRIzol reagent (ThermoFisher 
Scientific) and 200 uL chloroform (Sigma Aldrich) was added to each sample. Samples were 
shaken for 15 seconds then incubated at room temperature for 2-3 minutes before centrifuging 
for 15 minutes at 13,282 X g. Following centrifugation, the aqueous phase was removed and an 
equal amount of 70% ethanol (Greenfield Global, Brampton, ON) added. Following this step, 
samples were added to the silica columns provided in the RNEasy Mini Kit (Qiagen, Hilden, 
North Rhine-Westphalia, Germany) and processed according to the manufacturer’s instructions. 
For samples with low expected RNA yields, primarily those with less than 1 x 106 cells 
or PMNs, the RNA elution step was repeated once, and RNA was concentrated using the Savant 
Speed-Vac DNA concentrator SC110A (Thermo Electron Co., Milford, MA). 
4.6 RNA quality assessment 
RNA concentration and quality was determined using the Nanodrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE).  
4.7 cDNA Synthesis  
Synthesis of complementary DNA (cDNA) from RNA template was done following the 
manufacturer’s instructions for the Quantitect Reverse Transcription Kit (Qiagen). A 30 minute 
cDNA synthesis incubation step (42°C) was used to denature RNA secondary structure. Briefly, 
500 ng RNA was diluted in 6 L UltraPure DNAse/RNAse-Free Distilled Water (Invitrogen, 
Carlsbad, CA) and 1 L of 7x gDNA wipe-out buffer was added to remove genomic DNA. The 
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GeneAmp 9700 PCR System (Applied Biosystems, Foster City, CA) was used to incubate this 
mixture for 2 min at 42°C. Following incubation, 3 L master mix was added to each reaction. 
The master mix for each reaction consisted of 2 L 5x Quantiscript RT buffer, 0.5 L of primer 
mix, and 0.5 L reverse transcriptase. Following addition of the master mix, each reaction was 
incubated for 30 minutes at 42°C, followed by 3 minutes at 95°C.  
4.8 Reverse Transcription Quantitative PCR 
Reverse transcription quantitative polymerase chain reactions (RT-qPCR) were prepared 
with 5 L of 5ng/L cDNA providing 25 ng cDNA/reaction, and 10 L of master mix for a total 
reaction volume of 15 L. The master mix consisted of 7.5 L 2X PERFECTA-IQ SYBR Green 
Supermix (QuantaBio, Beverly, MA), 2.2 L UltraPure DNAse/RNAse-Free Distilled Water 
(Invitrogen), and 0.3 L of 10 M forward and reverse primer (3 pmoles; Table 4.1). Reactions 
were run in Hard Shell Low-Profile 96-well semi-skirted, clear shell and clear well PCR plates 
(BioRad, Hercules, CA). The CFX Connect Real Time System (BioRad) was used to run and 
quantify real time PCR reactions. Reactions were first run at 95°C for 2 min (once) to activate 
the hot-start Taq polymerase, then for 40 cycles at 95°C for 15 sec (denature), 60°C for 30 sec 
(anneal), and 72°C for 30 sec (extend). Following amplification, a melt curve was applied for 
detection of abnormal products. The melt curve started at 65°C, and the temperature held for 10 
seconds before increasing by 1°C. This pattern was repeated to a temperature of 95°C. Results 
were visualized using the CFX Manager/Maestro software and corrections for primer efficiency 
were included in Cq value calculations. 
4.9 Primer Design and Validation 
Primers were designed for the 9 known bovine AR genes (Table 4.1). CloneManager 
software was used to select for AR gene amplicons between 80 to 150 bp, and these primer sets 
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were screened against the bovine (Bos taurus) genome on the National Center for Biotechnology 
Information’s (NCBI’s) website. This software was used to select three primers for each gene 
which had a low likelihood of amplifying false products. These primers were tested to see if they 
amplified a product of the correct size and tested for efficiency. Primers which had high 
efficiency and amplified a product of the correct size had products sent for sequencing at the 
National Research Council (NRC). The β – Actin gene was chosen as a reference gene for 
analysis as it had previously been validated as a housekeeping gene in bovine blood (Robinson, 
Sutherland and Sutherland, 2007; González-Cano et al., 2014). The reference genes YWAHZ 
and GAPDH were also tested in combination with this reference gene, but the most consistent 
results were found to be obtained just using β-Actin. The forward and reverse β – Actin primers 
used were those published by González-Cano et al (2014). Oligonucleotides were ordered from 
Invitrogen by Thermo Fisher Scientific.  
4.10 Validation of Amplicon Size 
Confirmation that amplicons of the predicted size were generated with each primer pair 
was obtained by visualizing PCR products on a 1.5% UltraPure Agarose gel (Invitrogen). RNA 
for this analysis was isolated from bovine tissues predicted to have high AR transcript abundance 
and all primers generated a single visible product. 
4.11 Primer Efficiencies 
Primer products were ligated into plasmids and plasmids were amplified in E. coli. 
Plasmids were purified and diluted to the same concentrations. Primer efficiencies were 
determined by using serial 10-fold dilutions of digested plasmids containing individual ADR 
gene products and subsequent amplification using qPCR with 2X PERFECTA-IQ SYBR Green 
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Supermix (QuantaBio). Primer efficiency values were determined using the formula E = 10(-1/-
slope) (Pfaffl, 2001).  
All primers (Table 4.1) had an amplification efficiency greater than 85%. Selected 
primers were confirmed to generate a single peak on a melt curve, in addition to amplifying a 
single visible product on gel electrophoresis.  











F  5’ – CCTAGCCAACGTGGTGAAGG - 3’ 




F  5’ – TAGCCATCACGTCACCCTTC - 3’ 




F  5’ – TTCTGCCTCTGCGGGAACAC - 3’ 




F  5’ – GATTTCAGGCCCTCAGAAAC – 3’ 




F  5’ – CCCTTCTATGCCCTCTTCTC – 3’ 




F  5’ – CTTCCTGGCAGCCTTCATCC – 3’ 




F  5’ – CATCGGAGTGTTCGTGGTGT – 3’ 




F  5’ – GGTCTACCTGCGCATCTACC – 3’ 




F  5’ – TACTGCAACAGCTCGCTCAAC – 3’ 
R  5’ – CTCCGTCGGAAGAGGATGTG – 3’ 
89 89.9 
 
4.12 Primer Product Sequencing 
Following cloning of amplified primer products into vectors, the vector-integrated AR 
sequences amplified with primers demonstrating optimal efficiency (see Table 4.1) were sent to 
the National Research Council (NRC; University of Saskatchewan) for sequencing using 
fluorescence-based sequencing. The obtained sequences were aligned to the Bos taurus AR 
genes using the NCBI Basic Local Alignment Search Tool (BLAST). Two primers, ADRA1D 
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and ADRA2C, amplified products with 99% homology to the expected sequences. ADRA1D had 
a C → T single nucleotide polymorphism (SNP) at position 90, and ADRA2C had a T deletion at 
position 79. The remaining primers were all found to have 100% homology to the predicted AR 
sequences.   
4.13 Cell Labeling for Highspeed Sorting  
To sort monocytes (CD14+), B Cells (CD21+), Innate Lymphoid Cells (CD335+) and T 
cells (CD3+), 1x 108 PBMCs were re-suspended in 1 mL PBS and 5 μL primary mAb was added 
(see Table 4.2 for antibody information and concentrations). Cells were incubated for 20 minutes 
at 4°C, with mixing every 10 minutes. Following labelling with the primary mAb, cells were 
centrifuged for 8 minutes at 311 X g at 4°C, washed twice with 5 mL PBS, and re-suspended in 1 
ml PBS. A 5 μL aliquot of R-Phycoerythryin conjugated goat anti-mouse IgG1 polyclonal 
antibody was added to the cells and cells were incubated in the dark for 20 min at 4°C. The cells 
were once again pelleted for 8 min at 311 X g at 4°C and washed twice with PBS. Following 
labelling, PBMCs were suspended to a final concentration of 1 x 108 cells/mL for high-speed 
sorting. For sorting PMNs into neutrophils and eosinophils no antibody labeling was required. 
Bovine eosinophils were identified as auto-fluorescence high in the FL-1 channel, whereas 
neutrophils were identified as auto-fluorescence low in FL-1 (Anderson et al., Unpublished 
manuscript). Cytospin slides were prepared with cells sorted based on FL1 autofluorescence 
using the Cytospin-4 cytocentrifuge (Thermo Shandon, Asheville, NC) and cells were stained 
with Wright-Giemsa (Hemacolor® Stain Set; Sigma Aldrich).  
PMNs could also be gated as distinct subpopulations during flow cytometry when 
analyzing CD44-PE and CD16-FITC staining, CD44-PE and L-selectin (CD62L)-PerCPCy5.5 
staining, and CD44-PE and CD11b-APC staining (Figures 4.5 and 4.6). PMNs were stained with 
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mAbs using the above method and secondary antibodies used at concentrations shown in Table 
4.2. High-speed cell sorting was then performed for each of the PMN subpopulations identified 
to confirm the subpopulations identified effectively separated neutrophils from eosinophils. 
Cytospins were prepared for each high-speed sorted PMN subpopulation, stained with Wright-
Giemsa, and differential counts performed to determine neutrophil and eosinophil purity. 
4.14 Antibody Staining Protocol 
Proteins expressed on the surface of PMNs were indirectly labelled using mAbs and 
mAbs were then detected with fluorochrome-conjugated isotype-specific secondary polyclonal 
antibodies (Table 4.2). The indirect labelling protocol is briefly described as follows. First, 100 
μL of PMNs at a concentration of 1 x 107 cells/mL (1 x 106 PMNs) were added to 96-well plates 
(Thermo Fisher Scientific, Roskilde, Denmark). Plates were centrifuged at 349X g for 2 minutes 
at 4°C and the supernatant discarded. In each well, 25 μL each of the four primary mAbs were 
added at 4X concentrations (see Table 4.2) to each well to a final volume of 100 μL. In isotype 
control wells, 25 μL matched antibodies for each of the four mAb isotypes were similarly added 
at matched protein concentrations (see Table 4.2). PMNs were incubated for 20 minutes at 4°C. 
Following incubation, 100 μL PBS containing 0.03% sodium azide and 0.2% gelatin (PBSG) 
was added and the cells were centrifuged at 349Xg for 2 minutes at 4°C. Following discard of 
the supernatant, cells were washed with 200 μL PBSG. Secondary antibodies were added in the 
same manner as primary antibodies, incubated for 20 minutes at 4°C and similarly washed. 
Following labelling, cells were fixed using 2% formaldehyde and stored at 4oC in the 
dark until analyzed. Each cell sample was filtered with Falcon 35 μm nylon filter cap tubes 
(Catalogue # 352235, Corning, New York, NY) prior to analysis.  
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Table 4.2: Primary and secondary antibodies used to detect PBMC and PMN subsets and 
PMN activation markers 
Antibody 
Specificity 










CD11b 1° IgG2b 3.33 μg/mL VMRD, Inc1. MM10A 
CD16 1° IgG2a 1.25 μg/mL BioRad, Inc. ------------- 
L-selectin 
(CD62L) 
1° IgG1 1.25 μg/mL VMRD, Inc. BAQ92A 
CD44 1° IgG3 1.25 μg/mL VMRD, Inc S-BAG40A 




VMRD, Inc MM1A 
 




VMRD, Inc MM61A 
 




BioRad, Inc. MCA1424GA 
 







1° IgG2b 3.33 μg/mL BioRad, Inc. ------------- 
Mouse IgG2a 1° IgG2a 1.250 μg/mL Invitrogen ------------- 
Mouse IgG1 
Isotype Control 





1° IgG3 1.250 μg/mL VMRD Inc. COLIS41B 
Goat anti-mouse 
IgG1-PE 




















2° Polyclonal 0.3125 μg/mL Southern 
Biotechnology 
------------- 
1. VMRD Inc. is now the Monoclonal Antibody Center, Washington State University 
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4.15 Antibodies Used for Flow Cytometry 
Each antibody was optimized for specificity and sensitivity by analyzing cell staining intensity 
(mean fluorescent intensity; MFI) and percentage cells stained over a range of antibody 
concentrations. Isotype control antibodies were used at a concentration equivalent to the isotype-
matched primary mAbs (Table 4.2). 
4.16 High-Speed Cell Sorting of PBMC Subsets 
Prior to sorting, PBMCs labelled with mAbs were adjusted to a concentration of 1x108 
cells/mL and filtered through a 35 μm filter cap tube (BD Falcon, ON, CA) to remove cell 
aggregates. High-speed sorting was executed with a MoFlo XDP Cell Sorter (Beckman Coulter). 
The 488 nM Argon laser was used to excite FITC using a 529/28 band-pass filter (FL-1), PE was 
excited with a 575/25 band-pass filter (FL-2), and PerCP/Cy5.5 excitation was achieved with a 
625/26 band-pass filter (FL-3). The 633 nM HeNe laser was used to excite APC using a 670/30 
band-pass filter (FL-4). Sample processing and machine setup were as described previously by 
González-Cano et al. (2014). A primary sort region (R1) displaying FSC and SSC was used to 
exclude dead cells, contaminating red blood cells, and debris (Figure 4.1A). Cells within R1 
were then gated (R2) using FSC height and width to exclude doublets (Figure 4.1B). Cells in R2 
were gated based on fluorescence in FL2 (CD14+; R3; Figure 4.1C) to set a positive sort region.  
Purity of the cells sorted from R3 was then determined by analyzing the percent fluorescent cells 
in R5 (Figure 4.1D).  
 Following high-speed cell sorting, selected cell populations cells were centrifuged at 
850X g for 8 minutes, the supernatant decanted, and cell pellets were suspended in TRIzol 
















Figure 4.1: High-speed sorting of lineage-specific leukocyte subpopulation from PBMCs.  
Sorting parameters used for monocytes indirectly labeled with CD14 mAb and R-Phycoerythrin 
(PE) fluorochrome conjugated goat anti-mouse IgG1 are shown as an example. A: PBMCs were 
first gated (R1) using forward scatter height (size) and side scatter height (complexity) to exclude 
dead cells and debris. B: PBMCs were then gated using FSC height and width (R2) to exclude 
cell doublets and ensure sorting of single cells. C: The sort region for CD14-PE labelled cells 
(R3) was then set. D: Purity of sorted CD14 cells was routinely analyzed and determined to be 
97.2%. 
4.17 High-Speed Cell Sorting of Neutrophils and Eosinophils  
Highly enriched bovine neutrophil and eosinophil populations were obtained using the 
MoFlo XDP to do a two-way sort of PMNs isolated from bovine blood (initial gating on forward 
and side scatter; Figure 4.2). The gating strategy for two-way sorting of neutrophils and 
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eosinophils for RT-qPCR was based on the differential autofluorescence in FL1 for these two 
cell populations (Figure 4.3). High-speed cell sorting was also used to confirm neutrophils and 
eosinophils’ differentially expressed CD44 and CD16 (Figure 4.5 and 4.6), L-selectin, CD11b 
(data not shown), and autofluorescence in FL-2 and FL-3 (Figure 4.4) and to validate that flow 
cytometry analysis regions set using these surface proteins discriminated between neutrophils 
and eosinophils. Briefly, two-way sort regions for both resting and activated (bovine serum 
opsonized zymosan [BoZ] + rBoIFN) were set using PMNs co-labelled with mAbs specific for 
various combinations of two surface proteins (Figures 4.5 and 4.6).  
 
Figure 4.2: Forward scatter (size) and side scatter (complexity) gate (R1) used for sorting 
resting (A) and BoZ + rBoIFNγ activated (B) PMNs. Region (R1) excluded dead cells and 
debris. A greater number of events are shown in B. A small shift in forward and side scatter was 





Figure 4.3: High-speed sorting of neutrophils and eosinophils from PMNs based on 
autofluorescence in channel 1 (FL1). Forward scatter, or cell size, shown on the Y-axis and 
autofluorescence in FL1 shown on the X-axis. A: Two separate sort regions were set using 
autofluorescence in FL1 and a two-way sort separated FL1 low (B) and FL1 high (C) cells. 
Wright-Giemsa staining of cytospins prepared with sorted cells confirmed the FL1 low 






Figure 4.4: High-speed sorting of neutrophils and eosinophils from resting (A, B, C) and 
BoZ + rBoIFNγ activated (D, E, F) PMNs based on autofluorescence in fluorescent 
channels 2 and 3. A:  Resting PMNs were gated for two separate sort regions using FL2 and 
FL3 autofluorescence and a two-way sort separated FL2 and FL3 low (B) and FL2 and FL3 high 
(C) cells. D: BoZ + rBoIFNγ activated PMNs were gated into two sort regions using FL2 and 
FL3 autofluorescence and a two-way sort separated FL2 and FL3 low (E) and FL2 and FL3 high 
(F) cells. Wright-Giemsa staining of cytospins confirmed sort purity for resting neutrophils was 
100% and resting eosinophils was 98.0%. Sort purity of BoZ + rBoIFN activated neutrophils 




Figure 4.5: High-speed sorting of PMNs based on CD16 and CD44 expression. A: Two sort 
regions were set using CD16- FITC (FL1) and CD44- PE (FL2) and a two-way sort separated 
CD16 low, CD44 high (B) and CD16 high, CD44 low (C) cells. B: Wright-Giemsa stained CD44 
high, CD16 low cells confirming this population was 98.6% neutrophils (see inset for segmented 
nucleus and clear cytoplasm). C: Wright-Giemsa stained CD44 low, CD16 high cells confirming 
this population was 98.4% eosinophils (see inset for characteristic pink cytoplasmic granules). 




Figure 4.6: High-speed sorting of BoZ + rBoIFNγ activated PMNs based on CD16 and 
CD44 expression. A: Two sort regions were set using CD16- FITC and CD44- PE and a two-
way sort separated CD16 low, CD44 high (B) and CD16 high, CD44 low (C) cells. B: Wright-
Giemsa stained CD44 high, CD16 low cells confirmed 98.1 % were neutrophils (Inset: BoZ + 
rBoIFNγ activated neutrophils contain vacuoles containing bovine serum opsonized zymosan). 
C: Wright-Giemsa stained CD44 low, CD16 high cells confirmed 94.9 % were eosinophils with 
characteristic pink granules (Inset). Vacuoles were observed in BoZ rBoIFNγ activated 
eosinophils consistent with the uptake of BoZ particles. Scale bar = 20 μm; Magnification = 
400X.  
4.18 Stress Trial for Analysis of AR Gene Expression in Blood Leukocytes 
The study included four groups (n = 10/group) of 6-7 month old, suckling, female Hereford-cross 
calves (Goodale Farm, University of Saskatchewan). Group A remained in the pasture with their 
dams and had ad libitum access to brome-alfalfa hay and water. This group were controls for 
possible stress responses while calves were restrained for blood collection (Controls). Group B 
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calves also remained with their dams but were moved from pasture to a dry lot with ad libitum 
access to brome-alfalfa hay and water. This group served as controls for changing the 
environment from pasture to a dry lot (Controls). Group C calves were separated from their dams 
following sampling on Day 0 and housed in a dry lot adjacent to Group B (Weaning). Group D 
calves were separated from their mothers following sampling on Day 0, transported in a 
livestock trailer for approximately 5 h (Weaning + Transportation) and then co-housed with 
Group C calves. Blood was collected from calves in all groups on Day 0, and Days 2, 4, 8, 14 
and 28 post-weaning. Serum and blood leukocytes were isolated and aliquots of 10 X 106 blood 
leukocytes were pelleted and snap-frozen in liquid nitrogen before storing at -80 oC. Cell pellets 
were used for RNA extraction and RT-qPCR analysis of AR gene expression.  
4.19 Zymosan Opsonization  
Zymosan A from Saccharomyces cerevisiae (Sigma Aldrich) was opsonized with bovine 
serum using the method described by Roth and Kaeberle (1981) with minor adaptations. Briefly, 
fresh bovine serum was prepared by collecting blood in 10 ml SST Vacutainers (Becton 
Dickinson) and blood was incubated at room temperature for 1 hour. Blood was then centrifuged 
at 2000 X g for 15 minutes to separate serum. One gram Zymosan A was suspended in 100 mL 
cold Hank’s Buffered Saline Solution (HBSS) supplemented with Ca++ and Mg++. The zymosan 
suspension was vortexed at maximum speed for 1 minute and 100 mL of 10 mg/mL Zymosan A 
was added to 100 mL fresh bovine serum. The mixture was stirred vigorously for 1 hour at room 
temperature using a stir bar and magnetic stirrer and then centrifuged at room temperature for 10 
minutes at 250 X g. The supernatant was discarded before suspending the pellet in 200 mL 
0.01M EDTA and stirring for 15 minutes at room temperature to prevent conglutination. The 
mixture was then centrifuged at room temperature for 10 minutes at 250 X g and the supernatant 
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discarded. The pellet was re-suspended in 200 mL 0.01M EDTA and stirred for 15 minutes a 
room temperature. The mixture was again centrifuged at room temperature for 10 minutes at 250 
X g and the supernatant discarded. The pellet was re-suspended in 100 mL HBSS with Ca++ and 
Mg++ to a final concentration of 10 mg/mL and 500-1000 μL aliquots of bovine serum opsonized 
zymosan (BoZ) were stored at -20°C. Immediately prior to use, aliquots were thawed and 
vortexed at high speed for 2 minutes. 
4.2 PMN Culture Media 
PMNs were cultured using media previously optimized for cell viability during a 48 to 72 
h culture period (Whale et al. 2006). Briefly, phenol-red free AIM-V Medium (Thermo Fisher 
Scientific) was supplemented with 20% fetal bovine serum (FBS; SAFC Biosciences Inc., Cat 
#12103C-500mL, Lot #14G420) and 50 μM β-2 mercaptoethanol (Sigma Aldrich).  
4.21 Treatment of PMNs with Adrenergic Agonists 
Freshly isolated PMNs were plated in 6-well plates at a final concentration of 1 million 
cells /mL for a total of 5 million cells/well in 5 mLs culture media. Adrenergic agonists were 
then added at final concentrations varying between 0-100 nM (freshly diluted from powder to 
prevent oxidation and degradation) and cells were incubated for 30 minutes at 39°C. For resting 
PMNs, the cells were incubated an additional hour at 39°C before collecting cells for analyses 
(Figure 4.7A). For activated PMNs, following the 30-minute pre-incubation with adrenergic 
agonists, 10 ng/mL recombinant bovine IFNγ (rBoIFNγ) and 6.25 μg/mL BoZ were added and 
the cells were incubated for another hour at 39°C before collecting cells for analyses (Figure 
4.7B). Adrenergic agonists (all full agonists) tested included (+) epinephrine hydrochloride 
(Sigma Aldrich), DL-norepinephrine hydrochloride (Sigma Aldrich), (R)-(−)-Phenylephrine 
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hydrochloride (Sigma Aldrich) for α1-ARs, Dexmedetomidine hydrochloride (Sigma Aldrich) 
for α2-ARs, and (-)-Isoproterenol hydrochloride (Sigma Aldrich) for β-ARs. 
 
 
Figure 4.7: Protocol used to evaluate the effect of adrenergic agonists on bovine neutrophils 
and eosinophils. Each adrenergic agonist was titrated using 10-fold dilutions (100, 10, 1, 0.1 and 
0 nM) in the physiological range for E and NE in cattle. The adrenergic compounds used were all 
considered full agonists. Cultured PMNs were incubated for 30 minutes at 39°C with individual 
adrenergic agonist, and A. resting PMNs were then cultured for another hour before being 
collected for analysis of neutrophil and eosinophil activation. B. For PMN activation, 10 ng/ml 
rBoIFNγ and 6.25 μg/mL BoZ were added during the last hour of incubation. With this 
activation protocol, an absence of cell aggregation was confirmed on cytospin slides, cell 
recovery from tissue culture plates was determined to be >85%, and cell viability was 
determined to be >99% as determined by propidium iodide (PI) staining. Following recovery 
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from cultures, PMNs were stained for iROS and stained with mAbs to quantify surface 
expression of CD11b, CD16, CD44 and L-selectin.  
4.22 Recovery of Cultured PMNs   
Briefly, culture media was aspirated and gently discharged into the well 4-5 times to re-
suspend non-adherent cells before collecting all media from each well in the 6-well culture plate 
(Corning Life Sciences, Inc. Kennebunk, ME). Following media collection, 3 mL of 39°C 0.1% 
EDTA prepared in PBS (pH 7.3) was added to each well and plates were incubated for 5 minutes 
at 39°C in a humidified atmosphere with 5% CO2. The EDTA solution was collected and pooled 
with the previously collected media. Another 3 ml of 39°C 0.1% EDTA was added to each well. 
Plates were incubated at 39°C for 10 minutes before collecting the EDTA solution and pooling 
with previously collected media. Cells were pelleted by centrifuging at 300 X g for 8 minutes at 
4°C. Supernatant was discarded and the cell pellet re-suspended in 3 mL PBS containing 0.03% 
sodium azide and 0.2% gelatin (PBSG) adjusted to a pH of 7.3. Cells were pelleted again by 
centrifuging at 300 X g for 8 minutes at 4°C before discarding the supernatant and re-suspending 
cells in 400 μL PBS (PBS; pH of 7.3). 
4.23 Detection of Intracellular Reactive Oxygen Species 
The 2’,7’-dichlorofluorescein diacetate (DCFDA; Molecular Probes, Inc., Eugene, OR) 
dye was used to quantify intracellular reactive oxygen species (iROS) activity in PMNs. 
Following removal of the acetate group by iROS and intracellular esterases, the dye fluoresces 
and is detectable by flow cytometry (Invitrogen Reactive Oxygen Species Detection Reagents 
Protocol, 2006). DCFDA was dissolved in DMSO (Sigma Aldrich) at a concentration of 20mM 
and stored in 20 μL aliquots at -20°C. A fresh aliquot was thawed and diluted to 1 μM in PBS 
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immediately prior to use. DMSO concentrations in assays were tested to confirm they did not 
reduce cell viability. DCFDA dye concentration and incubation period with cells was optimized 
for bovine PMNs. The optimized protocol for bovine PMNs is as follows: one million bovine 
PMNs were added in 100 μl culture medium to each well of a 96-well plate. Cells were pelleted 
by centrifuging at 349 X g for 2 minutes at room temperature and supernatant was discarded. 
Cells were re-suspended in 100 μL PBS containing 1 μM DCFDA and incubated for 4 minutes at 
39°C. Cells were pelleted by centrifuging at 349 X g for 2 minutes at room temperature and re-
suspended in 200 μL 37°C neutrophil culture medium and incubated for 2 minutes at 39°C to 
allow hydrolyzation of acetate groups. Cells were pelleted, supernatant discarded, and cells re-
suspended in 200 μL PBS. FL-1 fluorescence of cells was analyzed with a FACSCalibur 
(Becton-Dickinson, Franklin Lakes, NJ) with 10,000 events acquired for each sample. 
4.24 Detection of PMN Apoptosis and Necrosis 
PMN apoptosis and necrosis was analyzed using flow cytometry to quantify staining by anti-
Annexin V antibodies and propidium iodide (PI) using the APC Annexin V Apoptosis Detection 
Kit with PI (Biolegend, Inc., San Diego, CA). Cell staining was performed according to kit 
instructions with the exception that PI was added immediately prior to analyzing each sample 
with the flow cytometer.  
4.25 Epinephrine and Norepinephrine: Dose Ranges and Pre-Incubation 
For experiments with E and NE, a dose range of 0.1 nM to 100 nM was chosen with 10-
fold incremental dilutions. The range of E and NE doses selected was based on information 
regarding basal and stress associated levels of E and NE in humans, rats, and cattle (Table 4.3; 
Adapted from Buhler et al. 1978). 
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Table 4.3: Basal and stressed levels of E and NE  
      Basal           Stress  
      (nM)        (nM) 
Human Epinephrine 0.306                 ---- 
Bovine Epinephrine 0.349                 ---- 
Rat Epinephrine 0.955             16.4 to 133.6 
Human 
Norepinephrine 0.898 
                ---- 
Bovine 
Norepinephrine 1.200 
                ---- 
Rat Norepinephrine 3.009             17.7 to 94.1 
      
4.26 Flow Cytometry Analysis of Neutrophil and Eosinophil Subpopulations  
Flow cytometric analysis of cultured PMNs and data acquisition was performed using a 
FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ). A primary analysis region was set using 
FSC and SSC (R1) to exclude dead cells, contaminating red blood cells, and debris (not shown) 
and 10,000 gated events were acquired. The 488 nM laser was used to excite FITC, PE and 
PerCP/Cy5.5. FITC fluorescence was acquired in FL-1 with a 530/30 filter. PE fluorescence was 
acquired in FL-2 with a 585/42 filter, and PerCP/Cy5.5 fluorescence in FL-3 with a 670 LP 
filter. The 635 nM laser was used to excite APC and fluorescence was detected in FL-4 with a 
661/16 filter. Manual compensation was used to eliminate fluorescence overlap between 
channels. Data was analyzed using the BD CellQuest Pro program (version 6.0).  
Fluorescence from DCFDA was detected in FL-1 and neutrophil and eosinophil 
subpopulations in PMNs were gated separately based upon differential auto-fluorescence in 
either FL-2 and FL-3 (see Figure 4.5 and Figure 4.6). Regions for selecting positive CD16, 
CD44, L-selectin and CD11b fluorescence were set using isotype-matched negative control 
mAbs (see Table 4.2). Neutrophils and eosinophils were discriminated by gating on CD44-PE 
and CD16-FITC (see Figure 4.8 and 4.9), as these regions were confirmed by high-speed cell 
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sorting to provide the highest purity for each PMN subpopulation. Example are shown for 
separate gating of neutrophils (Figure 4.8) and eosinophils (Figure 4.9) based on CD44-PE and 
CD16-FITC. 
 
Figure 4.8: Dot scatter plots of unstimulated PMNs gated for CD16-FITC low and CD44-
PE high cells. Cells in this region (R2) were confirmed to be neutrophils (B) and this region was 
used to analyze neutrophil responses to adrenergic agonists.  
    
Figure 4.9: Dot scatter plots of unstimulated PMNs gated for CD16- FITC high and CD44- 
PE low cells. Cells in this region (R2) were confirmed to be eosinophils (B) and this region was 





4.27 Analysis of PMN Morphology to Identify Neutrophils and Eosinophils 
PMNs and high-speed sorted subpopulations were diluted to 2 x 105 cells/mL in PBS 
supplemented with 1% bovine serum albumin (BSA). A 100 l aliquot of cells was deposited 
onto glass slides (Fisher Scientific) using the Cytospin-4 cytocentrifuge (Thermo Shandon, 
Kalamazoo, MI) set at 28 X g for 5 minutes. Slides were air dried before staining with the 
Harleco® Hemacolor Stain Set (Merck; Darmstadt, Germany). When slides were dry, a coverslip 
was mounted over the cytospin using Cytoseal 60 (Richard–Allan Scientific, Kalamazoo, MI) as 
a mounting medium. Differential counts of neutrophils and eosinophils were performed using an 
Olympus CX31 (Olympus Corporation, Tokyo, Japan) light microscope and digital images of 
cells were captured using the Zeiss Axio Observer 7 microscope (Zeiss, Oberkochen, Germany). 
4.28 Statistical Analysis 
Adrenergic receptor gene expression data for leukocytes isolated from whole blood was 
analyzed using a one-way analysis of variance (ANOVA). Adrenergic receptor gene expression 
data for PBMC, PMNs, neutrophils and eosinophils were analyzed using a matching two-way 
ANOVA with gene and cell type as variables. When significant differences were detected then 
post-hoc analysis testing for differences in expression of individual genes and among cell types 
was completed using Tukey’s multiple comparison test. Data was similarly analyzed for the 
expression of AR genes over time in blood leukocytes using a two-way, repeated measures 
ANOVA with time and treatment as variables.  
Activation of bovine PMNs with 10 ng/mL rBoIFNγ and 6.25 μg/mL BoZ was performed 
at three different time points for each animal, and PMN iROS, CD11b, CD16, CD44, and L-
selectin responses for each of the 5 animals were averaged across time points and used to 
compare the effect of different treatments. Changes in PMN activation responses for cells 
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isolated from individual animals were calculated as a percentage relative to unstimulated cells 
and comparisons between neutrophil and eosinophil responses were analyzed using a student’s t 
test. Comparisons between neutrophil and eosinophil expression of basal levels of activation 
markers were performed similarly. 
Data for treatment of PMNs with adrenergic receptor agonists were analyzed using a 
matching two-way ANOVA with dose and treatment as variables. Dunnett’s multiple 
comparisons test was used to analyze dose-dependent effects of treatment, whereas Sidak’s 
multiple comparisons test was used to compare responses among multiple agonists. All analyses 


















5.1 ADRENERGIC RECEPTOR GENE EXPRESSION IN BOVINE LEUKOCYTES 
5.1.1 Adrenergic Receptor Transcript Expression in Leukocytes Isolated from Whole Blood 
My first objective was to determine which AR genes were expressed at a detectable level 
in bovine blood leukocytes and whether transcript abundance varied significantly when 
comparing among individual AR genes. The RT-qPCR analysis of AR gene expression was 
performed using RNA extracted from leukocytes isolated from whole blood. A detectable level 
of transcript (Cq < 35) was present for all 9 ARs but significant (p < 0.05) variation in transcript 
abundance was observed when comparing among the 9 genes (Figure 5.1). The α2A-AR gene 
was unique in that its transcript abundance was significantly (p < 0.01) greater than all other AR 
genes. The α1A-AR was expressed at the next highest level with transcript abundance 
significantly (p < 0.05) greater than all other α1-, α2-, and β-ARs. A lower but similar transcript 
abundance was observed for the α1B-, α2C, and β2-AR genes. Finally, transcript abundance was 





Figure 5.1: Expression of nine known bovine AR genes in leukocytes isolated from whole 
blood. Gene expression data is expressed as 1/ΔCq and presented as the mean + 1 SD (n = 31 
cattle). The horizontal line indicates the lower cut-off for detection of transcript (>35 PCR 
cycles). A one-way ANOVA was used to compare transcript abundance among individual AR 
genes. Genes that are significantly (p < 0.05) different in transcript abundance are identified by 
different letters (a, b, c, d).  
5.1.2 Effect of Stress on Adrenergic Receptor Expression in Bovine Leukocytes 
 
Addressing my second objective analyzing AR gene expression in bovine leukocytes, I 
investigated whether stress associated with maternal separation (weaning) and transportation 
significantly altered AR gene expression in blood leukocytes. For this study, RNA was isolated 
from whole blood leukocytes following red blood cell lysis. The RT-qPCR analyses again 
confirmed transcript was detectable for all 9 ARs in blood leukocytes and there were no 
significant differences in the expression of the 9 AR genes when comparing calves suckling 
dams on pasture (Group A) versus suckling calves moved with their dams into a corral (Group 
B) (data not shown). This indicated a change in environment associated with moving animals 
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from pasture to a dry lot did not significantly alter AR gene expression. Furthermore, there were 
no significant temporal changes in the expression of AR genes within either group of suckling 
calves throughout the one-month sampling period. Therefore, data from the two groups of 
suckling calves (n = 20) were combined for all subsequent analyses.  
Expression of 4 of the 9 AR genes changed significantly (p < 0.05) in blood leukocytes 
isolated from calves following maternal separation, either with (Group D) or without (Group C) 
transportation. A significant (p < 0.01) increase in β2-AR gene expression was observed on Days 
2 and 4 post-weaning in Group C (weaned), and on Day 2 post-weaning in Group D (weaned + 
transport) relative to the control group (Figure 5.4). A significant (p < 0.05) increase in α2A-AR 
gene expression was also observed in Group C (weaned) on Day 4 and 8 post-weaning and on 
Day 8 post-weaning in Group D (weaned + transport) when compared to the control group 
(Figure 5.3). On Day 28 post-weaning significant (p < 0.01) increases in the expression of both 
β1- and β3-AR (Figure 5.4) were observed in Group D (weaned+transport) relative to the 
controls. For the β3-AR, there was also a significant difference on Day 28 in Group D 
(weaned+transport) relative to Group C (weaned), providing evidence the two stressors 
differentially regulated AR gene expression. Thus, maternal separation (Group C) was associated 
with significant changes in AR gene expression by blood leukocytes during the first 8 days post-
weaning but combining maternal separation with transportation was associated with both short-
term and long-term effects on blood leukocyte AR gene expression that were apparent 4 weeks 
post-weaning.  
Significant changes in AR gene expression in blood leukocytes following the stress of 
maternal separation and transportation could result from either altered AR gene transcription or 
changes in the cellular composition of the blood leukocyte population (Hickey, Drennan and 
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Earley, 2003; Yagi et al., 2004; Ishizaki and Kariya, 2010; O’Loughlin et al., 2012). Therefore, I 
investigated whether individual blood leukocyte lineages differed significantly in AR gene 
expression.  
 
Figure 5.2: Temporal changes in α1-AR gene expression in blood leukocytes following 
weaning, with or without transportation. Gene expression was quantified with RT-qPCR and 
data for each animal was expressed as fold change relative to Day 0 (prior to weaning). Gene 
expression was analyzed for three α1-AR (A, B, C) genes. A one-way ANOVA was used to 
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compare the three treatment groups at each time point and significant differences between the 
two treatment groups and the control group are indicated as * (p < 0.05) and ** (p < 0.01). 
 
Figure 5.3: Temporal changes in α2-AR gene expression in blood leukocytes following 
weaning, with or without transportation. Gene expression was quantified with RT-qPCR and 
data for each animal was expressed as fold change relative to Day 0 (prior to weaning). Gene 
expression was analyzed for three α2-AR (A, B, C) genes. A one-way ANOVA was used to 
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compare the three treatment groups at each time point and significant differences between the 
two treatment groups and the control group are indicated as * (p < 0.05) and ** (p < 0.01). 
 
Figure 5.4: Temporal changes in β-AR gene expression in blood leukocytes following 
weaning, with or without transportation. Gene expression was quantified with RT-qPCR and 
data for each animal was expressed as fold change relative to Day 0 (prior to weaning). Gene 
expression was analyzed for three β-AR (A, B, C) genes. A one-way ANOVA was used to 
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compare the three treatment groups at each time point and significant differences between the 
two treatment groups and the control group are indicated as * (p < 0.05) and ** (p < 0.01). 
5.1.3 Adrenergic Receptor Transcript Expression in Leukocyte Subpopulations  
5.1.3.1 Adrenergic Receptor Transcript Expression in PMNs and PBMCs 
Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear (PMNs) 
leukocytes are the two major leukocyte lineages that can easily be separated when studying 
blood leukocytes. When comparing PBMCs and PMNs, the RT-qPCR analysis revealed similar 
transcript abundance for all AR genes except for the α2A-AR gene (Figure 5.5). The α2A-AR 
gene was expressed at a significantly (p < 0.01) higher level in PBMCs than PMNs. 
Furthermore, within PBMCs the α2A-AR gene was expressed at a significantly (p < 0.05) higher 
level than all other AR genes and expression of the α1A- and β2-AR genes was similar but 
significantly (p < 0.05) higher than the α1B-, α1D-, α2B-, α2C-, β1- and β3-AR genes. Within 
PMNs, the α1A-, α2A-, and β2-AR genes were expressed at similar but significantly higher 
levels than all other AR genes. The α1B-, β1- and β3-AR genes were expressed at a similar but 
lower level that was significantly (p < 0.05) greater than the α1D-AR gene.   
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Collectively, this data confirmed all 9 AR genes were expressed at detectable levels in 
both PBMCs and PMNs (Figure 5.5). Furthermore, there was a significant difference in AR gene 
expression when comparing PBMCs and PMNs. 
 
Figure 5.5: Expression of nine known bovine AR genes in PBMCs and PMNs. Gene 
expression is expressed as 1/ΔCq and presented as the mean + 1 SD (n = 5 cattle). The horizontal 
line indicates the lower cut-off for detection of transcript (>35 PCR cycles). A two-way ANOVA 
was used to compare AR transcript abundance within and between the two leukocyte 
subpopulations. Genes that are significantly (p < 0.05) different in transcript abundance within 
PBMCs and within PMNs are identified by different letters (a, b, c, d). Significant differences in 
the expression of individual AR genes when comparing between PBMCs and PMNs are 
indicated** (p < 0.01). 
5.1.3.2 Adrenergic Receptor Gene Expression in PBMC Subpopulations  
The variation in AR gene expression observed within PBMCs suggested that even greater 
variation in AR gene expression may be apparent if PBMCs were separated into distinct 
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lymphocyte and myeloid cell lineages. Thus, high-speed cell sorting was used to isolate highly 
enriched (> 95% purity) T cell (CD3+), B cell (CD21+), and innate lymphoid cell (ILC; CD335+) 
populations and monocytes (CD14+ cells). RNA was extracted from each purified subpopulation 
to analyze AR gene expression.  
As expected, much greater differences in AR gene expression were apparent when 
comparing within and among the various PBMC subpopulations (Figure 5.6). These differences 
were most pronounced for several AR genes, including the α2A- and β2-AR genes. Expression 
of the α2A-AR gene was significantly (p < 0.05) higher in B cells than all other lymphocyte 
subpopulations and monocytes. Expression of the α2A-AR gene was also significantly (p < 0.01) 
higher in ILCs relative to monocytes, which had the lowest α2A-AR transcript abundance. 
Significantly (p < 0.01) higher β2-AR transcript expression was detected in ILCs relative to other 
lymphocyte subpopulations and monocytes. Monocytes, however, expressed the β2-AR gene at a 
significantly (p < 0.05) higher level than either B cells or T cells. Monocytes and B cells did not 
express detectable levels of transcript for either the α1D-, α2B- or α2C-AR genes. Otherwise, all 
AR genes were detectable in the PBMC subpopulations. 
Within monocytes, the β2-AR gene was the most highly expressed (p < 0.05), followed 
by the α2A-AR gene (p < 0.05), and the α1B- and β1-AR genes (p < 0.05). Expression of the 
α1A-AR gene was similar to the later three genes mentioned. The α1B- and β1-AR genes were 
expressed at a significantly (p < 0.05) higher level than the α1D- and α2B-AR genes, which were 
not detectable. Expression of the α2C- and β3-AR genes were also close to the limit of detection.  
Within B cells, the α2A-AR gene was expressed at a higher level (p < 0.05) than all the 
other AR genes. The β1-, β2-, α1A-, and α1B-AR genes were similarly expressed at the next 
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highest level, followed by β3-AR at a significantly (p < 0.05) lower level. Expressed near the 
limit of detection were the α2B-, α2C- and α1D-AR genes. 
CD335+ ILCs, which include conventional natural killer or NK cells and non-
conventional T cells, expressed the β2-AR gene at a significantly (p < 0.01) higher level than all 
other AR genes. The α1A and α2A-AR genes displayed similar levels of expression at a 
significantly (p < 0.05) lower level than the β2-AR gene but significantly (p < 0.05) higher than 
the α1B-AR gene. Low but detectable levels of transcript were present for the α2B-, α2C-, β1-, 
and β3-AR genes. 
Purified T cells displayed the least variation in AR gene expression. The AR gene 
expressed at the highest level was α2A but the β2- and α1A-AR genes were also expressed at 
similar levels. The α1B-, β1-, and α2C-AR are expressed at a significantly (p <0.05) different 
level from the α2A-AR.  Expression of the α1D-, α2B-, and β3-AR genes was barely detectable.  
Collectively, these data reveal that while monocytes, B cells, T cells, and ILCs are often 
analyzed together as PBMCs, there is marked variation in AR gene expression within and among 
these subpopulations. Differential expression of the α2A- and β2-AR genes was most marked 
when comparing among PBMC subpopulations, suggesting different capacities for cells within 
each subpopulation to respond to adrenergic agonists and that a change in the frequency of cells 
within an individual subpopulation could alter transcript abundance when analyzing AR gene 




Figure 5.6: Expression of the nine known bovine AR genes in lymphocyte subpopulations 
and monocytes. Lymphocyte subpopulations analyzed included T cells (CD3+), B cells 
(CD21+), and innate lymphoid cells (CD335+) and monocytes were identified as CD14+ cells. 
Data expressed as 1/ΔCq and presented as mean + 1 SD (n = 5 cattle). The horizontal line 
indicates the cutoff used to define detectable gene expression (>35 PCR cycles). A 2-way 
ANOVA was used to compare AR gene expression within and among the purified 
subpopulations. Genes that are significantly (p < 0.05) different in transcript abundance within 
individual PBMC subpopulations are identified by different letters (a, b, c, d). Significant 
differences in the expression of an individual AR gene when comparing among PBMC 




5.1.3.3 Adrenergic Receptor Gene Expression in PMN Subpopulations 
Marked differences in AR gene expression observed among PBMC subpopulations 
suggested significant differences in AR gene expression may also occur when comparing PMN 
subpopulations. PMNs in bovine blood are primarily neutrophils but eosinophils comprise an 
average of 3.6% of blood leukocytes in healthy animals, varying between 0-10.8% (George, 
Snipes and Lane, 2010). Differences in neutrophil and eosinophil autofluorescence in FL-1 were 
validated as a parameter that could be used with high-speed cell sorting to generate highly 
purified (> 95% purity) neutrophil and eosinophil subpopulations (Andersen et al. unpublished 
data). As a result, discrimination between neutrophils and eosinophils based on FL-1 
fluorescence was used to sort these PMN subpopulations. Validation for the effective separation 
of neutrophils and eosinophils based on FL-2 and FL-3 autofluorescence is demonstrated in the 
Materials and Methods (Figure 4.4). However, significantly (p < 0.01) higher eosinophil 
autofluorescence is observed in all channels on the FACSCalibur (Figure 5.7). Greater 




Figure 5.7: Autofluorescence of bovine neutrophils and eosinophils in four fluorescence 
(FL) channels. Autofluorescence is expressed as mean fluorescent intensity of each PMN 
subpopulation and presented as the mean + 1 SD (n = 5 cattle). Multiple t-tests were used to 
compare mean fluorescent intensity between the two PMN subpopulations. Significant 
differences in neutrophils and eosinophils autofluorescence are indicated ** (p < 0.01). 
RNA extracted from high-speed sorted neutrophils and eosinophils was used to complete 
RT-qPCR analysis of AR gene expression (Figure 5.8). Neutrophils expressed a detectable level 
of transcript for all 9 ARs with few significant differences when comparing among individual 
AR genes. Transcript was most abundant for the α2C-AR gene but was not significantly different 
from α2A-, α2B-, or the 2- and 3-AR genes. Expression of the α2C-AR gene was, however, 
significantly (p < 0.05) greater than all the 1-AR genes and the 1-AR gene. In contrast, 
eosinophils displayed a more varied expression when comparing among AR genes, with 
expression of the α1B- and α1D-AR genes at the limit of detection. In contrast, the 2A- and 2-
AR genes were expressed at a similar but significantly (p < 0.01) higher levels than all other AR 
genes. The remaining AR genes were expressed at similar but lower levels except for 1-AR, 
which was expressed at a significantly (p < 0.05) lower level than the 1A-AR gene.  
A comparison of neutrophils and eosinophils revealed significant (p < 0.01) differences 
in the expression of all AR genes except for the 1A-AR gene (Figure 5.8). Neutrophils 
displayed significantly (p < 0.01) greater expression of the 1B- and 1D-AR genes, the - 
and 2C-AR genes, and the 1- and 3-AR genes when compared to eosinophils. In contrast, 
eosinophils expressed the 2A- and 2-AR genes at significantly (p < 0.01) higher levels than 
neutrophils. Collectively, these analyses (n = 6) revealed that neutrophils and eosinophils, 
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although often grouped together as PMNs, display multiple differences in AR gene expression 
that may impact their responses to adrenergic hormones or agonists. These data strengthen the 
argument that neutrophils and eosinophils should be studied as individual cell populations and 
literature reporting the responses of PMNs to adrenergic agonists should not be directly 
extrapolated to neutrophils. 
 
Figure 5.8: Expression of AR genes in purified bovine neutrophils and eosinophils. Gene 
expression data is expressed as 1/ΔCq and presented as the mean + 1 SD (n = 6 cattle). The 
horizontal line indicates the lower cut-off for detection of transcript (>35 PCR cycles). A 2-way 
ANOVA was used to compare AR transcript abundance expression both within and between the 
two PMN subpopulations. Genes that are significantly (p < 0.05) different in transcript 
abundance within neutrophils and within eosinophils are identified by different letters (a, b, c, d). 
Significant differences in the expression of individual AR genes when comparing neutrophils 
and eosinophils are indicated as ** (p < 0.01). 
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In conclusion, numerous significant differences in transcript abundance of individual AR 
genes were observed when comparing among bovine leukocyte subpopulations (Figures 5.5, 5.6, 
and 5.8). Of note, the α2A-AR gene was the most highly expressed AR gene in B cells, ILCs, 
and eosinophils. The 2-AR gene was also highly expressed in ILCs, monocytes, and 
eosinophils. Among all the leukocyte subpopulations analyzed, neutrophils had the highest 
expression of the α2B-, α2C-, and β3-AR genes. These many differences in AR gene expression 
raise the possibility that individual leukocyte populations may respond very differently during a 
stress response characterized by increased release of epinephrine and norepinephrine. 
5.2 BOVINE NEUTROPHILS AND EOSINOPHILS 
5.2.1 Optimization of PMN Culture and Activation Conditions 
The analysis of AR gene expression in bovine leukocytes was followed by a more 
focused analysis of bovine PMNs to address the question which ARs regulate the function of 
both resting and activated PMNs. To address this question, bovine PMN culture, activation, and 
recovery conditions were optimized for flow cytometric analyses of single cells. Assays to 
measure PMN activation were also established, and culture conditions optimized for the analysis 
of PMN activation, viability, and recovery. The media used for all assays was AIM-V media 
supplemented with 20% FBS and β-2 mercaptoethanol (Whale et al. 2006) (see Materials and 
Methods) and PMNs were activated by co-stimulation with a combination of BoZ and rBoIFNγ 
for 1 hour at 39°C (normal bovine body temperature). Furthermore, the expression of L-selectin, 
CD44, CD16, CD11b, and iROS were assessed as quantitative measures of PMN activation 
(Figure 5.15 and 5.16).  
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The initial evaluation of BoZ as a method for PMN activation included assessing viable 
cell recoveries following BoZ treatment. Maximizing the number of viable PMNs recovered was 
considered important to ensure a representative cell population was analyzed. Both short-term 
(2h) and long-term (18h) PMN activation were analyzed. Increasing the dose of BoZ resulted in 
a numerical decrease in viable PMN recovery and this difference was significant (p < 0.05) when 
comparing media alone to 0.1 mg/mL BoZ (Figure 5.9). No significant dose-dependent 
differences in viable cell recovery were observed when PMNs were cultured for 18 h, even 
though there was again a numerical decline in the recovery of viable cells as the dose of BoZ 
increased (Figure 5.9). Furthermore, there were no significant differences in viable PMNs 
recovery at 2h versus 18h when comparing individual doses of BoZ (Figure 5.9). 
 
Figure 5.9: Recovery of viable PMNs following activation with BoZ. PMNs (5 x 106 
cells/well) were stimulated with different doses of opsonized zymosan (BoZ) for either 2 or 18 h 
prior to recovery and analysis of viable cell number. Data presented are values from independent 
experiments (n = 5) and the horizontal bar represents the mean value. Viable PMN recovery was 
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calculated by multiplying total cell counts with a hemocytometer by the proportion of cells 
negative for Annexin-V and Propidium Iodide staining. A two-way ANOVA was used to 
compare viable cell recovery for different BoZ doses within and between the two incubation 
periods. There were no significant differences when comparing between 2 and 18 h but 
significant (p < 0.05) differences in viable cell recovery at two hours are indicated (a, b). 
Evaluating BoZ as a method for activating PMNs included measuring the dose-dependent 
induction of iROS production. A dose-dependent increase in iROS production was observed as 
BoZ was increased from 0.01 mg/ml to a maximum of 0.2 mg/ml, although there was a marginal 
increase in fluorescence when comparing 0.1 versus 0.2 mg BoZ/mL (Figure 5.10). This analysis 
confirmed BoZ increased iROS production in PMNs. 
 
Figure 5.10: Intracellular (i)ROS production following PMN incubation with BoZ. 
Following a 2 h incubation in medium alone or with various doses of BoZ (0.01 mg/ml to 0.2 
mg/ml) cells were stained with propidium iodide (PI) to exclude dead (PI+) cells and DCFDA to 




Although BoZ had a dose-dependent effect on iROS production, as the dose of BoZ was 
increased there was also increased cell clumping (as demonstrated on cytospin slides; Figure 
5.11) and cell death (as demonstrated on FACS profiles; data not shown). Cells were filtered 
through a Falcon 35 μm filter to reduce cell clumping and PI staining was used to exclude dead 
cells from analysis. However, it was critical the recovered PMNs remained a single cell 
suspension to facilitate effective flow cytometric analysis of changes in the expression of cell 
surface markers and iROS. The generation of doublets or larger cell clumps increases the 
fluorescent signal for each event acquired by the flow cytometer. A method of cell activation 
which activated bovine PMNs without increasing cell aggregation or cell death was required.  
The final protocol for activating PMNs used was a combination of BoZ and recombinant 
bovine interferon gamma (rBoIFNγ). The two substances have a synergistic effect on bovine 
PMN activation (Sample and Czuprynski, 1990). Minimal cell clumping was observed following 
stimulation with rBoIFNγ and 6.25 ug/ml BoZ when cells were examined on cytospin slides 
(Figure 5.11); viable cell recovery from one-hour cultures was >85%, and cell viability was 




Figure 5.11: PMNs activated with (A) 0.05 mg/mL of BoZ vs. B) 6.25 μg/mL of BoZ and 10 
ng/mL of rBoIFNγ. A: PMNs were incubated for two hours at 37°C with 0.05 mg/mL of BoZ 
(see inset for greater consumption of BoZ alongside cell clumping). B: PMNs were incubated for 
one hour at 39°C with 6.25 μg/mL of BoZ and 10 ng/mL of rBoIFNγ (see inset for less 
consumption of BoZ and no cell clumping). Scale bar = 20 μm; Inset magnification = 400X. 
As observed in Figure 5.12, a substantial increase in both forward scatter (size) and side 
scatter (complexity) is observed in bovine PMNs activated for 2 h with 0.05 mg/mL of BoZ. Part 
of this may be a result of neutrophil and eosinophil phagocytosis of BoZ, which was confirmed 
by microscopy (Figure 5.9), but a proportion of this increase may also be the result of cell 
clumping.  
 
Figure 5.12: Dot scatter plots of cell size (Forward Scatter) and complexity (Side Scatter) of 
resting (A) and BoZ activated (B) PMNs. Resting PMNs were incubated in medium alone for 2 
hours at 37°C and activated PMNs were incubated for two hours with 0.05 mg/mL of BoZ. R1 
excludes dead cells and debris. 
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A smaller increase in forward scatter (size) and side scatter (complexity) was observed 
when PMNs were activated with the combination of BoZ and IFN (Figure 5.12) when compared 
to the much larger dose of BoZ alone (Figure 5.13). 
 
Figure 5.13: Dot scatter plots of cell size (Forward Scatter) and complexity (Side Scatter) of 
resting (A) and BoZ rBoIFNγ activated (B) PMNs. Resting PMNs were incubated in AIM-V 
medium for one hour at 39°C. PMNs were activated by incubation for one hour with 10 ng/mL 
rBoIFNγ and 6.25 μg/mL of BoZ. R1 excludes dead cells and debris. 
The final procedure for PMN activation (Figure 4.7) was optimized to maximize recovery 
of a viable single cell suspension. 
5.2.2 Percentage Neutrophils and Eosinophils in PMN Preparations 
Five calves were sampled at three different times (March to June, August to September, 
and late September) and gating on autofluorescence was used to identify eosinophils and 
neutrophils within the PMN preparation. The proportion of eosinophils and neutrophils in PMN 
preparations was observed to vary with the time of the year (Figure 5.14). Significantly (p < 
0.01) fewer eosinophils were observed when comparing the period of March to June (spring) to 
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the August to early September and late September (autumn) intervals. The percentage 
eosinophils in PMNs varied from a low of 1.8% to a high of 29.4%. Similarly, the percentage 
neutrophils in PMNs varied from a high of 97.8% to as low as 70.28%. Given the common 
practice of assuming eosinophils contribute little to PMN responses, these data indicate that in 
Saskatchewan, at certain times of the year, eosinophils may have a substantial influence when 
the collective response of PMNs is being measured.  
 
Figure 5.14: Percent (A) eosinophils and (B) neutrophils in PMNs isolated from the same 
five animals at different times of the year. Data presented are values for individual animals 
and the horizontal bar represents the mean. Individual animals are identified by different colours. 
A one-way ANOVA was used to compare the percent eosinophils and neutrophils at different 
times of the year. Eosinophils were identified by using flow cytometry to gate on 
autofluorescence high cells in fluorescent channel 2 and 3. Neutrophils were identified by using 
flow cytometry to gate on autofluorescence low cells in fluorescent channel 2 and 3. Significant 




5.2.3 Neutrophil and Eosinophil Basal Expression of Activation Markers 
Neutrophils and eosinophils were both > 98% positive for iROS, CD11b, L-selectin and 
CD44 (data not shown). The mean fluorescent intensity of iROS and CD11b was similar for both 
resting bovine neutrophils and eosinophils (Figure 5.15). L-selectin expression, however, was 
significantly (p < 0.01) greater on eosinophils than neutrophils and CD44 was expressed at a 
significantly (p < 0.01) higher level on neutrophils than eosinophils. This difference in CD44 
expression was subsequently used to discriminate between these two PMN subpopulations.  
CD16 expression was detectable on few resting eosinophils (< 1.0%) and was also expressed at a 
low but detectable level on a minor number of neutrophils (< 30.0%) (data not shown). However, 
higher eosinophil autofluorescence in FL-1 provided another effective parameter to discriminate 
between eosinophils and neutrophils.  
 
Figure 5.15: Expression of activation markers in bovine neutrophils and eosinophils 
following culture for one hour at 39°C. Data presented are mean fluorescence intensity + 1 SD 
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(n = 5 cattle). Seasonal variation in iROS expression of neutrophils and CD44 expression of 
eosinophils may contribute to the inter-animal variation that was observed. Multiple t-tests were 
used to compare expression of individual markers on neutrophils and eosinophils. Significant 
differences between neutrophils and eosinophils are indicated as ** (p < 0.01). 
5.2.4 Neutrophil and Eosinophil Activation Responses 
Treatment with BoZ + rBoIFNγ for one hour significantly alters the expression of 
multiple activation markers on neutrophils (Figure 5.16; Table 5.1 and 5.2). These changes 
include significantly (p < 0.01) increased iROS, increased CD11b, decreased L-selectin, and 
decreased CD44 expression. This activation protocol also significantly (p < 0.01) alters 
eosinophils, with increased ROS, increased CD11b, and decreased L-selectin. No change in 
CD16 expression was observed for either activated neutrophils or eosinophils. These changes in 
activation markers for both neutrophils and eosinophils confirmed both PMN subpopulations 
were activated when co-stimulated with BoZ + rBoIFNγ (Table 5.1 and 5.2). 
Significant differences in neutrophil and eosinophil responses to BoZ + rBoIFNγ were 
also observed (Figure 5.16; Table 5.1 and 5.2). CD11b increased significantly (p < 0.01) more on 
activated eosinophils than neutrophils. L-selectin decreased significantly (p < 0.01) more on 
activated eosinophils than neutrophils and CD44 decreased significantly (p< 0.01) on neutrophils 
but not eosinophils. Thus, for two of the activation markers eosinophils had a more pronounced 
reaction to BoZ + rBoIFNγ than neutrophils. As the percentage eosinophils increases within a 
PMN population these cells may make a substantial contribution when measuring the collective 




Figure 5.16: Expression of activation markers on bovine neutrophils and eosinophils 
following incubation with 10 ng/mL rBoIFNγ and 6.25 μg/mL BoZ for one hour. Data 
presented are mean fluorescence intensity + 1 SD (n = 5 cattle) and are expressed as a percent of 
baseline values for neutrophils and eosinophils cultured in media alone. A student’s t-test was 
used to compare expression levels of individual markers on activated neutrophils and 
eosinophils. Significant differences are indicated as ** (p < 0.01). 
Table 5.1: Bovine neutrophil and eosinophil ROS, CD11b, CD16, L-selectin, and CD44 




















iROS + 58.5% < 0.01 Yes + 65.4% < 0.01 Yes 
CD11b + 13.9 % < 0.01 Yes + 32.9 % < 0.01 Yes 
CD16 + 0.9% 0.68 No + 3.9% 0.14 No 
CD44 - 17.6% < 0.01 Yes + 3.6% 0.31 N/A 
L-selectin - 31.5% < 0.01 Yes - 47.7% < 0.01 Yes 
1. Data presented are mean fluorescence intensity calculated as a percentage of baseline 
(media alone).  




Table 5.2: References for ROS, CD11b, CD16, L-selectin and CD44 as markers of 
neutrophil and eosinophil activation.  
 
Expected 
Increase or  
Decrease 
Activation Hypothesis References1 
ROS  Increase Brown and Roth, 1991;Leino and Paape, 1993; Conejeros et al., 2011; 
Winterbourn, Kettle and Hampton, 2016;Sample and Czuprynski, 
1990;Kowanko and Ferrante, 1987; Chaves et al., 1996; Yukawa et al., 
1990 
CD11b  Increase In’t Veen et al., 1998; Scanzano et al., 2015; Margaryan et al., 2017; 
Brandau et al., 2011; Casanova-Acebes et al. 2013;Trabold, Gruber 
and Fröhlich, 2007 
CD16  Increase Davoine et al., 2002; Millrud et al., 2017; Brandau et al., 2011; Pillay 
et al., 2012 
CD44  Decrease Wang et al., 2002; Campanero et al., 1991 
L-selectin  Decrease Tak et al., 2017; Casanova-Acebes et al., 2013; Ivetic, Green and Hart, 
2019; Trabold, Gruber and Fröhlich, 2007; Margaryan et al., 2017; 
Hayashi, Means and Luster, 2003; 
Li et al., 2006; Diez-Fraile et al., 2003; Momose et al., 1999 
 
 
5.3 ADRENERGIC RECEPTOR FUNCTION IN BOVINE NEUTROPHILS AND 
EOSINOPHILS 
5.3.1 Effects of Adrenergic Agonists on iROS Production in Resting and Activated Bovine 
Neutrophils and Eosinophils 
Five adrenergic agonists were tested to determine if they influenced resting and activated 
neutrophils and eosinophils. These compounds included the endogenous agonists E and NE and 
synthetic agonists with known AR specificity. To address the question whether all families of 
ARs were possibly functional in eosinophils and neutrophils, compounds were selected with 
specificity for each AR family: phenylephrine (α1-AR agonist); dexmedetomidine (α2-AR 
agonist), and isoproterenol (β-AR agonist). The following data were normalized by expressing 
responses of cells from individual animals as a percentage of the response of isogenic cells 
cultured in media alone or activated by BoZ + rBoIFNγ in the absence of adrenergic agonist. 
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This normalization was used to minimize the effect of inter-animal variation in neutrophil and 
eosinophil responses to adrenergic agonists. 
5.3.1.1 Intracellular Reactive Oxygen Species (iROS) 
There is previous evidence that adrenergic agonists and antagonists can modulate ROS 
levels in bovine PMNs (LaBranche, Ehrich and Eyre, 2010). The production of iROS is an 
important effector mechanism for killing phagocytosed microbes and increased iROS production 
is also considered a sign of activation in both neutrophils (Winterbourn, Kettle and Hampton, 
2016) and eosinophils (Yukawa et al., 1990; Silveira et al., 2019). Therefore, modulating iROS 
activity during a stress response may be very important in altering host-pathogen interactions. 
All five adrenergic agonists tested altered iROS production in resting bovine neutrophils 
(Figure 5.17). Both physiological agonists, E and NE significantly (p < 0.05) increased iROS 
production. Norepinephrine significantly (p < 0.05) increased iROS production at all doses tested 
but the response was less consistent with E despite a numerical increase in iROS production at 
all doses tested.    
Phenylephrine, a non-selective α1-AR agonist, consistently suppressed iROS activity in 
resting neutrophils but this reduction was only significant (p < 0.05) at a dose of 1 nM. 
Dexmedetomidine, a non-selective α2-AR agonist, also induced a consistent decrease in iROS 
production that was significant (p < 0.01) at a dose of 1 nM. Isoproterenol, the non-selective β-
AR agonist, also inhibited iROS production with a significant (p < 0.05) effect at a concentration 
of 10 nM. At agonist concentrations of 0.1 and 100 nM, there were significant (p < 0.05) 
differences in the iROS response to E and NE relative to the synthetic adrenergic agonists 
phenylephrine, dexmedetomidine and isoproterenol. At the intervening doses of 1 and 10 nM, 
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this difference in iROS production when comparing E and NE with the synthetic adrenergic 
agonists was not always consistent but the same general trend was observed. Synthetic AR 
agonists, which target an individual AR family, suppressed iROS activity but both E and NE 
increased iROS activity in resting neutrophils. This apparent contradiction in the regulation of 
iROS activity by ARs was unexpected and suggests E and NE regulate iROS activity by 
signaling through more than just one AR family. 
 
Figure 5.17: Effect of adrenergic agonists on iROS activity in resting bovine neutrophils.  
Data presented are mean ± SEM (n = 5 cattle) of DCFDA mean fluorescence intensity (MFI) 
calculated as a percentage of DCFDA MFI intensity for neutrophils cultured in the absence of an 
adrenergic agonist. A two-way ANOVA was used to compare DCFDA MFI among different 
doses of each AR agonist and among different AR agonists at each dose. Significant differences 
in the expression of DCFDA MFI among treatments are identified by different letters (a, b, c). 
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Significant changes in DCFDA MFI relative to baseline are indicated for each treatment as * (p < 
0.05) and ** (p < 0.01). 
Among the five adrenergic agonists evaluated, only two agonists significantly (p < 0.05) 
altered iROS production following neutrophil activation by BoZ + IFNγ co-stimulation (Figure 
5.18). NE induced a numerical increase in iROS production at all doses tested and this effect was 
significant (p < 0.05) at 1 nM, 10 nM, and 100 nM. This response was similar to that observed 
with resting neutrophils. In contrast, E had no significant effect on iROS production in activated 
neutrophils. Thus, a marked difference in E and NE activity was apparent when evaluating 
activated neutrophils. Dexmedetomidine, the non-selective α2-AR agonist, was the only 
synthetic agonist to significantly (p < 0.05) reduce iROS activity in activated neutrophils at doses 
of 1 nM and 10 nM despite a numerical decrease in iROS activity at all doses tested. This 
response is consistent with that observed with resting neutrophils. In contrast, both the non-
selective α1-AR agonist (Phenylephrine) and β-AR agonist (Isoproterenol) failed to significantly 
alter iROS activity in activated neutrophils. There was, however, a numerical decrease in iROS 
production at both 1 and 10 nM doses for both AR agonists. There was a significant (p < 0.05) 
difference in iROS activity when comparing NE treatment with all synthetic adrenergic agonists 
at doses of 1 nM and higher. There was also a significant (p < 0.05) difference in iROS activity 
between NE and E treatments at 100 nM. These data indicate that regulation of iROS activity by 
adrenergic agonists can differ between resting and activated neutrophils and confirm NE 
stimulation of activated neutrophils is not replicated by a synthetic adrenergic agonist 




Figure 5.18: Effect of adrenergic agonists on iROS activity in activated bovine neutrophils. 
Data presented are mean ± SEM (n = 5 cattle) of DCFDA mean fluorescence intensity (MFI) 
calculated as a percentage of DCFDA MFI intensity for BoZ rBoIFNγ activated neutrophils 
cultured in the absence of an adrenergic agonist. A two-way ANOVA was used to compare 
DCFDA MFI at different doses of each AR agonist and among AR agonists at the same dose. 
Significant differences in DCFDA MFI among treatments are identified by different letters (a, b, 
c) and significant dose-dependent differences in DCFDA MFI are indicated as * (p < 0.05) and 
** (p < 0.01). 
Neither E nor NE had a significant effect on iROS activity in resting eosinophils but all 
three synthetic AR family specific agonists significantly reduced iROS activity (Figure 5.19). 
Phenylephrine, an α1-AR selective agonist, significantly (p < 0.01) reduced iROS expression at a 
concentration of 1, 10, and 100 nM. Dexmedetomidine, an α2-AR selective agonist, significantly 
(p < 0.01) reduced iROS expression at a concentration of 1 nM and isoproterenol, a β-AR 
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agonist, significantly (p < 0.01) reduced iROS at all doses tested. There were no significant 
differences in iROS suppression when comparing among the three synthetic adrenergic agonists 
but the response to isoproterenol was significantly different (p < 0.01) from E and NE at all 
doses tested. Significant differences between the synthetic agonists, dexmedetomidine and 
phenylephrine, and either E or NE were less consistent and only observed at doses between 1 to 
100 nM. Thus, modulation of iROS activity in resting eosinophils was very different from resting 
neutrophils for E and NE but a similar pattern of suppressed iROS was observed with the three 
synthetic agonists.  
 
Figure 5.19: Effect of adrenergic agonists on iROS activity in resting bovine eosinophils. 
Data presented are mean ± SEM (n = 5 cattle) of DCFDA mean fluorescence intensity (MFI) 
calculated as a percentage of DCFDA MFI intensity for eosinophils cultured in the absence of an 
adrenergic agonist. A two-way ANOVA was used to compare DCFDA MFI at different doses of 
each AR agonist and among AR agonists at the same dose. Significant differences in DCFDA 
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MFI among treatments are identified by different letters (a, b, c) and significant dose-dependent 
differences are indicated as * (p < 0.05) and ** (p < 0.01). 
Similar to resting eosinophils, iROS levels were not significantly changed when activated 
eosinophils were incubated with E and NE (Figure 5.20). In contrast, two of the three synthetic 
AR family specific agonists (phenylephrine and isoproterenol) significantly decreased iROS 
activity in activated eosinophils. Phenylephrine, an α1-AR selective agonist, significantly 
reduced (p < 0.05) iROS expression at concentrations of 1, 10, and 100 nM, similar to what was 
observed with resting eosinophils. Isoproterenol, the β-AR agonist, also significantly (p < 0.05) 
reduced iROS at concentrations of 1, 10, and 100 nM. Dexmedetomidine, the 2-AR agonist, 
had no significant effect on iROS activity in activated eosinophils despite having a significant 
effect on resting eosinophils. At a dose of both 1 nM and 10 nM, both phenylephrine and 
isoproterenol induced significantly (p < 0.05) lower iROS activity relative to NE. Thus, 
eosinophil activation did not change the suppression of iROS by 1-AR and β-AR agonists. 
However, activated neutrophils (Figure 5.18) and activated eosinophils (Figure 5.20) displayed 




Figure 5.20: Effect of adrenergic agonists on iROS production in activated bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of DCFDA mean fluorescence 
intensity (MFI) calculated as a percentage of DCFDA MFI intensity for BoZ + rBoIFNγ 
activated eosinophils cultured in the absence of an adrenergic agonist. A two-way ANOVA was 
used to compare DCFDA MFI among doses of each AR agonist and among different AR 
agonists at the same dose. Significant differences in DCFDA MFI among treatments are 
identified by different letters (a, b, c) and significant dose-dependent differences are indicated as 
* (p < 0.05) and ** (p < 0.01). 
5.3.2 Effects of Adrenergic Agonists on Adhesion Molecule Expression of Resting and Activated 
Bovine Neutrophils and Eosinophils 
The expression of adhesion molecules on neutrophils and eosinophils plays a critical role 
in cell recruitment and retention at sites of inflammation. They can also be used as markers for 
PMN activation (Walker et al., 1993; Mengelers et al., 1994; In’t Veen et al., 1998; Wang et al., 
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2002; Lee et al., 2007; Casanova-Acebes et al., 2013; Tak et al., 2017; Cassetta et al., 2019; 
Ivetic, Green and Hart, 2019). Stress has also been shown to alter neutrophil and eosinophil 
recruitment to tissues and their abundance in the blood in cattle (Hickey, Drennan and Earley, 
2003; Yagi et al., 2004; Ishizaki and Kariya, 2010; Hodgson et al., 2012; O’Loughlin et al., 
2011). Furthermore, in vivo studies have shown adrenergic agonists alter PMN recruitment to 
sites of infection such as wounds in mice (Gosain, Gamelli and DiPietro, 2009a; Kim et al., 
2014). Therefore, I investigated whether adrenergic agonists modulated the expression of key 
adhesion molecules, CD11b, L-selectin, and CD44, on both resting and activated neutrophils and 
eosinophils.  
5.3.2.1 CD11b  
CD11b plays a role in neutrophil adhesion to vascular endothelium and Fc receptor 
mediated degranulation (Coxon et al., 1996; Tang et al., 1997; Ince, Weber and Scheiermann, 
2019). Increased CD11b expression is indicative of neutrophil and eosinophil activation and 
increased responsiveness to pathogens such as bacteria and environmental fungi (Walker et al., 
1993; In’t Veen et al., 1998; Casanova-Acebes et al., 2013; Cassetta et al., 2019) and adrenergic 
agonists are reported to increase CD11b expression on PMNs (Trabold, Gruber and Fröhlich, 
2007; Kim et al., 2014; Scanzano et al., 2015; Margaryan et al., 2017). Therefore, the capacity of 
adrenergic agonists to modulate CD11b expression on resting and activated bovine neutrophils 
and eosinophils was investigated to determine if these two populations displayed similar 
responses.  
All adrenergic agonists tested increased the expression of CD11b on resting neutrophils 
(Figure 5.21). The physiological agonists E and NE significantly (p < 0.05) increase CD11b 
expression at 1, 10, and 100 nM concentrations. The α1-AR agonist phenylephrine also 
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significantly (p < 0.05) increases CD11b expression but only at the highest dose of 100 nM. This 
suggests the α1-AR family may contribute to the effect of E and NE on CD11b expression in 
bovine neutrophils but at 10 nM, NE induced a significantly (p < 0.05) greater CD11b response 
than any of the synthetic AR family specific agonists. Thus, no one family of ARs is implicated 
as being primarily responsible for mediating the effects of E and NE on CD11b expression. All 
synthetic adrenergic agonists did, however, induce a numerical if not significant increase in 
CD11b expression suggesting multiple ARs may be implicated in mediating the effect of E and 
NE.  
 
Figure 5.21: Effect of adrenergic agonists on CD11b expression on resting bovine 
neutrophils. Data presented are mean ± SEM (n = 5 cattle) of CD11b mean fluorescence 
intensity (MFI) calculated as a percentage of CD11b intensity for neutrophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare CD11b MFI among 
doses of each AR agonist and among AR agonists at the same dose. Significant differences in 
CD11b MFI among treatments are identified by different letters (a, b, c) and significant dose-
dependent differences are indicated as * (p < 0.05) and ** (p < 0.01). 
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Adrenergic agonists also increased CD11b expression on neutrophils activated with BoZ 
+ rBoIFNγ (Figure 5.22). Epinephrine and norepinephrine significantly (p < 0.05) increased 
CD11b expression only at the highest dose tested. Isoproterenol, the -AR agonist, significantly 
(p < 0.01) increased CD11b expression only at 0.1 nM but consistently increased CD11b 
expression at all doses evaluated. Furthermore, increased CD11b expression induced by 
isoproterenol at 0.1 nM was significantly (p < 0.01) greater than that observed with E but not 
NE. At 100 nM, NE, phenylephrine, and dexmedetomidine significantly (p < 0.05) increased 
CD11b expression but there was no difference in this response when comparing among agonists. 
Thus, the capacity of adrenergic agonists to increase CD11b was observed with both resting and 
activated neutrophils but the response varied, depending on the specific agonist. For example, E 
significantly increased CD11b expression in resting (Figure 5.21) but not activated (Figure 5.22) 
neutrophils.   
Similar to neutrophils, resting bovine eosinophils also responded to adrenergic agonists 
with an increase in CD11b expression (Figure 5.22). Both E and NE significantly (p < 0.01) 
increased CD11b expression at doses of 1 to 100 nM. In contrast, the synthetic adrenergic 
agonists induced a numerical increase in CD11b expression, but this effect was only significant 
(p < 0.01) for phenylephrine at a dose of 100 nM. At a dose of 10 nM, NE induced a 
significantly (p < 0.05) greater increase in CD11b expression than any of the synthetic agonists 
targeting individual AR families. This observation supports the conclusion that the effect of both 




Figure 5.22: Effect of adrenergic agonists on CD11b expression on activated bovine 
neutrophils. Data presented are mean ± SEM (n = 5 cattle) of CD11b mean fluorescence 
intensity (MFI) calculated as a percentage of CD11b intensity for neutrophils activated with BoZ 
+ rBoIFNγ in the absence of an adrenergic agonist. A two-way ANOVA was used to compare 
CD11b MFI among doses of each AR agonist and among AR agonists at the same dose. 
Significant differences in CD11b MFI among treatments are identified by different letters (a, b, 
c) and significant dose-dependent effects relative to baseline are indicated as * (p < 0.05) and ** 




Figure 5.23: Effect of adrenergic agonists on CD11b expression on resting bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of CD11b mean fluorescence 
intensity (MFI) calculated as a percentage of CD11b intensity for eosinophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare CD11b MFI among 
doses of each AR agonist and among AR agonists at the same dose. Significant differences in 
CD11b MFI among treatments are identified by different letters (a, b, c) and significant dose-
dependent effects relative to baseline are indicated as * (p < 0.05) and ** (p < 0.01). 
With activated eosinophils, all adrenergic agonists induced a numerical increase in 
CD11b expression but a significant effect was only observed at a few specific doses (Figure 
5.24). At a dose of 0.1 nM, the β-AR agonist isoproterenol induced a significant (p < 0.01) 
increase in CD11b expression. At a dose of 100 nM, the α1-AR agonist phenylephrine and α2-
AR agonist dexmedetomidine also induced significant (p < 0.01) increases in CD11b expression. 
Unlike resting eosinophils, neither E nor NE induced significant increases in CD11b expression 
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but there was a numerical increase in CD11b MFI at most doses evaluated. Thus, the pattern of 
adrenergic agonist activity was similar in both resting and activated eosinophils.  
 
Figure 5.24: Effect of adrenergic agonists on CD11b expression on activated bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of CD11b mean fluorescence 
intensity (MFI) calculated as a percentage of CD11b intensity for eosinophils activated with BoZ 
+ rBoIFNγ in the absence of an adrenergic agonist. A two-way ANOVA was used to compare 
CD11b MFI among doses of each AR agonist and among AR agonists at the same dose. No 
significant differences in CD11b MFI was observed among treatments but significant dose-
dependent differences relative to baseline are indicated as * (p < 0.05) and ** (p < 0.01).  
5.3.2.2 L-selectin 
L-selectin is an adhesion molecule which is “shed” during activation and maturation of 
neutrophils and eosinophils (Mengelers et al., 1994; Lee et al., 2007; Casanova-Acebes et al., 
2013; Tak et al., 2017; Ivetic, Green and Hart, 2019). Epinephrine and norepinephrine have been 
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reported to modulate L-selectin expression on human neutrophils (Trabold, Gruber and Fröhlich, 
2007) but there are no reports that adrenergic agonists modulate L-selectin levels on bovine 
neutrophils or eosinophils. Therefore, the effects of adrenergic agonists on the expression of L-
selectin on both resting and activated bovine neutrophils and eosinophils was investigated.  
All adrenergic agonists evaluated significantly (p < 0.01) reduced L-selectin expression 
on resting bovine neutrophils at all doses tested and the magnitude of this response was similar at 
0.1 nM and 100 nM for each agonist (Figure 5.25). The β-AR agonist isoproterenol consistently 
induced the greatest reduction in L-selectin expression and the magnitude of this response at 0.1 
nM was significantly (p < 0.05) greater than either of the physiological ligands, E and NE.  
However, at higher doses, no significant differences were observed among the five adrenergic 
agonists. These results confirm adrenergic agonists consistently induce rapid shedding of L-





Figure 5.25: Effect of adrenergic agonists on L-selectin levels on resting bovine neutrophils. 
Data presented are mean ± SEM (n = 5 cattle) of L-selectin mean fluorescence intensity (MFI) 
calculated as a percentage of L-selectin MFI intensity for resting neutrophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare L-selectin MFI 
among doses of each AR agonist and among AR agonists at the same dose. Significant 
differences in L-selectin MFI among treatments are identified by different letters (a, b, c) and 
significant dose-dependent differences within each treatment relative to baseline are indicated as 
* (p < 0.05) and ** (p < 0.01). 
Activation of bovine neutrophils with BoZ + rBoIFNγ results in a 50-60% reduction in L-
selectin (Figure 5.16) and adrenergic agonists had a less marked effect on L-selectin expression 
on activated bovine neutrophils (Figure 5.26). For most agonists, except for E, there was a 
numerical decrease in L-selectin expression that was dose-dependent. Dexmedetomidine, the 2 
agonist, significantly (p < 0.05) reduced L-selectin at doses of 1, 10, and 100 nM. At 100 nM, 
dexmedetomidine significantly (p < 0.05) reduced L-selectin levels relative to the physiological 
agonists E and NE. Isoproterenol, the -AR agonist, also significantly (p < 0.05) reduce L-
selectin expression a at 10 nM. Overall, the effect of adrenergic agonists on L-selectin shedding 
was much less pronounced in activated (Figure 5.26) versus resting (Figure 5.25) bovine 
neutrophils. This limited effect by adrenergic agonists may simply be a consequence of the 




Figure 5.26: Effect of adrenergic agonists on L-selectin levels on activated bovine 
neutrophils. Data presented are mean ± SEM (n = 5 cattle) of L-selectin mean fluorescence 
intensity (MFI) calculated as a percentage of L-selectin MFI intensity for BoZ + rBoIFNγ 
activated neutrophils cultured in the absence of an adrenergic agonist. A two-way ANOVA was 
used to compare L-selectin MFI among doses for each AR agonist and among AR agonists at the 
same dose. Significant differences in L-selectin MFI among treatments are identified by different 
letters (a, b, c) and significant dose-dependent differences relative to baseline are indicated as * 
(p < 0.05) and ** (p < 0.01). 
Adrenergic agonists both increased and decreased L-selectin levels on resting eosinophils 
(Figure 5.27). Surprisingly, NE significantly (p < 0.01) increased L-selectin levels at doses of 0.1 
and 1 nM and at these doses L-selectin levels on NE treated eosinophils were significantly (p < 
0.05) greater than on eosinophils treated with all other adrenergic agonists. In contrast, 
phenylephrine, the 1-AR agonist, significantly (p < 0.05) reduced L-selectin expression at 
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doses of 0.1, 1, and 10 nM. Isoproterenol, the -AR agonist, also significantly (p < 0.01) reduced 
L-selectin expression at 10 and 100 nM doses and at 10 nM isoproterenol induced significantly 
(p < 0.05) less L-selectin than both NE and dexmedetomidine treated eosinophils. 
Dexmedetomidine, the a2-AR agonist, and E had no significant effect on L-selectin levels on 
resting eosinophils. Thus, when analyzing L-selectin levels on resting eosinophils (Figure 5.27) 
these cells displayed a much more varied response to adrenergic agonists than neutrophils 
(Figure 5.25). Furthermore, the L-selectin response on resting eosinophils to synthetic adrenergic 
agonists confirmed both 1- and -ARs were functional but signaling by these AR families 
could not account for NE activity. Finally, the contradictory effect of NE on L-selectin levels in 
resting neutrophils and eosinophils further demonstrates the importance of separately analyzing 
the responses of these two PMN subpopulations.   
 
Figure 5.27: Effect of adrenergic agonists on L-selectin levels on resting bovine eosinophils. 
Data presented are mean ± SEM (n = 5 cattle) of L-selectin mean fluorescence intensity (MFI) 
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calculated as a percentage of L-selectin MFI intensity for eosinophils cultured in the absence of 
an adrenergic agonist. A two-way ANOVA was used to compare L-selectin MFI among doses 
for each AR agonist and among AR agonists at the same dose. Significant differences in L-
selectin MFI among treatments are identified by different letters (a, b, c) and significant dose-
dependent differences within individual treatments relative to baseline are indicated as * (p < 
0.05) and ** (p < 0.01). 
As observed with neutrophils, activation of eosinophils with BoZ + rBoIFNγ resulted in a 
marked reduction in L-selectin (Figure 5.16). None of the five adrenergic agonists evaluated, 
however, induced a further significant change in L-selectin levels on activated eosinophils with 
the exception of the α2-AR agonist dexmedetomidine (p < 0.01) at a dose of 100 nM, (Figure 
5.28). At this dose, the reduction in L-selectin by dexmedetomidine was significantly (p < 0.05) 
different when compared to E but none of the other AR agonists. This apparent lack of an effect 
by AR agonists on L-selectin levels on activated eosinophils was similar to the response 




Figure 5.28: Effect of adrenergic agonists on L-selectin levels on activated bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of L-selectin mean fluorescence 
intensity (MFI) calculated as a percentage of L-selectin MFI intensity for activated eosinophils 
cultured in the absence of an adrenergic agonist. A two-way ANOVA was used to analyze L-
selectin MFI among doses for each AR agonist and among AR agonists at the same dose. 
Significant differences in L-selectin MFI among treatments are identified by different letters (a, 
b) and there were no significant dose-dependent differences when comparing within treatment 
relative to baseline. 
5.3.2.3 CD44 
CD44 is a receptor that augments cell adhesion to and monitoring of hyaluronan in the 
extracellular matrix (Ponta, Sherman and Herrlich, 2003). Down-regulation of the CD44 receptor 
by cells such as neutrophils has been shown to increase their migration by reducing cell adhesion 
to hyaluronan (Wang et al., 2002). CD44 has also been found to be integral to allergic responses 
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by eosinophils, on the other hand, meaning decreased expression may inhibit function (Katoh et 
al., 2003). Therefore, determining whether adrenergic agonists modulate CD44 expression in 
either resting or activated neutrophils and eosinophils may provide insight into the effect of 
stress on recruitment of these cells to sites of inflammation.  
Although neutrophils express a much higher level of CD44 than eosinophils (Figure 5.15) 
none of the adrenergic agonists analyzed had a significant effect on CD44 expression on either 
resting (Figure 5.29) or BoZ + rBoIFNγ activated (Figure 5.30) bovine neutrophils.  
 
Figure 5.29: Effect of adrenergic agonists on CD44 expression on resting bovine 
neutrophils Data presented are mean ± SEM (n = 5 cattle) of CD44 mean fluorescence intensity 
(MFI) calculated as a percentage of CD44 MFI intensity for neutrophils cultured in the absence 
of an adrenergic agonist. A two-way ANOVA was used to compare CD44 MFI among doses of 
each AR agonist and among AR agonists at the same dose. No significant differences in CD44 
MFI among treatments were identified and no significant dose-dependent differences were 




Figure 5.30: Effect of adrenergic agonists on CD44 expression on activated bovine 
neutrophils. Data presented are mean ± SEM (n = 5 cattle) of CD44 mean fluorescence intensity 
(MFI) calculated as a percentage of CD44 MFI intensity for BoZ + rBoIFNγ activated 
neutrophils cultured in the absence of an adrenergic agonist. A two-way ANOVA was used to 
compare CD44 MFI among doses of each AR agonist and among AR agonists at each dose. No 
significant differences in CD44 MFI were identified among treatments and no significant dose-
dependent differences were observed within individual treatments. 
Endogenous AR agonists E and NE significantly increased CD44 expression on resting 
bovine eosinophils (Figure 5.31). At a dose of 1 nM, NE significantly (p < 0.01) increased CD44 
expression, but this effect was not significantly different when compared to other AR agonists. 
Similarly, at concentrations of 1 and 10 nM, E significantly (p < 0.05) increased CD44 
expression but again this effect was also not significantly different from other AR agonists. The 
synthetic AR agonists followed a similar trend with numerical increases in CD44 expression that 
were not, however, significantly different from baseline levels. These observations further 




Figure 5.31: Effect of adrenergic agonists on CD44 expression on resting bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of CD44 mean fluorescence intensity 
(MFI) calculated as a percentage of CD44 MFI intensity for resting eosinophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare CD44 MFI among 
doses for each AR agonist and among AR agonists at the same dose. There were no significant 
differences when comparing CD44 MFI among treatments but significant dose-dependent 
differences within individual treatments relative to baseline are indicated as * (p < 0.05) and ** 
(p < 0.01). 
Activation of bovine eosinophils by BoZ + rBoIFNγ does not significantly alter CD44 
levels (Figure 5.16). Treatment of activated eosinophils with AR agonists also had no significant 
effect on CD44 expression with the exception of E which at a dose of 1 nM induced a 
significantly (p < 0.05) reduction in CD44 (Figure 5.32). The synthetic AR agonists induced 
numerical but not significant dose-dependent increases in CD44 expression but 0.1 nM 
dexmedetomidine, the 2-AR agonist, induced significantly (p < 0.05) higher CD44 expression 
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than NE. Furthermore, at a dose of 1 nM, dexmedetomidine, phenylephrine, and isoproterenol 
induced significantly (p < 0.05) higher CD44 expression when compared to E. These results 
imply there may be some differences in eosinophil activation by endogenous and synthetic AR 
agonists. However, it should be noted that these differences in CD44 expression were small. 
 
Figure 5.32: Effect of adrenergic agonists on CD44 expression on activated bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of CD44 mean fluorescence intensity 
(MFI) calculated as a percentage of CD44 MFI intensity for activated eosinophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare CD44 MFI among 
doses for each AR agonist and among AR agonists at the same dose. Significant differences in 
the expression of CD44 MFI among treatments are identified by different letters (a, b, c) and 





5.3.3 Effects of Adrenergic Agonists on Expression of the Fc Receptor CD16 on Resting and 
Activated Bovine Neutrophils and Eosinophils 
CD16 is an Fc receptor that is considered a marker of both neutrophil and eosinophil 
activation and maturation (Huizinga et al., 1990; Kimberly et al., 1990; Davoine et al., 2002; 
Pillay et al., 2012; Millrud et al., 2017). It has been associated with multiple PMN activation 
responses such as oxidative burst and phagocytosis (Huizinga et al., 1990; Kimberly et al., 
1990). Thus, modulation of CD16 expression by AR agonists has implications for altering a wide 
array of neutrophil and eosinophil responses during a stress response.  
5.3.3.1 CD16 
CD16 expression (average MFI: 3.75) was detectable on approximately 30% of resting 
bovine neutrophils and treatment with the 5 AR agonists did not significantly alter CD16 
expression (Figure 5.33). The one exception was a small but significant (p < 0.05) reduction in 
CD16 expression when resting neutrophils were treated with NE. This response to NE was not 




Figure 5.33: Effect of adrenergic agonists on CD16 expression on resting bovine 
neutrophils. Data presented are mean ± SEM (n = 5 cattle) of CD16 mean fluorescence intensity 
(MFI) calculated as a percentage of CD16 MFI intensity for resting neutrophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare CD16 MFI among 
doses for each AR agonist and among AR agonists at the same dose. No significant differences 
in CD16 MFI was observed among treatments and a significant dose-dependent difference in 
expression within individual treatment relative to baseline is indicated as * (p < 0.05). 
Neutrophil activation with BoZ + rBoIFNγ did not significantly alter CD16 expression 
(Figure 5.16) and treatment of activated bovine neutrophils with all AR agonists, with the 
exception of isoproterenol, had no significant effect on CD16 expression (Figure 5.34). 
Treatment with 10 nM of the β-AR agonist isoproterenol induced a small but significant (p < 
0.05) reduction in CD16 expression.  
 
Figure 5.34: Effect of adrenergic agonists on CD16 expression on activated bovine 
neutrophils. Data presented are mean ± SEM (n = 5 cattle) of CD16 mean fluorescence intensity 
(MFI) calculated as a percentage of CD16 MFI intensity for BoZ + rBoIFNγ activated 
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neutrophils cultured in the absence of an adrenergic agonist. A two-way ANOVA was used to 
compare CD16 MFI among doses of each AR agonist and among AR agonists at the same dose. 
There were no significant differences in CD16 MFI when comparing among treatments and 
significant dose-dependent differences within individual treatment relative to baseline are 
indicated as * (p < 0.05) 
Less than one percent of resting eosinophils express a detectable level of CD16, but 
treatment with 0.1 and 1 nM NE significantly (p < 0.01) increased CD16 expression (Figure 
5.35). This effect by NE was unique (p < 0.05) among the AR agonists evaluated at a dose of 1.0 
nM. These results highlight that E and NE can have very different biological effects on a specific 
leukocyte subpopulation, such as eosinophils. Furthermore, the marked difference in NE 
modulation of CD16 on resting neutrophils (Figure 5.33) and eosinophils (Figure 5.35) provides 
evidence that differences in AR gene expression in these two populations (Figure 5.8) may 




Figure 5.35: Effect of adrenergic agonists on CD16 expression on resting bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of CD16 mean fluorescence intensity 
(MFI) calculated as a percentage of CD16 MFI intensity for resting eosinophils cultured in the 
absence of an adrenergic agonist. A two-way ANOVA was used to compare CD16 MFI among 
doses for each AR agonist and among AR agonists at the same dose. Significant differences in 
CD16 MFI among treatments are identified by different letters (a, b) and significant dose-
dependent differences within individual treatments relative to baseline are indicated as ** (p < 
0.01). 
Activation of eosinophils with BoZ + rBoIFNγ did not alter CD16 expression (Figure 
5.16) and no significant alteration in CD16 expression on activated eosinophils was observed 
following treatment with adrenergic agonists (Figure 5.36). Activation of eosinophils may 
modulate either AR expression or signaling since NE no longer induce increased CD16 
expression but rather induced a numerical decrease in CD16 expression.   
 
Figure 5.36: Effect of adrenergic agonists on CD16 expression on activated bovine 
eosinophils. Data presented are mean ± SEM (n = 5 cattle) of CD16 mean fluorescence intensity 
(MFI) calculated as a percentage of CD16 MFI intensity for BoZ + rBoIFNγ activated 
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eosinophils cultured in the absence of an adrenergic agonist. A two-way ANOVA was used to 
compare CD16 MFI among doses for each AR agonist and among AR agonists at each dose. No 
significant differences in CD16 MFI were observed among treatments and no significant dose-
dependent differences were observed. 
5.3.4 Summary: Adrenergic Receptor Function in Bovine Neutrophils and Eosinophils 
Treatment with each of the five adrenergic agonists caused significant changes in the 
expression of one or more of the activation markers evaluated for both resting neutrophils and 
resting eosinophils (Table 5.2). This summary highlights a number of important observations 
when comparing adrenergic agonists within each population and when comparing the effect of 
individual adrenergic agonists between neutrophils and eosinophils. 
Some primary effects observed in resting neutrophils included broad activation in the 
form of increased iROS, increased CD11b, and decreased L-selectin in response to the 
physiological agonists E and NE. The synthetic AR agonists phenylephrine (α1 agonist), 
dexmedetomidine (α2 agonist), and isoproterenol (β agonist) had a consistently suppressive 
effect on resting neutrophil iROS. However, phenylephrine treatment significantly increased 
CD11b, consistent with activation (In’t Veen et al., 1998; Brandau et al., 2011; Casanova-
Acebes et al., 2013; Margaryan et al., 2017). Also, all synthetic AR agonists demonstrated L-
selectin shedding, consistent with activation (Casanova-Acebes et al., 2013; Tak et al., 2017; 
Ivetic, Green and Hart, 2019). Based upon these results, adrenergic agonist treatment has many 
effects consistent with activation in resting neutrophils. However, the effect on iROS differs 
substantially when AR families are stimulated together rather than individually.  
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On resting eosinophils, several broad effects were also observed. E treatment increased 
the expression of CD11b and CD44, and NE increased CD11b, L-selectin, CD44, and CD16. 
Increased expression of CD11b, CD44 and CD16 on eosinophils is consistent with an activation 
phenotype (In’t Veen et al., 1998; Davoine et al., 2002; Katoh.et al., 2003) (Table 5.1). In 
contrast to neutrophils, neither E nor NE affected iROS. For the synthetic AR agonists, in 
contrast, a strong suppressive effect on iROS was observed in eosinophils. This effect was 
similar to what was observed in neutrophils in response to the synthetic AR agonists. 
Phenylephrine (an α1-AR agonist) appeared to have a similar effect on both neutrophils and 
eosinophils, with the drug both increasing CD11b and decreasing L-selectin. Taken together, 
adrenergic agonists had several activating effects on resting eosinophils. However, agonists 
targeting individual AR families created a strong and consistent suppression of iROS. Overall, 
NE had the broadest and most consistent activation effect on resting neutrophils and eosinophils. 
Table 5.3: Summary of adrenergic agonists’ effects on resting neutrophils and eosinophils.   
 Neutrophils Eosinophils 
 iROS1 CD11b1 L –
selectin1 
CD441 CD161 iROS1 CD11b1 L-
selectin1 
CD441 CD161 
Epinephrine ↑  ↑2  ↓3 -4 - - ↑ - ↑ - 
Norepinephrine ↑ ↑ ↓ - ↓ - ↑ ↑ ↑ ↑ 
Phenylephrine  ↓ ↑ ↓ - - ↓ ↑ ↓ - - 
Dexmedetomidine  ↓ - ↓ - - ↓ - - - - 
Isoproterenol  ↓ - ↓ - - ↓ - ↓ - - 
 
1. Changes in iROS, CD11b, L-selectin, CD44, and CD16 expression used to determine if 
functional AR expressed in each activated PMN subpopulation and to determine if 
biological differences were apparent when comparing between PMN subpopulations.  
2. Significant increases in expression are presented as green “↑” 
3. Significant decreases in expression are presented as red “↓”  
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4. No significant change in expression is shown as “-”. 
Activation of neutrophils and eosinophils with BoZ + rBoIFNγ influenced many of the 
parameters (Figure 5.16) used to evaluate the effect of adrenergic agonists. These changes, such 
as increased L-selectin shedding, may have limited the ability to assess the effect of adrenergic 
agonists but for many of the parameters it was still possible to evaluate the effects of adrenergic 
agonists in activated neutrophils and eosinophils (Table 5.3). This evaluation provided insight 
into possible changes in AR function when PMNs are activated and many of the changes induced 
by adrenergic agonists highlight that there are marked differences when comparing activated 
versus resting cells.  
Fewer changes were observed for activated neutrophils relative to resting neutrophils. A 
smaller number of effects, particularly, were observed for the markers iROS, L-selectin, and 
CD44. Similar to resting cells, NE induced increased iROS expression in activated neutrophils, 
and dexmedetomidine induced a decrease in iROS. However, there were no significant changes 
in iROS for the other three treatments. A decrease in L-selectin expression was observed for just 
two of the drug treatments: dexmedetomidine (an α2-AR agonist) and isoproterenol (a β-AR 
agonist). However, four of the five drugs (all treatments except E) induced increased CD11b 
expression in activated neutrophils. Overall, the effect of adrenergic agonists on activated 
neutrophils are primarily activating effects; however, these effects are smaller than those 
observed in resting neutrophils. 
For activated eosinophils, smaller effects were also observed relative to their resting 
counterparts in response to adrenergic agonists. A significant suppressive effect on iROS was 
observed for just two of the three synthetic AR agonists: phenylephrine (an α1-AR agonist) and 
isoproterenol (a β-AR agonist). In resting eosinophils, CD11b expression increased in response 
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to both physiological agonists, E and NE, and phenylephrine. In contrast, activated eosinophils, 
did not respond to E and NE, but did respond to the synthetic AR agonists. One adrenergic 
agonist, dexmedetomidine, was observed decreasing L-selectin expression in activated 
eosinophils, whereas three agonists, NE, phenylephrine and isoproterenol, were observed 
decreasing L-selectin expression in resting eosinophils. This possibly demonstrates a greater 
sensitivity to activation in resting eosinophils. However, resting eosinophils increased their 
expression of CD44 in response to E treatment (indicative of activation), whereas activated 
eosinophils decreased their expression of CD44 in response to the same treatment (indicative of 
suppression) (Katoh et al., 2003). Overall, the response in activated eosinophils appeared similar, 
but more muted relative to the response of resting eosinophils. However, some effects were 
notably different in activated cells. 
Table 5.4: Summary of adrenergic agonists’ effects on BoZ + rBoIFNγ activated 
neutrophils and eosinophils. 




CD441 CD161 iROS CD11b L-
selectin 
CD44 CD16 
Epinephrine -2 - - - - - - - ↓3 - 
Norepinephrine ↑4 ↑ - - - - - - - - 
Phenylephrine - ↑ - - - ↓ ↑ - - - 
Dexmedetomidine ↓ ↑ ↓ - - - ↑ ↓ - - 
Isoproterenol - ↑ ↓ - ↓ ↓ ↑ - - - 
1. Changes in iROS, CD11b, L-selectin, CD44, and CD16 expression used to determine if 
functional AR were expressed in each activated PMN subpopulation and to determine if 
biological differences were apparent when comparing between PMN subpopulations.  
2. No significant change in expression is shown as “-”. 
3. Significant decreases in expression are presented as red “↓”  
4. Significant increases in expression are presented as green “↑” 
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6.0  DISCUSSION 
A systematic survey of AR gene expression in blood leukocytes has not been completed 
in any species. This knowledge gap limits our understanding of AR subtype expression when 
comparing leukocyte populations within or among species. Previous research has demonstrated 
antibodies generated for ARs frequently lack specificity and are not an effective tool to 
discriminate among individual ARs. For example, antibodies reported to be specific for 
individual α1-AR subtypes gave a false positive reaction in mice following knockout of the 
relevant α1-AR subtype (Jensen, Swigart and Simpson, 2009). It has also been observed that 
antibodies targeting G-protein coupled receptors tend to lack specificity for these receptors. 
Although the reasons for this non-specificity remain unclear, it is theorized the non-specificity 
may, in part, be due to the similarity of all proteins in the G-protein coupled receptor family 
(Michel, Wieland and Tsujimoto, 2009). Furthermore, ligand binding studies (see section on 
Adrenergic Agonist and Antagonist Specificity) have also been limited by a lack of well-defined 
specificity for individual AR subtypes. Although transcript abundance does not always correlate 
directly with protein expression, highly specific methods such as RT-qPCR can provide more 
detailed information regarding probable expression of individual AR subtypes (ex: α2A vs. α2C-
ARs) within specific leukocyte subpopulations. Quantifying transcript for individual AR genes 
provides possible insight into why specific leukocyte subpopulations may differ in their 
responses to stress or treatment with adrenergic agonists or antagonists. In this investigation, AR 
gene expression was first analyzed in bovine total blood leukocytes to determine if all 9 AR 
genes were expressed and to determine if AR gene expression was altered by stress. Cell 
isolation methods were then used to determine if AR gene expression varied significantly among 
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leukocyte lineages and subpopulations within lineages. These analyses provided a systematic 
survey of all 9 AR genes expressed in bovine blood leukocytes. 
Leukocytes isolated from whole blood expressed the α1A- and α2A-AR genes at 
significantly higher levels than all other AR genes, suggesting these two ARs may play 
important roles in regulating bovine leukocyte function. Analysis of AR transcript in total blood 
leukocytes isolated from suckling calves, however, identified 4 AR genes that were significantly 
up-regulated following maternal separation (weaning) and transportation. These significant 
changes in AR gene expression involved the 2A- and all three -ARs suggesting not only - 
but also -ARs may play important roles in SAM axis mediated effects on bovine leukocyte 
function. Changes in AR gene expression following stress suggested that either AR gene 
expression was altered in blood leukocytes or stress induced changes in the cellular composition 
of blood leukocytes, known as a stress leukon. Changes in the cellular composition of circulating 
blood leukocytes may have contributed to the altered transcript abundance observed for 4 AR 
genes.   
Therefore, I addressed the question whether AR gene expression varied significantly 
among leukocyte subpopulations by separating blood leukocytes into individual cell lineages. 
Comparisons among leukocyte lineages revealed significant differences in AR gene expression. 
For example, there was the novel observation that the α2A-AR was expressed at a significantly 
higher level in B cells than all other leukocyte lineages analyzed. Furthermore, β2-AR gene 
expression was highest in the ILC subpopulation, consistent with previous reports regarding β2-
AR protein expression by human NK cells (Jetschmann et al., 1997). These observations not 
only confirmed bovine leukocyte lineages differed substantially in the expression of individual 
AR genes, but also suggested that individual ARs may serve different functions within each 
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leukocyte lineage. Furthermore, these observations suggested there may be similarities in 
leukocyte AR expression when comparing among mammalian species, such as bovine and 
human leukocytes. Therefore, studying neuroimmune interactions in one mammalian species 
may have relevance for other species. 
I then investigated whether functional AR were expressed by bovine leukocytes. The AR 
gene family is complex with three members within each of the α1-, α2-, and -AR subtypes. To 
reduce the complexity of this analysis, I focused on a single leukocyte lineage for which 
sufficient cells could be isolated to perform in vitro function studies. PMNs were chosen for their 
availability in blood and their important role in inflammation and host responses to a wide 
variety of infectious diseases. In particular, PMNs play an important role in the pathogenesis of 
bovine respiratory disease (McGuire and Babiuk, 1984; Slocombe et al., 1985; Breider et al., 
1988; Caswell et al., 1998; Li et al., 2002) and stress has also been implicated as an important 
factor in this disease complex (Taylor et al., 2010; Hodgson et al., 2012). Therefore, 
understanding the response of PMNs to adrenergic agonists may provide further insight into 
mechanisms by which stress increases the risk of fatal bovine respiratory disease (Hodgson et al. 
2012). To achieve my objectives, I first developed methods to work with both resting and 
activated PMNs and to analyze separately the responses of neutrophils and eosinophils to a 
variety of adrenergic agonists. 
Previous investigations of adrenergic receptors and adrenergic agonists usually analyzed 
PMNs collectively (Haskó et al., 1995a; Gu and Seidel, 1996; Szelenyi et al., 2006; Trabold, 
Gruber and Fröhlich, 2007; LaBranche, Ehrich and Eyre, 2010; Scanzano et al., 2015). There are 
no previous studies that directly compared AR gene expression and responses to adrenergic 
agonists in bovine neutrophils and eosinophils. There is also no prior information on bovine 
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eosinophil AR gene expression and responses to adrenergic agonists. Furthermore, there is no 
published evidence for either the expression or function of α-ARs in human eosinophils. 
Eosinophils can comprise almost a third of bovine blood PMNs depending on the individual 
animal and the time of year (Figure 5.14). My studies also determined that bovine neutrophils 
and eosinophils differ significantly in the expression of critical adhesion molecules (Figure 5.15), 
responses to activation stimuli (Figure 5.16), expression of AR genes (Figure 5.8), and responses 
to adrenergic agonists. Thus, these studies highlight the importance of analyzing individual PMN 
subpopulations when asking questions regarding the potential role of this leukocyte lineage when 
immune responses are altered by stress.   
The expression of functional ARs by bovine neutrophils and eosinophils was confirmed 
using the endogenous agonists E and NE and synthetic agonists selected for known specificity 
for individual AR families. All adrenergic agonists studied had an effect on both resting and 
activated neutrophils and eosinophils. The greatest effect by adrenergic agonists was observed 
when analyzing iROS expression (Figures 5.17 to 5.20) and the expression of the adhesion 
molecules CD11b (Figures 5.21 to 5.24) and L-selectin (Figures 5.25 to 5.28). Collectively these 
studies provided evidence all three AR families are functional on bovine neutrophils and 
eosinophils. Furthermore, contradictory responses were observed when neutrophils were 
stimulated with synthetic adrenergic agonists targeting an individual AR family versus the 
endogenous agonists, E and NE. Thus, it was not possible to identify a single AR family that was 
the primary mediator of PMN responses to endogenous adrenergic stress hormones. Another 
possibility is that E and NE bind multiple ARs and PMN responses to these endogenous agonists 




6.1 Adrenergic Receptor Gene Expression in Bovine Leukocytes 
6.1.1 Adrenergic Receptor Gene Expression in Whole Blood Leukocytes 
Transcript was detected for all 9 AR genes when RNA was isolated from leukocytes 
present in bovine blood (Figure 5.1). Expression of the α1A- and α2A-AR genes was 
significantly higher than all other AR genes, suggesting these two α-ARs may play predominant 
roles in mediating stress responses in bovine leukocytes. For the β-ARs, a transcript abundance 
ranking of β2 > β1 ~ β3 was observed, with both β1-ARs and β3-ARs exhibiting low relative 
expression that was near the limit of detection. In comparison, Mei et al. (2018), measured β-AR 
transcript in bovine spleen, among other tissues. They observed a transcript abundance ranking 
of β2 > β1 while β3-AR transcript was nearly undetectable. Thus, similar expression was 
observed in bovine spleen and leukocytes isolated from whole blood. Gene expression studies for 
all 9 ARs have not been previously published for leukocytes isolated from whole blood of any 
species that I am aware. However, the expression of some AR genes had been analyzed in human 
PBMCs and PMNs.  
6.1.2 Effect of Stress on Adrenergic Receptor Gene Expression in Bovine Leukocytes 
 
An investigation of AR gene expression in bovine blood leukocytes was completed 
following maternal separation (weaning) and transportation of suckling beef calves (Malmuthuge 
et al. Manuscript submitted). Weaning of suckling beef calves causes a transient increase in 
cortisol and a more sustained increase in NE concentrations (Hickey et al., 2003). In another 
study, weaning increased both E and NE concentrations in beef calves (Lefcourt and Elsasser, 
1995). Transportation stress has previously been reported to increase blood cortisol 
concentrations (Buckham Sporer et al., 2008; Ishizaki and Kariya, 2010) and NE concentrations 
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(Odore et al., 2004). Thus, it is well established that weaning and transportation can each induce 
a SAM response with elevated levels of both E and NE.  
A number of changes in AR gene expression were observed in response to weaning and 
transportation in calves. Our analysis demonstrated a significant up-regulation of β2-AR 
transcript at early time points (Days 2 and 4) following weaning and weaning + transportation 
(Figures 5.3 and 5.4). There was also a significant upregulation of α2A-AR transcript on Day 4 
in the weaning group when compared to suckling calves. In addition, there was a much later 
(Day 28 post-weaning) up-regulation of the β1-AR and β3-AR genes in calves subjected to 
weaning + transportation. No such AR response was observed in the group exposed to just the 
weaning stressor alone, indicating the two types of stressors may elicit different immune 
responses. Interestingly, no previous study has investigated changes in the immune system 28 
days following weaning and transportation. This data implies a combined stressor of weaning 
and transportation may have both short and long-term effects on the capacity of the bovine 
immune system to respond to adrenergic agonists.  
Increased AR gene expression in bovine leukocytes following weaning and transportation 
may be the result of several causes. Catecholamines or β-AR agonists administered exogenously 
or generated in vivo by stress have previously been demonstrated to increase expression of β-
ARs on human PBMCs (reviewed in Maisel et al., 1990). Glucocorticoids can also up-regulate 
the expression of AR genes (Hadcock, Wang and Malbon, 1989; Hadcock and Malbon, 1993). 
Increased activation of immune cells by inflammatory stimuli has also been associated with an 
up-regulation of AR gene expression (Rouppe Van Der Voort et al., 2000a, 2000b; Scanzano et 
al., 2015; Honke et al., 2020). Thus, catecholamines, cortisol, or inflammatory stimuli may have 
contributed to the up-regulation in AR gene expression observed following weaning and 
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transportation stress. However, body temperatures were monitored weekly throughout the study 
and only three calves had transient increases in temperature above 39°C at a single time point 
and none of the calves were diagnosed with or treated for respiratory disease.   
Up-regulation of AR gene expression following weaning and transportation suggests a 
possible increased capacity for neuromodulation of leukocyte functions. Some evidence for 
increased expression of AR genes correlating with an increased capacity for neuromodulation of 
leukocyte function has been reported. Scanzano et al. (2015) reported no effect by adrenergic 
drugs on resting human PMNs. However, following activation of human PMNs with fMLP, 
expression of 6 of the 9 ARs genes increased significantly. Furthermore, following activation 
with fMLP E, NE, isoproterenol, and other adrenergic drugs significantly altered PMN 
production of ROS, cell morphology, and expression of CD11b/CD18. Thus, activation by fMLP 
increased AR gene expression in human PMNs and the cells were more sensitive to adrenergic 
modulation of function. Similarly, increased expression of ARs on bovine leukocytes post-
weaning and transportation may make them more sensitive to the effects of E and NE. Both E 
and NE had pro-inflammatory effects on bovine PMNs (Tables 5.2 and 5.3), suggesting 
increased expression of ARs by bovine leukocytes may increase pro-inflammatory responses if 
there is co-incidental activation of the SAM system.  
Further research is needed, however, to determine if ARs also mediate pro-inflammatory 
responses by other leukocyte subpopulations. A major limitation of the suckling calf stress study 
was that all leukocyte lineages present in blood were analyzed together. Therefore, it is not 
known if 1, 2, 3 and 2A-AR gene expression was increased in one or more leukocyte 
lineages. Furthermore, stress can alter the cellular composition of blood leukocytes which is 
referred to as a stress leukon (Hickey, Drennan and Earley, 2003; Yagi et al., 2004; Ishizaki and 
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Kariya, 2010; O’Loughlin et al., 2012; Lynch et al. 2010). Therefore, another possibility is that 
altered AR gene expression in blood leukocytes following weaning and transportation may 
simply reflect changes in the cellular composition of leukocytes circulating in blood. Our RT-
qPCR analysis of AR gene expression in individual leukocyte lineages (Figures 5.6 and 5.8) 
revealed transcript abundance for individual AR genes varied greatly among individual bovine 
leukocyte lineages. Therefore, future studies investigating the effect of stress on AR gene 
expression would be more informative if RNA was isolated from individual leukocyte lineages.  
6.1.3 Adrenergic Receptor Gene Expression in Leukocyte Subpopulations 
 
Bovine PBMCs and PMNs expressed detectable levels of transcript for all 9 AR genes 
(Figure 5.5). The β2 and α2-AR protein has been detected on human PBMCs (Blankesteijn et al., 
1993). Expression of the α2A, β2, and β1-AR genes has also been studied in human PBMCs 
(Light et al., 2009; White et al., 2012). A numerical difference was reported for transcript 
abundance of these three genes in PBMCs, although transcript abundance for individual AR 
genes was not statistically analyzed. Light et al. (2009) reported PBMCs isolated from control 
subjects expressed AR genes with transcript abundance ranking β2 > α2A > β1. White et al. 
(2012) reported a transcript abundance ranking of β2 > β1 > α2A. By comparison, ranking of AR 
gene transcript abundance in bovine PBMCs indicated α2A > β2 > β1. These differences in the 
ranking of β2-AR and α2A-AR transcript abundance when comparing human and bovine 
PBMCs suggests β2-AR may play a more prominent role in human PBMCs, whereas the α2A-
AR may play a more important role in bovine PBMCs. Alternatively, these differences in AR 
gene expression may simply reflect differences in the cellular composition of bovine and human 
PBMCs that influences the overall transcript abundance of individual AR genes.  
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Interestingly, mRNA for α1A-, α1B-, and α1D-AR genes was not detected in PBMCs 
isolated from healthy humans (Rouppe van der Voort et al., 1999). However, when PBMCs were 
treated with dexamethasone, a glucocorticoid receptor agonist, or phytohemagglutinin, a T-cell 
mitogen, then expression of all three α1-AR genes was detected. Furthermore, PBMCS isolated 
from patients with juvenile rheumatoid arthritis, an inflammatory disease, expressed all three α1-
AR genes with the α1D-AR gene being the most abundant (Rouppe van der Voort et al., 2000b). 
These ARs were also shown to be functional on PBMCs isolated from these patients (Heijnen et 
al., 1996). In contrast, all six α-ARs were detected in PBMCs isolated from healthy cattle. These 
differences suggest that α-ARs play a more important role in bovine than human PBMCs.  
Expression of all 9 AR genes has also been studied in human PMNs (Scanzano et al., 
2015). Transcript for the α2B-AR gene was not detected in human PMNs. In bovine PMNs, 
transcript for the α2B-AR gene was detectable at a very low level. In bovine PMNs, the ranking 
of AR gene transcript abundance indicated expression varied with α2A ~ β2 ~ α1A > α1B ~ β1 ~ 
β3 > α2C ~ α2B ~ α1D. Although Scanzano et al. (2015) did not statistically analyze expression 
of AR genes in human PMNs, numerical differences were apparent in the data presented. Human 
PMNs had an approximate ranking of AR gene expression with β3 > β2 > α1A > α2A > β1 > 
α1B > α1D > α2C. Transcript abundance was greatest for both the β2- and α1A-AR genes in 
human and bovine PMNs, suggesting there may be conserved roles for these ARs in regulating 
granulocyte function. However, transcript abundance for the β3-AR gene differed markedly in 
bovine and human PMNs, suggesting that there may also be species-specific aspects to AR gene 
expression and function.  
Bovine PBMCs and PMNs, when not separated into subpopulations, had similar 
transcript abundance for all AR genes, except for the α2A-AR gene. There were, however, 
128 
 
marked differences in the expression of individual AR genes within each population. 
Furthermore, when PBMCs and PMNs were separated into subpopulations more pronounced 
differences in AR gene expression were apparent. For example, expression of the α2A-AR gene 
was significantly (p < 0.01) higher in CD21+ B cells than all other leukocyte subpopulations 
analyzed. B cells may be the primary population contributing to the higher α2A-AR gene 
expression observed in PBMCs. There are no previous reports of α-AR gene expression in either 
bovine B cells or B cells of other species. 
Some previous research has been completed to analyze α-AR protein expression and 
function in lymphocytes. McPherson and Summers (1982) reported [3H]-clonidine, an α2-AR 
agonist that also binds 5-HT1A receptors at a lower level (Newman-Tancredi et al., 1998), 
reversibly bound to lymphocytes isolated from guinea pig spleens. Titinchi and Clark (1984) also 
observed binding of clonidine and yohimbine, another α2-AR antagonist, to human PBMCs. 
These authors did note, however, that platelets also have a high level of α-ARs and platelets may 
have been present in their PBMC preparations. In my experiments, platelets should not be 
present since high-speed cell sorting was used to isolate bovine B cells. In 1991, Goin et al. 
isolated lymphocytes from patients with B cell leukemia (leukocytes from these patients were 
75-94% lymphocytes). Monocytes were depleted from lymphocyte preparations using plastic 
adherence in culture. These B cell enriched lymphocytes were noted to express a high density of 
α2-ARs as measured with [3H]-yohimbine. The α1-AR antagonist, [3H]-prazosin, bound at a 
low level but [3H]-dihydroalprenolol, a β-AR antagonist, was also observed to have significant 
binding. Treatment with isoproterenol increased cAMP levels while clonidine decreased cAMP 
levels. These responses provided evidence that both β-ARs and α2-ARs were functional in these 
cells. Although these preparations likely contained primarily B cells, some contaminating T cells 
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and ILCs may have been present. Furthermore, these B cells were isolated from patients with B 
cell leukemia and may not represent normal B cells. Thus, prior evidence that the α2-AR gene is 
expressed in non-transformed B cells circulating in blood remains ambiguous. However, 
previous research has indicated that α-ARs may be present and functional on lymphocytes, and 
potentially on normal B cells. 
There is additional evidence that α2-AR agonists can alter B cell function, Sanders and 
Munson (1985) treated mouse splenocytes with either methoxamine, an α1-AR agonist, 
phenylephrine, an α1-AR agonist, or clonidine, an 2-AR agonist. Methoxamine increased IgM 
antibody production by 63% 4 days after treatment. Phenylephrine treatment decreased IgM 
antibody production on day 5 but increased IgM antibody production by 50% on day 6 and 64% 
on day 7. In contrast, clonidine induced a 50% decrease in IgM antibody production five days 
after treatment. These results provide evidence that α1-ARs can increase antibody production but 
α2-ARs inhibited antibody production. However, a major limitation of these studies is that they 
did not use purified B cell populations. Thus, the possibility remains that the AR agonists had 
indirect effect on B cells by stimulating other cells present in the splenocyte preparation (Kohm 
and Sanders (2001). However, Honke et al. (2020), used magnetic activated cell sorting to isolate 
murine splenic B cells to 98% purity. Following CpG ODN treatment, the purified B cells were 
then treated with either the α1-AR agonist phenylephrine or the α2-AR agonist dexmedetomidine 
hydrochloride. Both AR agonists induced significant reductions in IL-10 production, providing 
direct evidence for α-AR activity on B regulatory cells. 
There are no published reports of α-AR gene expression in B cells of any species. 
Furthermore, there is no direct evidence that either human or bovine B cells respond to either α1- 
or α2-AR agonists. Analysis of AR transcript (Figure 5.6) does, however, indicate α2A-AR is 
130 
 
expressed at a high level by CD21+ B cells present in bovine blood. Transcript for α2B- and 
α2C-ARs was either undetectable or just at the level of detection. Functional α1-ARs may also 
be expressed by bovine B cells since transcript was detectable for both α1A- and α1B-ARs but 
α1D-AR gene transcript was very low. Further analysis of both α-AR expression and function in 
bovine B cells may provide insight into how stress and certain drugs, such as the anesthetic 
dexmedetomidine or xylazine, may impact antibody responses.  
Significantly higher β2-AR gene expression was also observed in bovine ILCs, 
monocytes, and eosinophils relative to other blood leukocyte populations (Figure 5.6 and 5.7). 
High relative expression of β2-AR protein (1420 sites/cell) has been reported for human NK 
cells. Similar to my results for transcript expression, a lower density of α1-ARs (663 sites/cell) 
and α2-ARs (397 sites/cell) was also observed on NK cells (Jetschmann et al., 1997). High 
expression of the β2-AR gene in ILCs and monocytes is also consistent with previous studies of 
β-AR protein expression in PBMCs isolated from healthy humans. In human PBMC 
subpopulations, the relative abundance of β-ARs was reported to be NK cells > monocytes ~ B 
cells ~T suppressor/cytotoxic > T helper cells (Maisel et al., 1990). A similar relative abundance 
for 2-AR gene transcript in bovine PBMC subpopulations was observed with ILCs > 
monocytes > T cells ~ B cells. This suggests that the expression and possibly the function of the 
β2-AR may be similar in bovine and human ILCs and cattle may provide a good model for 
studying the effects of stress and adrenergic agonists or antagonists on ILC function.   
T cells were also observed to express α2A-AR mRNA, albeit at a significantly lower 
level relative to that observed in B cells and ILCs. Transcript for other α-ARs was also detected 
in T cells. Thus, when splenocytes or lymphocytes were tested in other species, these cells may 
have contributed to the binding of radiolabeled α-AR ligands. It is important to note that bovine 
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T cells were not fractionated into specific subpopulations, including CD4+ T helper 
lymphocytes, CD8+ cytotoxic T lymphocytes, and T regulatory cells. Thus, expression of AR 
mRNA may vary substantially among specific bovine T cell subpopulations, as has been 
demonstrated in other species (Maisel et al., 1990). 
When PMNs were fractionated, neutrophils expressed a higher level of most ARs relative 
to eosinophils (Figure 5.7). However, the α2A- and β2-AR genes were expressed at significantly 
higher levels in eosinophils relative to neutrophils. Previous research demonstrated both the 
expression and function of β2-ARs by human, mouse, and guinea pig eosinophils (Yukawa et al., 
1990; Noguchi et al., 2015; Kainuma et al., 2017). Thus, the current result for -AR gene 
expression in bovine eosinophils is consistent with results from a number of other species.   
No research has quantified the expression or reported evidence for functional α-ARs in 
either human or bovine eosinophils. Expression of the α1A-AR gene was observed with bovine 
eosinophils isolated from blood while transcript for both α1B and α1D-AR genes was barely 
detectable. There was also robust expression of the α2A-AR gene with transcript barely 
detectable for both the α2B- and α2C-AR genes (Figure 5.7). My studies also provided the first 
evidence that both the α1- and α2-ARs were functional, mediating eosinophil responses to 
specific agonists (Tables 5.2 and 5.3). These data suggest that the role α-ARs play in regulating 
bovine and human eosinophils responses should be studied further.  
It should be noted, however, that the expression of ARs by eosinophils may depend on 
the immune compartment or tissue from which these cells are isolated. Liu et al. (2020) analyzed 
the expression of all 9 ARs genes in eosinophils isolated from the murine conjunctiva. 
Expression of the α1A-AR gene was detected but there was not a detectable level of transcript 
for the remaining 8 AR genes. Thus, eosinophils localized to specific tissue sites may change AR 
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gene expression, indicating transcript analyses with eosinophils isolated from blood should not 
be extrapolated to eosinophils present in other tissues. It may be of considerable value to 
compare AR gene expression and function on the same leukocyte subpopulations isolated from 
blood and specific tissue locations, such as the lung or gut. This may reveal whether the response 
of a leukocyte subpopulation during a stress response can vary at different sites throughout the 
body.   
High expression of the β2-AR gene was also observed in bovine monocytes (Figure 5.6). 
This is consistent with a previous study of β-ARs on human monocytes (Maisel et al., 1990). 
Furthermore, although macrophages are the tissue-differentiated form of monocytes, this result is 
consistent with a previous study that demonstrated β2-ARs were functional on bovine alveolar 
macrophages (Gu and Seidel, 1996). Similar to B cells, undetectable (>35 PCR cycles) levels of 
α1D- and α2B-AR transcript were observed in bovine monocytes and they also expressed very 
low levels of α2C-AR gene transcript. Thus, it is unlikely that there is substantial protein 
expression or function associated with these AR subtypes. However, adrenergic agonist studies 
with bovine monocytes and macrophages would be required to determine if AR signaling was 
restricted primarily to the β2-AR. 
The three most highly expressed AR genes among the bovine leukocyte subpopulations 
analyzed included β2-, α2A-, and α1A-ARs. These three AR genes were also associated with 
significant differences in transcript abundance when comparing among leukocyte 
subpopulations. Further study of individual AR subtypes may reveal unique differences in the 
functional responses mediated by these receptors when comparing among bovine leukocyte 
lineages. Variation in AR gene expression when comparing among leukocyte subpopulations 
reveals substantial potential for individual leukocyte lineages to respond differently to either 
133 
 
stress-induced release of catecholamines or the therapeutic administration of synthetic adrenergic 
agonists or antagonists. This lineage-specific variation in leukocyte AR gene expression may 
provide insight into the many contradictory reports that stress can either enhance or inhibit 
immune responses. 
6.2 Bovine Neutrophils and Eosinophils 
PMNs were selected for further analysis of AR gene expression and AR function since 
neutrophils play an important role in inflammation and mediate much of the lung pathology 
observed during BRD (McGuire and Babiuk, 1984; Slocombe et al., 1985; Breider et al., 1988; 
Caswell et al., 1998; Li et al., 2002). Also, it was hypothesized that modulation of neutrophil 
function by E and NE may be one mechanism by which stress increases BRD mortality. 
Furthermore, PMNs are easily separated from blood with minimum handling or manipulation 
and culture conditions have been optimized for the in vitro study of bovine PMNs (Whale et al., 
2006). Agonists specifically targeting the β2-AR were previously shown to alter bovine PMN 
responses (LaBranche, Ehrich and Eyre, 2010) and there was evidence from Holroyde and Eyre 
(1976) that α1-ARs inhibited histamine release by bovine PMNs stimulated with  a high 
concentration (10-3 M) of E. When Diez-Fraile et al. (2000) tested the α1-AR agonist 
phenylephrine with whole blood leukocytes, they reported no effect on bovine PMN expression 
of CD11b. However, this non-responsiveness may have been due to indirect effects by other cells 
in the culture, such as T cells, B cells or monocytes. There have been no studies of the direct 
effects of α2-AR agonists on bovine PMNs. However, Amouzadeh (1991) reported high 
concentrations of xylazine, an α2-AR agonist used as a veterinary sedative, caused death in cattle 
by pleural effusion. Some evidence was provided that this treatment may have induced TNFα 
and ROS mediated damage in the lung but this pathology was not directly linked to PMNs. In 
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contrast, α2-ARs have been found to mediate primarily anti-inflammatory responses in humans 
following administration of the anaesthetic dexmedetomidine, an α2-AR agonist. These 
responses included decreased levels of TNFα, IL-6 and C-reactive protein (Kallioinen et al., 
2019; Wang et al., 2019b). My research provides a systematic analysis of AR gene expression 
and AR function in bovine neutrophils and eosinophils which may be useful for better 
understanding interactions between stress, inflammation, and infectious disease in cattle. 
6.2.1 Optimization of PMN Culture and Activation Conditions 
PMN activation conditions were optimized for the recovery of viable single cell 
suspensions to facilitate flow cytometric analysis of iROS and protein expression by individual 
cells. Flow cytometric analyses provided a quantitative measure of responses induced by 
adrenergic agonists and facilitated an independent analysis of neutrophil and eosinophil 
responses. Several new criteria for measuring the activation of bovine neutrophils and 
eosinophils were also optimized. Quantitative measures of neutrophil and eosinophil activation 
included an analysis of iROS and the expression of CD16, L-selectin, CD44, and CD11b.  These 
parameters revealed how adrenergic agonists may alter the activation state of both resting and 
activated bovine neutrophils and eosinophils.  
Culture media was previously optimized to support PMN survival in culture for three 
days (Whale et al., 2006) which facilitated an analysis of both neutrophil and eosinophil 
responses with minimal loss of viable cells. Published information was used initially to identify a 
dose of BoZ that induced bovine PMN activation. Stimulation of bovine PMNs with 1 mg 
BoZ/mL was reported to activate a variety of bovine PMN functions (Brown and Roth, 1991) but 
this protocol was not used for flow cytometric analyses or long term assays of cell function. We 
confirmed BoZ induced a dose-dependent increase in bovine PMN iROS activity (Figure 5.10) 
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but there was also a dose-dependent increase in apoptosis and cell death, resulting in decreased 
recovery of viable cells (Figure 5.9). Treatment of PMNs with as little as 0.05 mg BoZ/mL 
resulted in BoZ particle uptake by neutrophils and eosinophil degranulation (Figure 5.11A). 
However, cell clumping was still observed with this much lower dose of BoZ, which was also 
evident in flow cytometry as increased FSC and SSC (Figure 5.12). As a result of these 
observations, the use of BoZ as an activating agent for bovine PMNs was further optimized to 
ensure recovery of a viable, single cell suspension of bovine PMNs. 
Several different PMN activation protocols were evaluated to identify stimuli that would 
provide viable, single cell suspensions which would be compatible with flow cytometric 
analyses. Furthermore, PMN culture temperature was changed from 37°C to 39°C, to better 
represent normal bovine body temperature (Wrenn, Bitman and Sykes, 1958). The final PMN 
activation protocol used for my research combined a much lower dose of BoZ (6.25 μg/mL) than 
used in previous studies (Sample and Czuprynski, 1990; Brown and Roth, 1991) and co-
stimulation with 10 ng/mL rBoIFNγ. PMNs recovered following this co-stimulation were > 99% 
viable and > 85% of the input cells were recovered (Figure 5.9). Also, the recovered PMNs did 
not clump, as confirmed by cytospins (Figure 5.11B) and flow cytometric profiles of FSC and 
SSC (Figure 5.13). PMN activation following co-stimulation with BoZ and rBoIFN was evident 
with ingestion of BoZ in neutrophils (Figure 4.6 and 5.11) and eosinophils (Figure 4.6 and 5.11). 
Furthermore, both neutrophils and eosinophils displayed a broad activation response to this 
combined stimulus (Figure 5.16). Finally, a flow cytometric analysis gate was set based on FSC 
and SSC that excluded doublets (Figure 5.13) and ensured changes in the expression of iROS 




6.2.2 Percentage Neutrophils and Eosinophils in PMN Preparations 
There are few well-established methods to separate neutrophil and eosinophil populations 
within bovine blood PMNs. Separation of bovine eosinophils was previously described based on 
the use of Percoll density gradients (Freiburghaus and Jörg, 1990). However, this method took a 
significant amount of time and required large volumes of blood (i.e 6 L). Therefore, I developed 
a new method to discriminate between neutrophil and eosinophil subpopulations in PMNs 
isolated from blood. Following multicolour staining of PMN surface proteins, a distinct 
subpopulation of CD44 low, L-selectin high, FL-1 high cells was identified (Figure 5.15, 5.7, 4.8 
and 4.9). This subpopulation had an abundance similar to the frequency of eosinophils observed 
in isolated bovine PMN preparations. High-speed cell sorting confirmed this subpopulation was 
indeed eosinophils (Figure 4.5 and 4.6) and the CD44 high subpopulation was neutrophils. 
Previously, high-speed sorting was used to isolate bovine blood eosinophils based on their higher 
autofluorescence in FL-1 relative to neutrophils (Anderson et al. Manuscript in preparation). 
High-speed cell sorting to separate neutrophils and eosinophils for RT-qPCR analysis of AR 
gene expression in the present project replicated these previous results. Furthermore, the high 
autofluorescence subpopulation in both FL-2 and FL-3 channels was also confirmed to be 
eosinophils and the autofluorescence low subpopulation was confirmed to be neutrophils. These 
methods were effective with both resting and BoZ + rBoIFNγ co-stimulated cells (Figure 4.4). 
High-speed sorting was used to validate the flow cytometry gates used to discriminate between 
neutrophils and eosinophils in bovine PMNs, facilitating a separate analysis of these two 
subpopulations following stimulation with adrenergic agonists.   
Diez-Fraile et al. (2003) reported identifying neutrophils and eosinophils as distinct 
subpopulations in whole blood leukocytes based on differences in cell size (FSC) and complexity 
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(SSC). Eosinophils were identified as a cell population with much higher SSC and lower FSC 
than neutrophils. However, the identity of the alleged eosinophil population was never 
independently confirmed and when we performed high-speed sorting of neutrophils and 
eosinophils there was very little difference in the FSC and SSC profiles of the purified 
subpopulations.  
Diez-Fraile et al. (2003) also reported an intracellular staining method to identifying 
bovine neutrophils and eosinophils using three mAbs, CH138A, Du12-116b and VPM65. 
Intracellular staining required fixation and permeabilization of cells, and again no direct 
evidence was provided to confirm this antibody staining protocol effectively discriminated 
between neutrophils and eosinophils. This paper also described L-selectin and CD11b/CD18 on 
bovine neutrophils and eosinophils. However, without validation of the specificity of neutrophil 
and eosinophil identification, the validity of this data is questionable.   
The percentage eosinophils in PMNs isolated from bovine blood varied substantially 
among individual animals and with time of year (Figure 5.14). A significantly higher percentage 
of eosinophils was present in PMNs isolated from cattle during late summer and autumn than 
during spring in Saskatoon (SK, Canada). Thus, the abundance of eosinophils in isolated PMNs 
could significantly alter responses measured to a specific stimulus when neutrophils and 
eosinophils differ in their response to this stimulus. Historically, the potential impact of 
eosinophils on PMN responses was largely ignored. For example, LaBranche, Ehrich and Eyre 
(2010) studied bovine PMNs, as opposed to analyzing neutrophils and eosinophils independently 
when measuring responses induced by the β2-AR. Furthermore, one of the most recent and 
detailed studies characterizing adrenergic function in human neutrophils actually studied PMNs 
as opposed to purified neutrophils (Scanzano et al., 2015). Therefore, in my studies I developed 
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methods to separately analyze neutrophil and eosinophil responses when working with bovine 
PMNs. 
6.2.3 Basal Expression of Activation Markers on Resting Neutrophils and Eosinophils 
Notable similarities and differences were observed when comparing the five parameters 
used to detect neutrophil and eosinophil activation. CD16 was nearly undetectable (< 1.0% 
positive cells) on resting eosinophils but a low level of CD16 was observed on a larger subset of 
neutrophils (< 30.0% positive cells). Human eosinophils are reported to lack CD16 expression, 
except in individuals with inflammatory or allergic conditions (Davoine et al., 2002, Davoine et 
al., 2004). Detectable expression of CD16 on bovine neutrophils means this low-affinity Fc 
receptor may be involved in mediating responses such as NETosis, as high CD16 expression has 
been associated with NET formation on human neutrophils (Millrud et al., 2017) or phagocytosis 
(Huizinga et al., 1990; Kimberly et al., 1990). 
No significant difference was observed when comparing basal expression of iROS and 
CD11b by resting bovine neutrophils or eosinophils (Figure 5.15). This observation supports the 
conclusion that neutrophils and eosinophils circulating in blood have similar iROS metabolism 
and possibly CD11b-mediated adhesion to vasculature (Coxon et al., 1996; Ince, Weber and 
Scheiermann, 2019). Furthermore, these two parameters couldn’t be used to differentiate 
between neutrophils and eosinophils. In contrast, L-selectin and CD44 expression were markedly 
different when comparing resting neutrophils and eosinophils. This is the first time CD44 
expression has been analyzed on bovine eosinophils but CD44 expression was previously 
analyzed on bovine neutrophils (Gonen et al., 2008; Blagitz et al., 2017). The specificity of 
lower CD44 expression on eosinophils was confirmed with high-speed cell sorting (Figure 4.5 
and 4.6) and CD44 provided an excellent marker to differentiate between both resting and 
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activated neutrophils and eosinophils. Differential L-selectin expression could also be used to 
separate neutrophils from eosinophils (data not shown) but high-speed sorting of L-selectinHi and 
L-selectinLo PMN subpopulations revealed there was not complete separation of neutrophils from 
eosinophils based on this parameter alone.  
CD44 and L-selectin are important molecules involved in regulating cell migration, and 
differential expression of these molecules by bovine neutrophils and eosinophils suggests the 
migration and retention of these two populations in tissues may also differ. L-selectin plays an 
important role in cell adhesion to endothelium, a first step in cell homing (Ivetic, Green and Hart, 
2019). Higher L-selectin expression by eosinophils circulating in bovine blood may augment 
greater eosinophil adhesion and rolling on vasculature relative to neutrophils. CD44 binds to 
hyaluronan in the extracellular matrix and this interaction can slow cell migration through tissues 
(Wang et al., 2002). Higher CD44 expression by neutrophils may impede their migration through 
tissues when compared to eosinophils. Thus, modulation of CD44 and L-selectin expression by 
catecholamines may have important effects on neutrophil and eosinophil migration and 
localization at sites of inflammation during stress responses.  
6.2.4 Neutrophil and Eosinophil Activation Responses 
Co-stimulation of bovine PMNs with rBoIFNγ and BoZ increased both iROS and CD11b 
expression (Figure 5.16). Increased iROS and CD11b expression has previously been reported 
for activated bovine PMNs (Sample and Czuprynski, 1990; Brown and Roth, 1991; Diez-Fraile 
et al., 2000). Sample and Czuprynski (1990) reported a synergistic effect on ROS production in 
bovine PMNs following co-stimulation with rBoIFNγ and BoZ. They measured ROS using 
several different methods. Luminol dependent chemiluminescence was used to measure 
primarily O2- superoxide anions that are both intracellular and extracellular (Bedouhène et al., 
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2017). They also measured superoxide anions with a cytochrome C oxidase assay and hydrogen 
peroxide production with a colorimetric microassay. My flow cytometric assay used DCFDA to 
indirectly measure a variety of secondary intracellular ROS, including alkoxyl, peroxyl, 
CO3·(carbonate) and OH· oxygen radicals (Halliwell and Whiteman, 2004). Sample and 
Czuprynski (1980) reported an approximately 40% increase in ROS activity with their activation 
protocol and subsequent ROS measurement assay. However, Sample and Czuprysnki (1980) 
used a much larger dose of BoZ (~1 mg/mL). With a much lower dose of BoZ (6.25 μg/mL) and 
rBoIFNγ co-stimulation there was a 58% increase in neutrophil iROS and a 65.4% increase in 
eosinophil iROS (Figure 5.16; Table 5.1 and 5.2). Thus, my PMN stimulation protocol and iROS 
detection system was at least as effective as that published previously which used over a 150-
fold higher dose of BoZ.  
Neutrophil activation studies have been performed with cells isolated from multiple 
species. Human neutrophils have previously been shown to “shed” L-selectin in response to 
activating factors such as Toll-like receptor (TLR) agonists (Hayashi, Means and Luster, 2003) 
and phorbol myristate acetate (PMA) (Li et al., 2006). A variety of activating factors have also 
been found to have differing effects on L-selectin “shedding” by bovine PMNs. Diez-Fraile et al. 
(2003) reported that when bovine whole blood samples were incubated with platelet activating 
factor (PAF) for one hour at 37°C then decreased L-selectin was detected on PMNs, identified by 
FSC and SSC during a flow cytometric analysis. However, Swain et al. (1998) reported L-
selectin levels increased on bovine PMNs when whole blood samples were incubated for 15 
minutes at 37°C with PAF. L-selectin expression in this study was also analyzed with flow 
cytometry using FSC and SSC to identify PMNs. The difference in PMN responses to PAF in 
these two studies may have been due to differences in the post-stimulation time when L-selectin 
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expression was analyzed or the use of different diluents to dissolve the PAF. In my studies, I 
observed that both bovine neutrophils and eosinophils “shed” L-selectin in response to a 
combined stimulus of BoZ + rBoIFNγ, and that eosinophils shed L-selectin at a significantly 
greater level than neutrophils in response to this stimulation (Figure 5.16; Table 5.1 and 5.2). 
CD44 expression by human neutrophils has also been reported to decrease in response to 
activating factors such as TNFα, fMLP and PMA (Campanero et al., 1991). Activated T cells 
isolated from cattle infected with Mycobacterium bovis were reported to have reduced levels of 
CD44 (Waters et al., 2003) but the effect of activating factors on CD44 expression by cultured 
bovine neutrophils and eosinophils has not been studied. In response to BoZ + rBoIFNγ, bovine 
neutrophils were observed to significantly decrease their expression of CD44, whereas 
eosinophils expressed no change in CD44 (Figure 5.16; Table 5.1 and 5.2).  
The effect of co-stimulation with opsonized zymosan and IFNγ has also been studied in 
human neutrophils (Kowanko and Ferrante, 1987). This co-stimulation increased neutrophil 
production of hydrogen peroxide (H2O2), a form of ROS, as well as chemiluminescence. Chaves 
et al. (1996), confirmed opsonized zymosan and IFNγ co-stimulation of human neutrophils had a 
similar effect on ROS production. Thus, while the effect of opsonized zymosan and IFNγ co-
stimulation on ROS production has been studied with PMNs from cattle and other species there 
has been no analysis of how this co-stimulation affects the expression of other proteins by 
neutrophils. This is the first report of CD11b up-regulation, L-selectin “shedding” and CD44 
“shedding” on neutrophils following co-stimulation with opsonized zymosan and IFNγ (Figure 
5.16; Table 5.1 and 5.2). However, the changes observed in these activation markers are 
consistent with previous studies that analyzed responses in activated neutrophils (Kowanko and 
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Ferrante, 1987; Sample and Czuprynski, 1990; Campanero et al., 1991; Diez-Fraile et al., 2000; 
Hayashi, Means and Luster, 2003; Li et al., 2006). 
Studies have also been completed to analyze activation of human eosinophils. Human 
eosinophils “shed” L-selectin and up-regulated expression of the CD11b/CD18 complex Mac-1 
within 30 minutes after IL-5 and GM-CSF stimulation. However, it has also been shown that 
human eosinophils up-regulate L-selectin expression 12 hours after incubation with IFNγ 
(Momose et al., 1999). The effect of opsonized zymosan on human eosinophils has also been 
studied and found to increase release of superoxide anions and eosinophil peroxidase (Yukawa et 
al., 1990). However, the effect of opsonized zymosan and IFN co-stimulation has not been 
studied with eosinophils isolated from any species. The current investigation is the first report 
that this co-stimulation activates a broad range of responses in bovine eosinophils, inducing 
significant increases in iROS and CD11b expression and L-selectin “shedding”. 
Separate analyses of eosinophils and neutrophils revealed that decreased CD44 
expression was unique to neutrophils and CD44 expression remained unchanged on activated 
eosinophils (Figure 5.16). Furthermore, significant differences were also observed when 
comparing expression of CD11b and L-selectin on neutrophils and eosinophils following co-
stimulation with BoZ + rBoIFNγ (Figure 5.16). Thus, separate phenotypic analysis of activated 
bovine neutrophils and eosinophils confirmed that these two PMN subpopulations can differ in 
their responses in multiple ways. This further highlights the importance of not analyzing bovine 





6.3 Adrenergic Receptor Function in Bovine Neutrophils and Eosinophils 
The effects of the physiological agonists, E and NE, and synthetic agonists targeting α1- 
α2- and β-ARs were tested on both resting and activated bovine PMNs. Furthermore, the 
responses of neutrophils and eosinophils were analyzed separately. This discrimination between 
the two major PMN subpopulations revealed for the first time that neutrophils and eosinophils 
not only differ in their expression of AR genes but also display differences in their response to 
adrenergic agonists. 
All adrenergic agonists evaluated had effects on both neutrophils and eosinophils. This 
not only provided evidence that both PMN subpopulations expressed functional ARs but also 
provided evidence that at least one member of each of the three AR families was able to 
transduce signals in neutrophils and eosinophils that altered cell function. AR signaling resulted 
in diverse cellular responses including regulating iROS activity and changing the expression of 
adhesion molecules, such as CD11b and L-selectin. These AR agonists also had selective effects 
on the expression of CD16 and CD44 in neutrophils and eosinophils.  
Resting neutrophils responded to E and NE stimulation with a consistent pro-
inflammatory response, including increased iROS production (Figure 5.17). BoZ + rBoIFNγ 
activated neutrophils demonstrated a similar response to NE but not to E. This pro-inflammatory 
effect was somewhat unexpected, as previous literature on E, NE, β2-AR agonists, and α2A-AR 
agonists reported a suppressive effect on activated human neutrophils (Trabold, Gruber and 
Fröhlich, 2007; Scanzano and Cosentino, 2015; Chen et al., 2016; Margaryan et al., 2017). In 
BoZ activated bovine PMNs, a suppressive effect on ROS production was reported with a β2-AR 
agonist (LaBranche, Ehrich and Eyre, 2010). Margaryan et al. (2017) similarly observed a 
suppressive effect by E with LPS-activated human PMNs. However, increased expression of 
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CD11b and IL-8 production was observed in resting human PMNs following stimulation with E, 
indicating a pro-inflammatory effect. This increase in CD11b is consistent with my results on 
resting bovine neutrophils and eosinophils. My research suggests that stress-induced release of 
catecholamines such as NE may further exacerbate inflammatory responses mediated by 
neutrophils circulating in blood and possibly by activated neutrophils present in either blood or 
tissues. The CD11b molecule has several functions in PMNs including being a complement 
receptor (complement receptor three; CR3) (Berends et al., 1993), influencing Fc-receptor 
mediated degranulation (Tang et al. 1997), and mediating adhesion to endothelium via ICAM-1 
(Coxon et al., 1996; Ince, Weber and Scheiermann, 2019b). CD11b enhances PMN attachment 
to endothelium following the initial attachment and rolling on endothelium mediated by 
molecules such as L-selectin (Ivetic, Green and Hart, 2019). These results provide insight into a 
possible mechanism by which stress may further increase neutrophil activation while circulating 
in blood and also alter PMN migration. 
O’Loughlin et al. (2011) reported weaning stress in calves induced a stress leukon 
characterized by a neutrophilia and increased expression of pro-inflammatory cytokine genes, 
and TLR4 in bovine leukocytes isolated from whole blood. Increased expression of TNFα, IFNγ, 
IL-8 and IL-1β genes was also observed and it was concluded that weaning stress enhanced 
rather than suppressed immune responses. In my studies, ex vivo stimulation of PMNs with E 
and NE similarly induced a pro-inflammatory response in bovine neutrophils and eosinophils. 
Thus, the in vivo inflammatory responses observed during weaning stress are consistent with 
activation of neutrophils and eosinophils by E and NE and further research is warranted to focus 
specifically on the expression and function of ARs in bovine neutrophils following maternal 
separation (weaning) and transportation. 
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Lynch et al. (2010) also reported decreased L-selectin expression on bovine blood 
neutrophils in weaned versus control animals. This effect was observed in conjunction with the 
classic short-term neutrophilia frequently observed during stress. In my experiments, decreased 
L-selectin expression was observed in response to adrenergic agonist stimulation of both resting 
(Figures 5.25) and activated (Figures 5.26) neutrophils. Thus, one possible mechanism by which 
increased L-selectin shedding occurred on blood neutrophils following weaning stress may be 
through increased stimulation by either E or NE. L-selectin attaches to glycans such as the sialyl 
LewisX (sLex) antigen on endothelium and initiates the first attachment and subsequent “rolling” 
of leukocytes, such as neutrophils, along the endothelium (Ivetic, Green and Hart, 2019). Thus, 
L-selectin shedding should reduce this first step of attachment and rolling. Lynch et al. (2010) 
did not study CD11b expression on bovine neutrophils, but there is evidence that L-selectin 
shedding reduces attachment and invasion of endothelium even if CD11b is elevated (Enders et 
al., 1995). This may be one mechanism contributing to the short-term neutrophilia observed 
following stressors, such as weaning. For example, mice lacking ADAM17, the metalloprotease 
which cleaves L-selectin, in circulating neutrophils were compared with normal mice (Long et 
al., 2012). Mouse neutrophils that could not shed L-selectin were found to have significantly 
increased invasion of inflamed tissues in response to E. coli infection, whereas mice that could 
shed L-selectin had greater numbers of circulating neutrophils (Long et al., 2012). Short term 
exposure to stress hormones such as catecholamines in cattle appears to cause L-selectin 
shedding on neutrophils, possibly preventing egress of neutrophils from circulation and 
contributing to the classic neutrophilia which is part of the stress leukon. The neutrophilia 
observed as part of the stress leukon is usually attributed in part to a decrease in the marginal 
granulocyte pool (neutrophils transiently attached to endothelium), resulting in an increased 
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circulating granulocyte pool (Cornell University College of Veterinary Medicine, 2020). L-
selectin “shedding” from marginated neutrophils may contribute to neutrophil detachment from 
endothelium and entry into the circulating pool. Thus, L-selectin shedding from neutrophils in 
response to catecholamines may be one mechanism by which short-term neutrophilia occurs in 
response to stress. Evidence for this theory exists, as catecholamine-induced neutrophilia is 
dominated by mature neutrophils in ruminants (Jones and Allison, 2007). It remains to be 
determined if this neutrophilia enhances or inhibits innate immune defenses during a stress 
response. 
The current research also demonstrates a potentially important role for eosinophils during 
a stress response. Specifically, resting eosinophils increased CD11b, CD44, and CD16 levels in  
response to NE. Increased expression of these surface proteins has previously been identified as 
characteristic of an activated or allergic phenotype for eosinophils (In’t Veen et al., 1998; 
Davoine et al., 2002; Katoh.et al., 2003) (Table 5.2). It is interesting to note that the level of L-
selectin increased on resting eosinophils in response to NE. This increase in L-selectin 
expression would likely increase initial eosinophil binding and rolling on vasculature (Ivetic, 
Green and Hart, 2019), and firm adhesion by increased CD11b could also be promoted (Coxon et 
al., 1996; Ince, Weber and Scheiermann, 2019). Changes in L-selectin expression induced by 
NE, for example, suggest eosinophils circulating in blood may more readily migrate into tissues 
during a stress response and respond to pathogens or allergens present at these sites. In humans, 
NE injection was reported to decrease eosinophils in blood by 10% (Koch Weser, 1968) but 
similar studies have not been performed with cattle. Collectively, the ex vivo response of 
eosinophils to NE is indicative of increased cell activation with an increased capacity to migrate 
into tissues (Enders et al., 1995). Understanding stress induced changes in eosinophil function 
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may help improve the control and treatment of  conditions such as parasitic infections in cattle 
(Gånheim, Höglund and Waller, 2004; Doster, 2010; Shapiro, Peregrine and Caswell, 2017) and 
in other species such as pigs, or even humans. These changes in eosinophil function may also be 
important for understanding the pathogenesis of allergic reactions such as allergic rhinitis in 
cattle (Van Metre, 1997). 
One surprising result was that the responses of neutrophils and eosinophils to synthetic 
AR agonists targeting individual AR families often differed from responses observed with E and 
NE. Increased CD11b expression and L-selectin “shedding,” were generally consistent with 
granulocyte activation and these responses were observed with both E and NE and synthetic 
agonists targeting individual AR subtypes. However, synthetic agonists specific for individual 
ARs subtypes induced a significant decrease in iROS expression in both resting and, less 
consistently, in activated neutrophils and eosinophils (Figures 5.17, 5.18, 5.19, 5.20). This 
response to synthetic agonists is consistent with previously published results. For example, 
LaBranche, Ehrich and Eyre (2010) reported the β2-AR agonist, terbutaline, decreased iROS in 
BoZ activated bovine PMNs. However, they did not study resting PMNs or specifically analyze 
neutrophils and eosinophils. One study with resting human PMNs (Margaryan et al., 2017), also 
observed increased levels of CD11b expression and IL-8 secretion in response to E. This result is 
consistent with the current results with resting bovine neutrophils and eosinophils (Figure 5.21 
and 5.23 and Table 5.3). Scanzano et al. (2015), however, analyzed both resting and activated 
human PMNs, as well as endogenous and synthetic adrenergic drugs. No responses were 
observed with resting human PMNs, in contrast to my studies with bovine PMNs and the results 
by Margaryan et al. (2017). Furthermore, similar to the work of LaBranche, Ehrich and Eyre 
(2010), E, NE and isoproterenol (β-AR agonist) were found to have a suppressive effect on 
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activation parameters such as ROS and CD11b expression in fMLP-activated PMNs. These 
results demonstrated a consistency between endogenous and synthetic AR agonists. The ROS 
response to E could also be reversed by propranolol, a β-AR antagonist. Propranolol, prazosin, 
an α1-AR antagonist, and yohimbine, an α2-AR antagonist, could also reverse E-induced 
suppression of CD11b expression in activated human PMNs. In contrast, CD11b expression was 
increased by all three synthetic AR agonists on activated bovine neutrophils and eosinophils 
(Table 5.3). Thus, it appears AR on activated human and bovine PMNs may mediate different 
responses. However, it may be difficult to directly compare these studies, as two different 
methods, fMLP versus BoZ + rBoIFNγ, were used to activate human and bovine PMNs. It has 
previously been observed with human and murine macrophages that different activation stimuli, 
such as LPS versus PMA, can change cell responses induced by β-AR agonists. If LPS is used to 
activate cells, then β-ARs mediates a suppressive effect. However, with PMA, an activator of 
protein kinase C, the β-ARs induced a pro-inflammatory response (Szelényi et al., 2000). The 
observed discrepancy between iROS responses when comparing E and NE with individual 
synthetic AR agonists needs to be further explored to determine if this observation is unique to 
the culture conditions used in the current study. One possible explanation for this phenomenon 
could be that stimulation of multiple ARs by E and NE induces signaling that is different from 
signaling induced by activation of individual AR subtypes. 
Most studies of PMN and macrophage responses to adrenergic agonists concluded these 
agonists act primarily on activated cells (Haskó et al., 1995a; Gu and Seidel, 1996; Szelenyi et 
al., 2006; Trabold, Gruber and Fröhlich, 2007; LaBranche, Ehrich and Eyre, 2010; Scanzano et 
al., 2015). Thus, it was somewhat unexpected to observe that resting neutrophils and eosinophils 
displayed a range of responses with all the adrenergic agonists tested. For human PMNs, for 
149 
 
example, the difference between resting and activated PMNs may reflect changes in AR 
expression following cell activation. For example, Scanzano et al. (2015) reported resting human 
PMNs did not respond to adrenergic agonists. However, PMNs activated with fMLP increased 
AR gene expression and cell responses to adrenergic agonists were subsequently observed. Thus, 
it remains to be determined whether bovine PMNs truly have a different level of basal AR gene 
expression and function or whether the protocol I used to isolate bovine PMNs may have 
induced increased AR gene expression. Activation of bovine PMNs by co-stimulation with BoZ 
and IFN may also alter AR gene expression in both neutrophils and eosinophils. Further studies 
are required to investigate whether this activation alters expression of individual AR genes 
relative to resting cells and to determine whether any changes in AR gene expression correlate 
with the changes observed in response to adrenergic agonists. 
There may be other reasons why the response of activated bovine neutrophils and 
eosinophils to adrenergic agonists differed relative to responses observed with resting cells 
(Table 5.2 and 5.3). Another factor contributing to these differences may not be changes in AR 
expression but rather an altered capacity of cells to respond to adrenergic agonists. Further study 
is required to determine if AR signaling is altered due to changes in adaptor molecules involved 
in signaling pathways. For example, resting neutrophils consistently “shed” L-selectin in 
response to all adrenergic agonists (Table 5.2) but this response was markedly decreased in 
activated neutrophils. BoZ + rBoIFNγ activated neutrophils have already “shed” approximately 
30% of their L-selectin (Figure 5.16) and this may then reduce the cell’s capacity for further L-
selectin “shedding.’ Similarly, activated neutrophils up-regulated iROS activity by 
approximately 60% (Figure 5.16). Further up-regulation of iROS in activated neutrophils and 
eosinophils by adrenergic agonists may be difficult to achieve if this reflects maximum cell 
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activity within the timeframe of the assay. Thus, there may be multiple reasons why resting and 
activated bovine PMNs differ in their response to adrenergic agonists. There also appear to be 
species differences in both the expression and function of ARs on PMNs which may also 
contribute to the unique responses observed with bovine PMNs.  
The multiple effects of catecholamines and adrenergic drugs observed with resting PMNs 
isolated from bovine blood suggests adrenergic agonists can rapidly alter the phenotype of 
circulating neutrophils and eosinophils to a more activated form. For neutrophils, this activated 
form includes decreased L-selectin expression, potentially increasing the short term pool of 
circulating neutrophils available for pathogen surveillance and clearance (Enders et al., 1995; 
Lynch et al., 2010; Long et al., 2012; Ivetic, Green and Hart, 2019; Cornell University College 
of Veterinary Medicine, 2020). It also includes increased neutrophil CD11b expression, 
increasing the ability of neutrophils to phagocytose pathogens, degranulate and respond to tissue 
inflammation (Berends et al., 1993; Tang et al. 1997; Coxon et al., 1996; Ince, Weber and 
Scheiermann, 2019). Increased iROS in neutrophils would also increase their capacity to kill 
phagocytosed pathogens (Paiva and Bozza, 2014). Thus, acute stress responses with increased 
catecholamine release into blood could enhance host defenses in response to an invading 
pathogen.  
Increased eosinophil CD44 expression induced by NE may have detrimental effects in 
allergic individuals (Katoh et al., 2003). Furthermore, increased L-selectin, CD11b and CD16 
expression was observed in response to catecholamines, potentially increasing eosinophil 
migration into tissue during a stress response and increasing eosinophils’ capacity to 
phagocytose and respond to pathogens (Berends et al., 1993; Enders et al., 1995; Coxon et al., 
1996; Tang et al., 1997; In’t Veen et al., 1998; Davoine et al., 2002; Ince, Weber and 
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Scheiermann, 2019; Ivetic, Green and Hart, 2019). These functional changes may be important 
in ensuring cattle are better able to cope with tissue damage or infectious disease when exposed 
to stressful situations.  
Overall, these changes in granulocytes could possibly result in phenomena such as the 
short-term neutrophilia observed as part of the stress leukon, as well as a stronger inflammatory 
response by circulating or tissue granulocytes in response to infections that may follow stressful 
experiences such as weaning and transportation. It is interesting to note that serum antibody 
responses to the opportunistic respiratory pathogens, M. haemolytica and P. multocida, also 
increased significantly in calves subjected to maternal separation and transportation 
(Malmuthuge et al, 2021; Manuscript submitted). Increased serum antibody responses are 
indicative of increased systemic exposure to these potential pathogens, but none of the calves 
displayed clinical signs of respiratory disease. Thus, further study of the mechanisms of stress on 
the adaptive immune system are also worth exploring. 
6.4 Conclusions 
My research provided the first complete analysis of AR gene expression in bovine 
leukocyte lineages and confirmed all three AR families are functional in bovine neutrophils and 
eosinophils. Further study of the effects of AR agonists on individual bovine leukocyte 
subpopulations, such as B cells and NK cells, could yield a much better understanding of how 
stress, acting through the SAM axis, alters a diverse range of immune functions. Differences in 
bovine neutrophil and eosinophil responses to AR agonists also indicate that future investigations 
of PMN responses to adrenergic agonists, as well as inflammatory stimuli, would be improved 
by analyzing separately these two PMN subpopulations. Any analysis of the effect of AR 
agonists, whether endogenous or synthetic, is complicated by the expression of multiple AR 
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genes within each PMN subpopulation and the expression of functional receptors within all three 
AR subtype families. Given the important role neutrophils play as a primary line of defense 
against infectious agents and mediator of inflammation and tissue repair, the current research 
suggests E and NE can modulate both host defenses and inflammation. This research also 
demonstrates a potentially important role for eosinophils during a stress response, with the 
development of an activated or allergic phenotype in response to agonists such as NE. 
Collectively, my studies demonstrate a potentially important role for the SAM axis in regulating 















7.0  CONCLUSIONS AND RECOMMENDATIONS 
Several general conclusions can be made from my research, as well as recommendations 
for improving future research in this area. Most studies reporting responses of bovine neutrophils 
have used PMNs. It was observed that eosinophils, depending on the individual animal and time 
of year, can comprise almost one third of PMN preparations. Further investigations into the 
impact of these temporal fluctuations in eosinophil abundance on the function of the bovine 
immune system should be completed. 
Bovine neutrophils and eosinophils, when analyzed separately, were shown to differ in 
their expression of L-selectin, CD16, and CD44. Differences in the expression of these proteins 
may provide clues as to why neutrophils and eosinophils differ in their cell migration and 
responses to stimuli differently. Neutrophils and eosinophils also differed in their expression of 8 
of the 9 adrenergic receptors and when activated by BoZ + rBoIFNγ responded differently to 
multiple adrenergic drugs. Collectively, the current data provides substantial evidence that 
neutrophils and eosinophils differ sufficiently in a variety of functions, and that that analyzing 
PMNs is not an effective approach to understanding responses to AR agonists. One factor not 
addressed in my in vitro studies was the potential that neutrophils and eosinophils may have 
effects on each other. Further AR agonist research with purified neutrophils and eosinophils 
could clarify if there is significant crosstalk between these two PMN subpopulations. It would be 
important to ensure, however, that the method used to purify PMN subpopulations did not alter 
expression or function of ARs.  
Maternal separation and transportation of suckling beef calves resulted in significant 
changes in blood leukocyte AR gene expression. Some unique changes in AR gene expression 
were observed with each type of stressor indicating that how experimental animals are handled 
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may alter immune cell expression of AR genes. Furthermore, it was surprising that significant 
changes in AR gene expression were observed as much as 4 weeks after the initial stress. 
Therefore, a one-to-two-week adaptation period after animals are transported or moved to a new 
environment may not be sufficient to address these concerns. Further research is required to 
determine if stress alters AR gene expression in specific leukocyte subpopulations and confirm 
whether changes in AR transcript expression significantly leukocyte responses to AR agonists.  
Based on the study of AR transcript expression in PBMC and PMN subpopulations, there 
are several cell populations with high AR transcript expression that could be investigated more 
thoroughly. Given there has been little previous study of AR activity on bovine immune cells, 
high AR transcript expression provides clues regarding which cell populations may be more 
responsive to E, NE, and other adrenergic drugs. For example, B cells were unique among all 
leukocyte lineages in having the highest level of α2A-AR gene expression and undetectable 
expression of the α2B and α2C-AR genes. Further research, using specific α2-AR agonists, such 
as dexmedetomidine, may reveal how the α2-AR regulates B cell activation, proliferation, and 
antibody production. Such studies would provide insight into the role of the α2A-AR in B cells 
and how stress may alter B cell function. 
Bovine CD335+ ILCs, which includes both conventional NK cells and non-conventional 
T cells, displayed high expression of the β2, α1A and α2A-AR genes. The effect of the β2-
agonist zilpaterol on CD335+ ILCs might provide insight into how this drug alters immune 
function when given to feedlot cattle. Some key ILC functions that may be altered by a β2-AR 
agonist could include cytotoxicity against virally infected cells, production of IFNγ, and the 
expression of CD16. For all leukocyte lineages, it may be useful to investigate the function of 
individual AR subtypes. Specific agonists exist to study individual β-AR subtypes and as more 
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α-AR subtype-specific agonists become available it will be possible to analyze the function of 
individual α-AR subtypes on neutrophils and eosinophils. This may provide more clarity whether 
individual AR subtypes mediate specific functions and their potential as therapeutic targets.  
My research also provided evidence that all three AR families were expressed and 
functional in both neutrophils and eosinophils. Of interest, it was observed that both E and NE 
augmented inflammatory responses in neutrophils and eosinophils. These observations are of 
interest given the association between inflammation and increased neutrophil recruitment to the 
lung during BRD. Further analyses is now required to determine if E and NE play a direct role in 
this enhanced pro-inflammatory response and increased neutrophil migration and whether 
specific AR agonists or blockers can ameliorate these effects. It was interesting that synthetic 
adrenergic agonists had a strong suppressive effect on iROS, Also, both neutrophils and 
eosinophils increased CD11b levels in response to E, NE and synthetic agonists targeting 
individual AR. This increase in CD11b expression would suggest that stress can activate PMNs 
circulating in blood and they may have a more potent pro-inflammatory effect when recruited to 
the lung during BRD. Treatment with AR antagonists prior to the stress of weaning and 
transportation may be a novel therapeutic approach to reduce lung inflammation and the severity 
of BRD.  Perhaps an important place to start would be to replicate the work of Rašková et al. 
(1987) to confirm a β-AR blocker reduces BRD morbidity and mortality with a model of 
controlled stress and respiratory infection. This may provide an opportunity to analyze neutrophil 
and eosinophil function and recruitment to infected lungs and determine if a beta-blocker 
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